id	sid	tid	token	lemma	pos
work_u6osxdbbyvcabphnodfjupybae	1	1	Impact	impact	NN
work_u6osxdbbyvcabphnodfjupybae	1	2	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	1	3	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	1	4	ASCO	ASCO	NNP
work_u6osxdbbyvcabphnodfjupybae	1	5	2007	2007	CD
work_u6osxdbbyvcabphnodfjupybae	1	6	Presentation	Presentation	NNP
work_u6osxdbbyvcabphnodfjupybae	1	7	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	1	8	HOG	HOG	NNP
work_u6osxdbbyvcabphnodfjupybae	1	9	Lun	Lun	NNP
work_u6osxdbbyvcabphnodfjupybae	1	10	01	01	CD
work_u6osxdbbyvcabphnodfjupybae	1	11	-	-	SYM
work_u6osxdbbyvcabphnodfjupybae	1	12	24	24	CD
work_u6osxdbbyvcabphnodfjupybae	1	13	/	/	SYM
work_u6osxdbbyvcabphnodfjupybae	1	14	USO-023	uso-023	CD
work_u6osxdbbyvcabphnodfjupybae	1	15	on	on	IN
work_u6osxdbbyvcabphnodfjupybae	1	16	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	1	17	Prescribing	Prescribing	NNP
work_u6osxdbbyvcabphnodfjupybae	1	18	Plans	Plans	NNPS
work_u6osxdbbyvcabphnodfjupybae	1	19	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	1	20	American	American	NNP
work_u6osxdbbyvcabphnodfjupybae	1	21	Medical	Medical	NNP
work_u6osxdbbyvcabphnodfjupybae	1	22	Oncologists	Oncologists	NNPS
work_u6osxdbbyvcabphnodfjupybae	1	23	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	1	24	Patients	Patients	NNPS
work_u6osxdbbyvcabphnodfjupybae	1	25	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	1	26	Stage	Stage	NNP
work_u6osxdbbyvcabphnodfjupybae	1	27	IIIB	IIIB	NNP
work_u6osxdbbyvcabphnodfjupybae	1	28	Non	non	JJ
work_u6osxdbbyvcabphnodfjupybae	1	29	-	-	JJ
work_u6osxdbbyvcabphnodfjupybae	1	30	small	small	JJ
work_u6osxdbbyvcabphnodfjupybae	1	31	Cell	Cell	NNP
work_u6osxdbbyvcabphnodfjupybae	1	32	Lung	Lung	NNP
work_u6osxdbbyvcabphnodfjupybae	1	33	Cancer	Cancer	NNP
work_u6osxdbbyvcabphnodfjupybae	1	34	ORIGINAL	ORIGINAL	NNP
work_u6osxdbbyvcabphnodfjupybae	1	35	ARTICLE	article	NN
work_u6osxdbbyvcabphnodfjupybae	1	36	Impact	impact	NN
work_u6osxdbbyvcabphnodfjupybae	1	37	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	1	38	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	1	39	ASCO	ASCO	NNP
work_u6osxdbbyvcabphnodfjupybae	1	40	2007	2007	CD
work_u6osxdbbyvcabphnodfjupybae	1	41	Presentation	Presentation	NNP
work_u6osxdbbyvcabphnodfjupybae	1	42	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	1	43	HOG	HOG	NNP
work_u6osxdbbyvcabphnodfjupybae	1	44	Lun	Lun	NNP
work_u6osxdbbyvcabphnodfjupybae	1	45	01	01	CD
work_u6osxdbbyvcabphnodfjupybae	1	46	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	1	47	24/	24/	NNP
work_u6osxdbbyvcabphnodfjupybae	1	48	USO-023	uso-023	NN
work_u6osxdbbyvcabphnodfjupybae	1	49	on	on	IN
work_u6osxdbbyvcabphnodfjupybae	1	50	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	1	51	Prescribing	Prescribing	NNP
work_u6osxdbbyvcabphnodfjupybae	1	52	Plans	Plans	NNPS
work_u6osxdbbyvcabphnodfjupybae	1	53	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	1	54	American	American	NNP
work_u6osxdbbyvcabphnodfjupybae	1	55	Medical	Medical	NNP
work_u6osxdbbyvcabphnodfjupybae	1	56	Oncologists	Oncologists	NNPS
work_u6osxdbbyvcabphnodfjupybae	1	57	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	1	58	Patients	Patients	NNPS
work_u6osxdbbyvcabphnodfjupybae	1	59	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	1	60	Stage	Stage	NNP
work_u6osxdbbyvcabphnodfjupybae	1	61	IIIB	IIIB	NNP
work_u6osxdbbyvcabphnodfjupybae	1	62	Non	non	JJ
work_u6osxdbbyvcabphnodfjupybae	1	63	-	-	JJ
work_u6osxdbbyvcabphnodfjupybae	1	64	small	small	JJ
work_u6osxdbbyvcabphnodfjupybae	1	65	Cell	Cell	NNP
work_u6osxdbbyvcabphnodfjupybae	1	66	Lung	Lung	NNP
work_u6osxdbbyvcabphnodfjupybae	1	67	Cancer	Cancer	NNP
work_u6osxdbbyvcabphnodfjupybae	1	68	Mark	Mark	NNP
work_u6osxdbbyvcabphnodfjupybae	1	69	R.	R.	NNP
work_u6osxdbbyvcabphnodfjupybae	1	70	Green	Green	NNP
work_u6osxdbbyvcabphnodfjupybae	1	71	,	,	,
work_u6osxdbbyvcabphnodfjupybae	1	72	MD	MD	NNP
work_u6osxdbbyvcabphnodfjupybae	1	73	,	,	,
work_u6osxdbbyvcabphnodfjupybae	1	74	*	*	NFP
work_u6osxdbbyvcabphnodfjupybae	1	75	Howard	Howard	NNP
work_u6osxdbbyvcabphnodfjupybae	1	76	West	West	NNP
work_u6osxdbbyvcabphnodfjupybae	1	77	,	,	,
work_u6osxdbbyvcabphnodfjupybae	1	78	MD,†	MD,†	NNP
work_u6osxdbbyvcabphnodfjupybae	1	79	Mark	Mark	NNP
work_u6osxdbbyvcabphnodfjupybae	1	80	A.	A.	NNP
work_u6osxdbbyvcabphnodfjupybae	1	81	Socinski	Socinski	NNP
work_u6osxdbbyvcabphnodfjupybae	1	82	,	,	,
work_u6osxdbbyvcabphnodfjupybae	1	83	MD,‡	MD,‡	NNP
work_u6osxdbbyvcabphnodfjupybae	1	84	Joanne	Joanne	NNP
work_u6osxdbbyvcabphnodfjupybae	1	85	Willey	Willey	NNP
work_u6osxdbbyvcabphnodfjupybae	1	86	,	,	,
work_u6osxdbbyvcabphnodfjupybae	1	87	RN	RN	NNP
work_u6osxdbbyvcabphnodfjupybae	1	88	,	,	,
work_u6osxdbbyvcabphnodfjupybae	1	89	OCN	OCN	NNP
work_u6osxdbbyvcabphnodfjupybae	1	90	,	,	,
work_u6osxdbbyvcabphnodfjupybae	1	91	*	*	NFP
work_u6osxdbbyvcabphnodfjupybae	1	92	Laura	Laura	NNP
work_u6osxdbbyvcabphnodfjupybae	1	93	Daniels	Daniels	NNP
work_u6osxdbbyvcabphnodfjupybae	1	94	,	,	,
work_u6osxdbbyvcabphnodfjupybae	1	95	BA	BA	NNP
work_u6osxdbbyvcabphnodfjupybae	1	96	,	,	,
work_u6osxdbbyvcabphnodfjupybae	1	97	*	*	NFP
work_u6osxdbbyvcabphnodfjupybae	1	98	Kristine	Kristine	NNP
work_u6osxdbbyvcabphnodfjupybae	1	99	Lemke	Lemke	NNP
work_u6osxdbbyvcabphnodfjupybae	1	100	,	,	,
work_u6osxdbbyvcabphnodfjupybae	1	101	MBA	MBA	NNP
work_u6osxdbbyvcabphnodfjupybae	1	102	,	,	,
work_u6osxdbbyvcabphnodfjupybae	1	103	*	*	NFP
work_u6osxdbbyvcabphnodfjupybae	1	104	George	George	NNP
work_u6osxdbbyvcabphnodfjupybae	1	105	Rafferty	Rafferty	NNP
work_u6osxdbbyvcabphnodfjupybae	1	106	,	,	,
work_u6osxdbbyvcabphnodfjupybae	1	107	BA	BA	NNP
work_u6osxdbbyvcabphnodfjupybae	1	108	,	,	,
work_u6osxdbbyvcabphnodfjupybae	1	109	*	*	NFP
work_u6osxdbbyvcabphnodfjupybae	1	110	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	1	111	Lou	Lou	NNP
work_u6osxdbbyvcabphnodfjupybae	1	112	Iovino	Iovino	NNP
work_u6osxdbbyvcabphnodfjupybae	1	113	,	,	,
work_u6osxdbbyvcabphnodfjupybae	1	114	MA	MA	NNP
work_u6osxdbbyvcabphnodfjupybae	1	115	*	*	NFP
work_u6osxdbbyvcabphnodfjupybae	1	116	Introduction	introduction	NN
work_u6osxdbbyvcabphnodfjupybae	1	117	:	:	:
work_u6osxdbbyvcabphnodfjupybae	1	118	Nonoperative	nonoperative	JJ
work_u6osxdbbyvcabphnodfjupybae	1	119	treatment	treatment	NN
work_u6osxdbbyvcabphnodfjupybae	1	120	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	1	121	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	1	122	III	iii	CD
work_u6osxdbbyvcabphnodfjupybae	1	123	non	non	JJ
work_u6osxdbbyvcabphnodfjupybae	1	124	-	-	JJ
work_u6osxdbbyvcabphnodfjupybae	1	125	small	small	JJ
work_u6osxdbbyvcabphnodfjupybae	1	126	cell	cell	NN
work_u6osxdbbyvcabphnodfjupybae	1	127	lung	lung	NN
work_u6osxdbbyvcabphnodfjupybae	1	128	cancer	cancer	NN
work_u6osxdbbyvcabphnodfjupybae	1	129	has	have	VBZ
work_u6osxdbbyvcabphnodfjupybae	1	130	evolved	evolve	VBN
work_u6osxdbbyvcabphnodfjupybae	1	131	over	over	IN
work_u6osxdbbyvcabphnodfjupybae	1	132	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	1	133	past	past	JJ
work_u6osxdbbyvcabphnodfjupybae	1	134	30	30	CD
work_u6osxdbbyvcabphnodfjupybae	1	135	years	year	NNS
work_u6osxdbbyvcabphnodfjupybae	1	136	.	.	.
work_u6osxdbbyvcabphnodfjupybae	2	1	The	the	DT
work_u6osxdbbyvcabphnodfjupybae	2	2	current	current	JJ
work_u6osxdbbyvcabphnodfjupybae	2	3	approach	approach	NN
work_u6osxdbbyvcabphnodfjupybae	2	4	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	2	5	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	2	6	Unites	Unites	NNP
work_u6osxdbbyvcabphnodfjupybae	2	7	States	States	NNPS
work_u6osxdbbyvcabphnodfjupybae	2	8	most	most	RBS
work_u6osxdbbyvcabphnodfjupybae	2	9	often	often	RB
work_u6osxdbbyvcabphnodfjupybae	2	10	includes	include	VBZ
work_u6osxdbbyvcabphnodfjupybae	2	11	concurrent	concurrent	JJ
work_u6osxdbbyvcabphnodfjupybae	2	12	chemoradiotherapy	chemoradiotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	2	13	.	.	.
work_u6osxdbbyvcabphnodfjupybae	3	1	Methods	method	NNS
work_u6osxdbbyvcabphnodfjupybae	3	2	:	:	:
work_u6osxdbbyvcabphnodfjupybae	3	3	We	-PRON-	PRP
work_u6osxdbbyvcabphnodfjupybae	3	4	have	have	VBP
work_u6osxdbbyvcabphnodfjupybae	3	5	used	use	VBN
work_u6osxdbbyvcabphnodfjupybae	3	6	live	live	RB
work_u6osxdbbyvcabphnodfjupybae	3	7	,	,	,
work_u6osxdbbyvcabphnodfjupybae	3	8	case	case	NN
work_u6osxdbbyvcabphnodfjupybae	3	9	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	3	10	based	base	VBN
work_u6osxdbbyvcabphnodfjupybae	3	11	research	research	NN
work_u6osxdbbyvcabphnodfjupybae	3	12	events	event	NNS
work_u6osxdbbyvcabphnodfjupybae	3	13	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	3	14	docu-	docu-	VB
work_u6osxdbbyvcabphnodfjupybae	3	15	ment	ment	JJ
work_u6osxdbbyvcabphnodfjupybae	3	16	prescribing	prescribing	NN
work_u6osxdbbyvcabphnodfjupybae	3	17	plans	plan	NNS
work_u6osxdbbyvcabphnodfjupybae	3	18	among	among	IN
work_u6osxdbbyvcabphnodfjupybae	3	19	American	american	JJ
work_u6osxdbbyvcabphnodfjupybae	3	20	medical	medical	JJ
work_u6osxdbbyvcabphnodfjupybae	3	21	oncologists	oncologist	NNS
work_u6osxdbbyvcabphnodfjupybae	3	22	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	3	23	first	first	JJ
work_u6osxdbbyvcabphnodfjupybae	3	24	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	3	25	line	line	NN
work_u6osxdbbyvcabphnodfjupybae	3	26	therapy	therapy	NN
work_u6osxdbbyvcabphnodfjupybae	3	27	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	3	28	patients	patient	NNS
work_u6osxdbbyvcabphnodfjupybae	3	29	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	3	30	N3	N3	NNP
work_u6osxdbbyvcabphnodfjupybae	3	31	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	3	32	IIIB	IIIB	NNP
work_u6osxdbbyvcabphnodfjupybae	3	33	non	non	JJ
work_u6osxdbbyvcabphnodfjupybae	3	34	-	-	JJ
work_u6osxdbbyvcabphnodfjupybae	3	35	small	small	JJ
work_u6osxdbbyvcabphnodfjupybae	3	36	cell	cell	NN
work_u6osxdbbyvcabphnodfjupybae	3	37	lung	lung	NN
work_u6osxdbbyvcabphnodfjupybae	3	38	cancer	cancer	NN
work_u6osxdbbyvcabphnodfjupybae	3	39	.	.	.
work_u6osxdbbyvcabphnodfjupybae	4	1	Changes	change	NNS
work_u6osxdbbyvcabphnodfjupybae	4	2	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	4	3	prescribing	prescribe	VBG
work_u6osxdbbyvcabphnodfjupybae	4	4	plans	plan	NNS
work_u6osxdbbyvcabphnodfjupybae	4	5	documented	document	VBN
work_u6osxdbbyvcabphnodfjupybae	4	6	before	before	RB
work_u6osxdbbyvcabphnodfjupybae	4	7	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	4	8	after	after	IN
work_u6osxdbbyvcabphnodfjupybae	4	9	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	4	10	2007	2007	CD
work_u6osxdbbyvcabphnodfjupybae	4	11	American	American	NNP
work_u6osxdbbyvcabphnodfjupybae	4	12	Society	Society	NNP
work_u6osxdbbyvcabphnodfjupybae	4	13	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	4	14	Clinical	Clinical	NNP
work_u6osxdbbyvcabphnodfjupybae	4	15	Oncology	Oncology	NNP
work_u6osxdbbyvcabphnodfjupybae	4	16	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	4	17	ASCO	ASCO	NNP
work_u6osxdbbyvcabphnodfjupybae	4	18	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	4	19	presen-	presen-	VBP
work_u6osxdbbyvcabphnodfjupybae	4	20	tation	tation	NN
work_u6osxdbbyvcabphnodfjupybae	4	21	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	4	22	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	4	23	Hoosier	Hoosier	NNP
work_u6osxdbbyvcabphnodfjupybae	4	24	Oncology	Oncology	NNP
work_u6osxdbbyvcabphnodfjupybae	4	25	Group	Group	NNP
work_u6osxdbbyvcabphnodfjupybae	4	26	trial	trial	NN
work_u6osxdbbyvcabphnodfjupybae	4	27	testing	test	VBG
work_u6osxdbbyvcabphnodfjupybae	4	28	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	4	29	role	role	NN
work_u6osxdbbyvcabphnodfjupybae	4	30	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	4	31	consol-	consol-	NNP
work_u6osxdbbyvcabphnodfjupybae	4	32	idation	idation	NNP
work_u6osxdbbyvcabphnodfjupybae	4	33	docetaxel	docetaxel	NNP
work_u6osxdbbyvcabphnodfjupybae	4	34	chemotherapy	chemotherapy	NNP
work_u6osxdbbyvcabphnodfjupybae	4	35	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	4	36	this	this	DT
work_u6osxdbbyvcabphnodfjupybae	4	37	setting	setting	NN
work_u6osxdbbyvcabphnodfjupybae	4	38	are	be	VBP
work_u6osxdbbyvcabphnodfjupybae	4	39	presented	present	VBN
work_u6osxdbbyvcabphnodfjupybae	4	40	.	.	.
work_u6osxdbbyvcabphnodfjupybae	5	1	Results	result	NNS
work_u6osxdbbyvcabphnodfjupybae	5	2	:	:	:
work_u6osxdbbyvcabphnodfjupybae	5	3	Data	datum	NNS
work_u6osxdbbyvcabphnodfjupybae	5	4	from	from	IN
work_u6osxdbbyvcabphnodfjupybae	5	5	2007	2007	CD
work_u6osxdbbyvcabphnodfjupybae	5	6	show	show	VB
work_u6osxdbbyvcabphnodfjupybae	5	7	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	5	8	post	post	JJ
work_u6osxdbbyvcabphnodfjupybae	5	9	-	-	JJ
work_u6osxdbbyvcabphnodfjupybae	5	10	ASCO	asco	NN
work_u6osxdbbyvcabphnodfjupybae	5	11	shift	shift	VB
work_u6osxdbbyvcabphnodfjupybae	5	12	away	away	RB
work_u6osxdbbyvcabphnodfjupybae	5	13	from	from	IN
work_u6osxdbbyvcabphnodfjupybae	5	14	plans	plan	NNS
work_u6osxdbbyvcabphnodfjupybae	5	15	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	5	16	docetaxel	docetaxel	NNP
work_u6osxdbbyvcabphnodfjupybae	5	17	consolidation	consolidation	NN
work_u6osxdbbyvcabphnodfjupybae	5	18	,	,	,
work_u6osxdbbyvcabphnodfjupybae	5	19	increased	increase	VBN
work_u6osxdbbyvcabphnodfjupybae	5	20	use	use	NN
work_u6osxdbbyvcabphnodfjupybae	5	21	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	5	22	concurrent	concurrent	JJ
work_u6osxdbbyvcabphnodfjupybae	5	23	chemora-	chemora-	NNP
work_u6osxdbbyvcabphnodfjupybae	5	24	diotherapy	diotherapy	NNP
work_u6osxdbbyvcabphnodfjupybae	5	25	alone	alone	RB
work_u6osxdbbyvcabphnodfjupybae	5	26	,	,	,
work_u6osxdbbyvcabphnodfjupybae	5	27	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	5	28	stable	stable	JJ
work_u6osxdbbyvcabphnodfjupybae	5	29	to	to	IN
work_u6osxdbbyvcabphnodfjupybae	5	30	increased	increase	VBN
work_u6osxdbbyvcabphnodfjupybae	5	31	plans	plan	NNS
work_u6osxdbbyvcabphnodfjupybae	5	32	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	5	33	concurrent	concurrent	JJ
work_u6osxdbbyvcabphnodfjupybae	5	34	chemoradiation	chemoradiation	NN
work_u6osxdbbyvcabphnodfjupybae	5	35	followed	follow	VBN
work_u6osxdbbyvcabphnodfjupybae	5	36	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	5	37	additional	additional	JJ
work_u6osxdbbyvcabphnodfjupybae	5	38	cycles	cycle	NNS
work_u6osxdbbyvcabphnodfjupybae	5	39	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	5	40	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	5	41	chemotherapy	chemotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	5	42	used	use	VBN
work_u6osxdbbyvcabphnodfjupybae	5	43	during	during	IN
work_u6osxdbbyvcabphnodfjupybae	5	44	concurrent	concurrent	JJ
work_u6osxdbbyvcabphnodfjupybae	5	45	management	management	NN
work_u6osxdbbyvcabphnodfjupybae	5	46	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	5	47	20	20	CD
work_u6osxdbbyvcabphnodfjupybae	5	48	%	%	NN
work_u6osxdbbyvcabphnodfjupybae	5	49	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	5	50	.	.	.
work_u6osxdbbyvcabphnodfjupybae	6	1	Preliminary	preliminary	JJ
work_u6osxdbbyvcabphnodfjupybae	6	2	data	datum	NNS
work_u6osxdbbyvcabphnodfjupybae	6	3	from	from	IN
work_u6osxdbbyvcabphnodfjupybae	6	4	2008	2008	CD
work_u6osxdbbyvcabphnodfjupybae	6	5	confirm	confirm	VB
work_u6osxdbbyvcabphnodfjupybae	6	6	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	6	7	durability	durability	NN
work_u6osxdbbyvcabphnodfjupybae	6	8	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	6	9	these	these	DT
work_u6osxdbbyvcabphnodfjupybae	6	10	changes	change	NNS
work_u6osxdbbyvcabphnodfjupybae	6	11	.	.	.
work_u6osxdbbyvcabphnodfjupybae	7	1	Conclusions	conclusion	NNS
work_u6osxdbbyvcabphnodfjupybae	7	2	:	:	:
work_u6osxdbbyvcabphnodfjupybae	7	3	The	the	DT
work_u6osxdbbyvcabphnodfjupybae	7	4	findings	finding	NNS
work_u6osxdbbyvcabphnodfjupybae	7	5	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	7	6	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	7	7	Hoosier	Hoosier	NNP
work_u6osxdbbyvcabphnodfjupybae	7	8	Oncology	Oncology	NNP
work_u6osxdbbyvcabphnodfjupybae	7	9	Group	Group	NNP
work_u6osxdbbyvcabphnodfjupybae	7	10	trial	trial	NN
work_u6osxdbbyvcabphnodfjupybae	7	11	support	support	VBP
work_u6osxdbbyvcabphnodfjupybae	7	12	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	7	13	transition	transition	NN
work_u6osxdbbyvcabphnodfjupybae	7	14	away	away	RB
work_u6osxdbbyvcabphnodfjupybae	7	15	from	from	IN
work_u6osxdbbyvcabphnodfjupybae	7	16	docetaxel	docetaxel	NNP
work_u6osxdbbyvcabphnodfjupybae	7	17	consolidation	consolidation	NN
work_u6osxdbbyvcabphnodfjupybae	7	18	.	.	.
work_u6osxdbbyvcabphnodfjupybae	8	1	A	a	DT
work_u6osxdbbyvcabphnodfjupybae	8	2	trend	trend	NN
work_u6osxdbbyvcabphnodfjupybae	8	3	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	8	4	this	this	DT
work_u6osxdbbyvcabphnodfjupybae	8	5	direction	direction	NN
work_u6osxdbbyvcabphnodfjupybae	8	6	among	among	IN
work_u6osxdbbyvcabphnodfjupybae	8	7	American	american	JJ
work_u6osxdbbyvcabphnodfjupybae	8	8	medical	medical	JJ
work_u6osxdbbyvcabphnodfjupybae	8	9	oncologists	oncologist	NNS
work_u6osxdbbyvcabphnodfjupybae	8	10	is	be	VBZ
work_u6osxdbbyvcabphnodfjupybae	8	11	clear	clear	JJ
work_u6osxdbbyvcabphnodfjupybae	8	12	from	from	IN
work_u6osxdbbyvcabphnodfjupybae	8	13	our	-PRON-	PRP$
work_u6osxdbbyvcabphnodfjupybae	8	14	data	datum	NNS
work_u6osxdbbyvcabphnodfjupybae	8	15	.	.	.
work_u6osxdbbyvcabphnodfjupybae	9	1	However	however	RB
work_u6osxdbbyvcabphnodfjupybae	9	2	,	,	,
work_u6osxdbbyvcabphnodfjupybae	9	3	nearly	nearly	RB
work_u6osxdbbyvcabphnodfjupybae	9	4	20	20	CD
work_u6osxdbbyvcabphnodfjupybae	9	5	%	%	NN
work_u6osxdbbyvcabphnodfjupybae	9	6	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	9	7	oncologists	oncologist	NNS
work_u6osxdbbyvcabphnodfjupybae	9	8	studied	study	VBN
work_u6osxdbbyvcabphnodfjupybae	9	9	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	9	10	2008	2008	CD
work_u6osxdbbyvcabphnodfjupybae	9	11	still	still	RB
work_u6osxdbbyvcabphnodfjupybae	9	12	plan	plan	VBP
work_u6osxdbbyvcabphnodfjupybae	9	13	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	9	14	use	use	VB
work_u6osxdbbyvcabphnodfjupybae	9	15	docetaxel	docetaxel	NNP
work_u6osxdbbyvcabphnodfjupybae	9	16	consolidation	consolidation	NN
work_u6osxdbbyvcabphnodfjupybae	9	17	.	.	.
work_u6osxdbbyvcabphnodfjupybae	10	1	Furthermore	furthermore	RB
work_u6osxdbbyvcabphnodfjupybae	10	2	,	,	,
work_u6osxdbbyvcabphnodfjupybae	10	3	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	10	4	majority	majority	NN
work_u6osxdbbyvcabphnodfjupybae	10	5	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	10	6	those	those	DT
work_u6osxdbbyvcabphnodfjupybae	10	7	studied	study	VBN
work_u6osxdbbyvcabphnodfjupybae	10	8	after	after	IN
work_u6osxdbbyvcabphnodfjupybae	10	9	ASCO	ASCO	NNS
work_u6osxdbbyvcabphnodfjupybae	10	10	2007	2007	CD
work_u6osxdbbyvcabphnodfjupybae	10	11	continue	continue	VBP
work_u6osxdbbyvcabphnodfjupybae	10	12	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	10	13	report	report	VB
work_u6osxdbbyvcabphnodfjupybae	10	14	plans	plan	NNS
work_u6osxdbbyvcabphnodfjupybae	10	15	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	10	16	use	use	VB
work_u6osxdbbyvcabphnodfjupybae	10	17	more	more	JJR
work_u6osxdbbyvcabphnodfjupybae	10	18	than	than	IN
work_u6osxdbbyvcabphnodfjupybae	10	19	two	two	CD
work_u6osxdbbyvcabphnodfjupybae	10	20	cycles	cycle	NNS
work_u6osxdbbyvcabphnodfjupybae	10	21	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	10	22	chemotherapy	chemotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	10	23	as	as	IN
work_u6osxdbbyvcabphnodfjupybae	10	24	part	part	NN
work_u6osxdbbyvcabphnodfjupybae	10	25	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	10	26	their	-PRON-	PRP$
work_u6osxdbbyvcabphnodfjupybae	10	27	preferred	preferred	JJ
work_u6osxdbbyvcabphnodfjupybae	10	28	treatment	treatment	NN
work_u6osxdbbyvcabphnodfjupybae	10	29	recommendation	recommendation	NN
work_u6osxdbbyvcabphnodfjupybae	10	30	despite	despite	IN
work_u6osxdbbyvcabphnodfjupybae	10	31	no	no	DT
work_u6osxdbbyvcabphnodfjupybae	10	32	level	level	NN
work_u6osxdbbyvcabphnodfjupybae	10	33	I	-PRON-	PRP
work_u6osxdbbyvcabphnodfjupybae	10	34	evidence	evidence	VBP
work_u6osxdbbyvcabphnodfjupybae	10	35	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	10	36	support	support	VB
work_u6osxdbbyvcabphnodfjupybae	10	37	this	this	DT
work_u6osxdbbyvcabphnodfjupybae	10	38	approach	approach	NN
work_u6osxdbbyvcabphnodfjupybae	10	39	.	.	.
work_u6osxdbbyvcabphnodfjupybae	11	1	Key	key	JJ
work_u6osxdbbyvcabphnodfjupybae	11	2	Words	word	NNS
work_u6osxdbbyvcabphnodfjupybae	11	3	:	:	:
work_u6osxdbbyvcabphnodfjupybae	11	4	Non	non	JJ
work_u6osxdbbyvcabphnodfjupybae	11	5	-	-	JJ
work_u6osxdbbyvcabphnodfjupybae	11	6	small	small	JJ
work_u6osxdbbyvcabphnodfjupybae	11	7	cell	cell	NN
work_u6osxdbbyvcabphnodfjupybae	11	8	lung	lung	NN
work_u6osxdbbyvcabphnodfjupybae	11	9	cancer	cancer	NN
work_u6osxdbbyvcabphnodfjupybae	11	10	,	,	,
work_u6osxdbbyvcabphnodfjupybae	11	11	Stage	Stage	NNP
work_u6osxdbbyvcabphnodfjupybae	11	12	III	III	NNP
work_u6osxdbbyvcabphnodfjupybae	11	13	,	,	,
work_u6osxdbbyvcabphnodfjupybae	11	14	Chemoradio-	Chemoradio-	NNP
work_u6osxdbbyvcabphnodfjupybae	11	15	therapy	therapy	NN
work_u6osxdbbyvcabphnodfjupybae	11	16	,	,	,
work_u6osxdbbyvcabphnodfjupybae	11	17	Consolidation	consolidation	NN
work_u6osxdbbyvcabphnodfjupybae	11	18	chemotherapy	chemotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	11	19	,	,	,
work_u6osxdbbyvcabphnodfjupybae	11	20	Phase	phase	NN
work_u6osxdbbyvcabphnodfjupybae	11	21	III	iii	CD
work_u6osxdbbyvcabphnodfjupybae	11	22	trial	trial	NN
work_u6osxdbbyvcabphnodfjupybae	11	23	.	.	.
work_u6osxdbbyvcabphnodfjupybae	12	1	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	12	2	J	J	NNP
work_u6osxdbbyvcabphnodfjupybae	12	3	Thorac	Thorac	NNP
work_u6osxdbbyvcabphnodfjupybae	12	4	Oncol	Oncol	NNP
work_u6osxdbbyvcabphnodfjupybae	12	5	.	.	.
work_u6osxdbbyvcabphnodfjupybae	13	1	2009;4	2009;4	LS
work_u6osxdbbyvcabphnodfjupybae	13	2	:	:	:
work_u6osxdbbyvcabphnodfjupybae	13	3	983–987	983–987	CD
work_u6osxdbbyvcabphnodfjupybae	13	4	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	13	5	The	the	DT
work_u6osxdbbyvcabphnodfjupybae	13	6	most	most	RBS
work_u6osxdbbyvcabphnodfjupybae	13	7	recent	recent	JJ
work_u6osxdbbyvcabphnodfjupybae	13	8	figures	figure	NNS
work_u6osxdbbyvcabphnodfjupybae	13	9	from	from	IN
work_u6osxdbbyvcabphnodfjupybae	13	10	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	13	11	American	American	NNP
work_u6osxdbbyvcabphnodfjupybae	13	12	Cancer	Cancer	NNP
work_u6osxdbbyvcabphnodfjupybae	13	13	Societysuggest	Societysuggest	NNP
work_u6osxdbbyvcabphnodfjupybae	13	14	that	that	IN
work_u6osxdbbyvcabphnodfjupybae	13	15	we	-PRON-	PRP
work_u6osxdbbyvcabphnodfjupybae	13	16	should	should	MD
work_u6osxdbbyvcabphnodfjupybae	13	17	expect	expect	VB
work_u6osxdbbyvcabphnodfjupybae	13	18	215,000	215,000	CD
work_u6osxdbbyvcabphnodfjupybae	13	19	new	new	JJ
work_u6osxdbbyvcabphnodfjupybae	13	20	cases	case	NNS
work_u6osxdbbyvcabphnodfjupybae	13	21	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	13	22	lung	lung	NN
work_u6osxdbbyvcabphnodfjupybae	13	23	cancer	cancer	NN
work_u6osxdbbyvcabphnodfjupybae	13	24	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	13	25	2008	2008	CD
work_u6osxdbbyvcabphnodfjupybae	13	26	.	.	.
work_u6osxdbbyvcabphnodfjupybae	14	1	Approximately	approximately	RB
work_u6osxdbbyvcabphnodfjupybae	14	2	85	85	CD
work_u6osxdbbyvcabphnodfjupybae	14	3	%	%	NN
work_u6osxdbbyvcabphnodfjupybae	14	4	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	14	5	these	these	DT
work_u6osxdbbyvcabphnodfjupybae	14	6	new	new	JJ
work_u6osxdbbyvcabphnodfjupybae	14	7	cases	case	NNS
work_u6osxdbbyvcabphnodfjupybae	14	8	will	will	MD
work_u6osxdbbyvcabphnodfjupybae	14	9	have	have	VB
work_u6osxdbbyvcabphnodfjupybae	14	10	nonsmall	nonsmall	NNP
work_u6osxdbbyvcabphnodfjupybae	14	11	cell	cell	NN
work_u6osxdbbyvcabphnodfjupybae	14	12	histology	histology	NN
work_u6osxdbbyvcabphnodfjupybae	14	13	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	14	14	about	about	RB
work_u6osxdbbyvcabphnodfjupybae	14	15	one	one	CD
work_u6osxdbbyvcabphnodfjupybae	14	16	third	third	NN
work_u6osxdbbyvcabphnodfjupybae	14	17	will	will	MD
work_u6osxdbbyvcabphnodfjupybae	14	18	have	have	VB
work_u6osxdbbyvcabphnodfjupybae	14	19	regional	regional	JJ
work_u6osxdbbyvcabphnodfjupybae	14	20	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	14	21	N2–N3	N2–N3	NNP
work_u6osxdbbyvcabphnodfjupybae	14	22	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	14	23	disease	disease	NN
work_u6osxdbbyvcabphnodfjupybae	14	24	at	at	IN
work_u6osxdbbyvcabphnodfjupybae	14	25	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	14	26	time	time	NN
work_u6osxdbbyvcabphnodfjupybae	14	27	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	14	28	diagnosis.1	diagnosis.1	NNS
work_u6osxdbbyvcabphnodfjupybae	14	29	Based	base	VBN
work_u6osxdbbyvcabphnodfjupybae	14	30	on	on	IN
work_u6osxdbbyvcabphnodfjupybae	14	31	these	these	DT
work_u6osxdbbyvcabphnodfjupybae	14	32	figures	figure	NNS
work_u6osxdbbyvcabphnodfjupybae	14	33	,	,	,
work_u6osxdbbyvcabphnodfjupybae	14	34	nearly	nearly	RB
work_u6osxdbbyvcabphnodfjupybae	14	35	64,000	64,000	CD
work_u6osxdbbyvcabphnodfjupybae	14	36	individual	individual	JJ
work_u6osxdbbyvcabphnodfjupybae	14	37	Americans	Americans	NNPS
work_u6osxdbbyvcabphnodfjupybae	14	38	should	should	MD
work_u6osxdbbyvcabphnodfjupybae	14	39	be	be	VB
work_u6osxdbbyvcabphnodfjupybae	14	40	identified	identify	VBN
work_u6osxdbbyvcabphnodfjupybae	14	41	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	14	42	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	14	43	III	iii	CD
work_u6osxdbbyvcabphnodfjupybae	14	44	non	non	JJ
work_u6osxdbbyvcabphnodfjupybae	14	45	-	-	JJ
work_u6osxdbbyvcabphnodfjupybae	14	46	small	small	JJ
work_u6osxdbbyvcabphnodfjupybae	14	47	cell	cell	NN
work_u6osxdbbyvcabphnodfjupybae	14	48	lung	lung	NN
work_u6osxdbbyvcabphnodfjupybae	14	49	cancer	cancer	NN
work_u6osxdbbyvcabphnodfjupybae	14	50	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	14	51	NSCLC	NSCLC	NNP
work_u6osxdbbyvcabphnodfjupybae	14	52	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	14	53	during	during	IN
work_u6osxdbbyvcabphnodfjupybae	14	54	this	this	DT
work_u6osxdbbyvcabphnodfjupybae	14	55	calendar	calendar	NN
work_u6osxdbbyvcabphnodfjupybae	14	56	year	year	NN
work_u6osxdbbyvcabphnodfjupybae	14	57	.	.	.
work_u6osxdbbyvcabphnodfjupybae	15	1	Nonoperative	nonoperative	JJ
work_u6osxdbbyvcabphnodfjupybae	15	2	treatment	treatment	NN
work_u6osxdbbyvcabphnodfjupybae	15	3	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	15	4	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	15	5	III	III	NNP
work_u6osxdbbyvcabphnodfjupybae	15	6	NSCLC	NSCLC	NNP
work_u6osxdbbyvcabphnodfjupybae	15	7	has	have	VBZ
work_u6osxdbbyvcabphnodfjupybae	15	8	evolved	evolve	VBN
work_u6osxdbbyvcabphnodfjupybae	15	9	during	during	IN
work_u6osxdbbyvcabphnodfjupybae	15	10	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	15	11	past	past	JJ
work_u6osxdbbyvcabphnodfjupybae	15	12	30	30	CD
work_u6osxdbbyvcabphnodfjupybae	15	13	years	year	NNS
work_u6osxdbbyvcabphnodfjupybae	15	14	from	from	IN
work_u6osxdbbyvcabphnodfjupybae	15	15	largely	largely	RB
work_u6osxdbbyvcabphnodfjupybae	15	16	palliative	palliative	JJ
work_u6osxdbbyvcabphnodfjupybae	15	17	radiation	radiation	NN
work_u6osxdbbyvcabphnodfjupybae	15	18	therapy	therapy	NN
work_u6osxdbbyvcabphnodfjupybae	15	19	,	,	,
work_u6osxdbbyvcabphnodfjupybae	15	20	through	through	IN
work_u6osxdbbyvcabphnodfjupybae	15	21	sequential	sequential	JJ
work_u6osxdbbyvcabphnodfjupybae	15	22	chemotherapy	chemotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	15	23	followed	follow	VBN
work_u6osxdbbyvcabphnodfjupybae	15	24	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	15	25	radiation	radiation	NN
work_u6osxdbbyvcabphnodfjupybae	15	26	,	,	,
work_u6osxdbbyvcabphnodfjupybae	15	27	to	to	IN
work_u6osxdbbyvcabphnodfjupybae	15	28	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	15	29	current	current	JJ
work_u6osxdbbyvcabphnodfjupybae	15	30	use	use	NN
work_u6osxdbbyvcabphnodfjupybae	15	31	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	15	32	concurrent	concurrent	JJ
work_u6osxdbbyvcabphnodfjupybae	15	33	chemoradiother-	chemoradiother-	NN
work_u6osxdbbyvcabphnodfjupybae	15	34	apy.2	apy.2	NFP
work_u6osxdbbyvcabphnodfjupybae	15	35	In	in	IN
work_u6osxdbbyvcabphnodfjupybae	15	36	many	many	JJ
work_u6osxdbbyvcabphnodfjupybae	15	37	cases	case	NNS
work_u6osxdbbyvcabphnodfjupybae	15	38	,	,	,
work_u6osxdbbyvcabphnodfjupybae	15	39	physicians	physician	NNS
work_u6osxdbbyvcabphnodfjupybae	15	40	have	have	VBP
work_u6osxdbbyvcabphnodfjupybae	15	41	used	use	VBN
work_u6osxdbbyvcabphnodfjupybae	15	42	two	two	CD
work_u6osxdbbyvcabphnodfjupybae	15	43	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	15	44	four	four	CD
work_u6osxdbbyvcabphnodfjupybae	15	45	additional	additional	JJ
work_u6osxdbbyvcabphnodfjupybae	15	46	chemotherapy	chemotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	15	47	cycles	cycle	NNS
work_u6osxdbbyvcabphnodfjupybae	15	48	as	as	IN
work_u6osxdbbyvcabphnodfjupybae	15	49	either	either	DT
work_u6osxdbbyvcabphnodfjupybae	15	50	induction	induction	NN
work_u6osxdbbyvcabphnodfjupybae	15	51	or	or	CC
work_u6osxdbbyvcabphnodfjupybae	15	52	consol-	consol-	NN
work_u6osxdbbyvcabphnodfjupybae	15	53	idation	idation	NN
work_u6osxdbbyvcabphnodfjupybae	15	54	therapy	therapy	NN
work_u6osxdbbyvcabphnodfjupybae	15	55	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	15	56	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	15	57	expectation	expectation	NN
work_u6osxdbbyvcabphnodfjupybae	15	58	that	that	IN
work_u6osxdbbyvcabphnodfjupybae	15	59	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	15	60	added	add	VBN
work_u6osxdbbyvcabphnodfjupybae	15	61	chemo-	chemo-	NN
work_u6osxdbbyvcabphnodfjupybae	15	62	therapy	therapy	NN
work_u6osxdbbyvcabphnodfjupybae	15	63	would	would	MD
work_u6osxdbbyvcabphnodfjupybae	15	64	improve	improve	VB
work_u6osxdbbyvcabphnodfjupybae	15	65	survival	survival	NN
work_u6osxdbbyvcabphnodfjupybae	15	66	.	.	.
work_u6osxdbbyvcabphnodfjupybae	16	1	In	in	IN
work_u6osxdbbyvcabphnodfjupybae	16	2	2006	2006	CD
work_u6osxdbbyvcabphnodfjupybae	16	3	,	,	,
work_u6osxdbbyvcabphnodfjupybae	16	4	data	datum	NNS
work_u6osxdbbyvcabphnodfjupybae	16	5	from	from	IN
work_u6osxdbbyvcabphnodfjupybae	16	6	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	16	7	Cancer	Cancer	NNP
work_u6osxdbbyvcabphnodfjupybae	16	8	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	16	9	Leukemia	Leukemia	NNP
work_u6osxdbbyvcabphnodfjupybae	16	10	Group	Group	NNP
work_u6osxdbbyvcabphnodfjupybae	16	11	B	B	NNP
work_u6osxdbbyvcabphnodfjupybae	16	12	randomized	randomized	JJ
work_u6osxdbbyvcabphnodfjupybae	16	13	phase	phase	NN
work_u6osxdbbyvcabphnodfjupybae	16	14	III	iii	CD
work_u6osxdbbyvcabphnodfjupybae	16	15	trial	trial	NN
work_u6osxdbbyvcabphnodfjupybae	16	16	failed	fail	VBD
work_u6osxdbbyvcabphnodfjupybae	16	17	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	16	18	demonstrate	demonstrate	VB
work_u6osxdbbyvcabphnodfjupybae	16	19	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	16	20	survival	survival	NN
work_u6osxdbbyvcabphnodfjupybae	16	21	advantage	advantage	NN
work_u6osxdbbyvcabphnodfjupybae	16	22	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	16	23	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	16	24	addition	addition	NN
work_u6osxdbbyvcabphnodfjupybae	16	25	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	16	26	two	two	CD
work_u6osxdbbyvcabphnodfjupybae	16	27	cycles	cycle	NNS
work_u6osxdbbyvcabphnodfjupybae	16	28	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	16	29	full	full	JJ
work_u6osxdbbyvcabphnodfjupybae	16	30	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	16	31	dose	dose	JJ
work_u6osxdbbyvcabphnodfjupybae	16	32	carboplatin	carboplatin	NNP
work_u6osxdbbyvcabphnodfjupybae	16	33	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	16	34	paclitaxel	paclitaxel	NNP
work_u6osxdbbyvcabphnodfjupybae	16	35	followed	follow	VBN
work_u6osxdbbyvcabphnodfjupybae	16	36	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	16	37	defin-	defin-	JJ
work_u6osxdbbyvcabphnodfjupybae	16	38	itive	itive	JJ
work_u6osxdbbyvcabphnodfjupybae	16	39	radiation	radiation	NN
work_u6osxdbbyvcabphnodfjupybae	16	40	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	16	41	concurrent	concurrent	JJ
work_u6osxdbbyvcabphnodfjupybae	16	42	weekly	weekly	JJ
work_u6osxdbbyvcabphnodfjupybae	16	43	paclitaxel	paclitaxel	NNP
work_u6osxdbbyvcabphnodfjupybae	16	44	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	16	45	carboplatin	carboplatin	NNP
work_u6osxdbbyvcabphnodfjupybae	16	46	compared	compare	VBN
work_u6osxdbbyvcabphnodfjupybae	16	47	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	16	48	definitive	definitive	JJ
work_u6osxdbbyvcabphnodfjupybae	16	49	radiation	radiation	NN
work_u6osxdbbyvcabphnodfjupybae	16	50	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	16	51	concurrent	concurrent	JJ
work_u6osxdbbyvcabphnodfjupybae	16	52	weekly	weekly	JJ
work_u6osxdbbyvcabphnodfjupybae	16	53	paclitaxel	paclitaxel	NNP
work_u6osxdbbyvcabphnodfjupybae	16	54	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	16	55	carboplatin	carboplatin	NNP
work_u6osxdbbyvcabphnodfjupybae	16	56	alone.3	alone.3	NNP
work_u6osxdbbyvcabphnodfjupybae	16	57	However	however	RB
work_u6osxdbbyvcabphnodfjupybae	16	58	,	,	,
work_u6osxdbbyvcabphnodfjupybae	16	59	up	up	IN
work_u6osxdbbyvcabphnodfjupybae	16	60	until	until	IN
work_u6osxdbbyvcabphnodfjupybae	16	61	recently	recently	RB
work_u6osxdbbyvcabphnodfjupybae	16	62	,	,	,
work_u6osxdbbyvcabphnodfjupybae	16	63	phase	phase	NN
work_u6osxdbbyvcabphnodfjupybae	16	64	II	ii	CD
work_u6osxdbbyvcabphnodfjupybae	16	65	data	datum	NNS
work_u6osxdbbyvcabphnodfjupybae	16	66	reported	report	VBN
work_u6osxdbbyvcabphnodfjupybae	16	67	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	16	68	multiple	multiple	JJ
work_u6osxdbbyvcabphnodfjupybae	16	69	investigators	investigator	NNS
work_u6osxdbbyvcabphnodfjupybae	16	70	suggested	suggest	VBD
work_u6osxdbbyvcabphnodfjupybae	16	71	that	that	IN
work_u6osxdbbyvcabphnodfjupybae	16	72	immediate	immediate	JJ
work_u6osxdbbyvcabphnodfjupybae	16	73	concurrent	concurrent	JJ
work_u6osxdbbyvcabphnodfjupybae	16	74	chemoradiotherapy	chemoradiotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	16	75	followed	follow	VBN
work_u6osxdbbyvcabphnodfjupybae	16	76	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	16	77	con-	con-	NNP
work_u6osxdbbyvcabphnodfjupybae	16	78	solidation	solidation	NNP
work_u6osxdbbyvcabphnodfjupybae	16	79	chemotherapy	chemotherapy	NNP
work_u6osxdbbyvcabphnodfjupybae	16	80	produced	produce	VBD
work_u6osxdbbyvcabphnodfjupybae	16	81	excellent	excellent	JJ
work_u6osxdbbyvcabphnodfjupybae	16	82	outcomes	outcome	NNS
work_u6osxdbbyvcabphnodfjupybae	16	83	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	16	84	nonoperative	nonoperative	JJ
work_u6osxdbbyvcabphnodfjupybae	16	85	therapy	therapy	NN
work_u6osxdbbyvcabphnodfjupybae	16	86	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	16	87	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	16	88	III	iii	CD
work_u6osxdbbyvcabphnodfjupybae	16	89	patients	patient	NNS
work_u6osxdbbyvcabphnodfjupybae	16	90	.	.	.
work_u6osxdbbyvcabphnodfjupybae	17	1	One	one	CD
work_u6osxdbbyvcabphnodfjupybae	17	2	such	such	JJ
work_u6osxdbbyvcabphnodfjupybae	17	3	approach	approach	NN
work_u6osxdbbyvcabphnodfjupybae	17	4	developed	develop	VBN
work_u6osxdbbyvcabphnodfjupybae	17	5	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	17	6	Southwest	Southwest	NNP
work_u6osxdbbyvcabphnodfjupybae	17	7	Oncology	Oncology	NNP
work_u6osxdbbyvcabphnodfjupybae	17	8	Group	Group	NNP
work_u6osxdbbyvcabphnodfjupybae	17	9	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	17	10	SWOG	SWOG	NNP
work_u6osxdbbyvcabphnodfjupybae	17	11	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	17	12	investi-	investi-	.
work_u6osxdbbyvcabphnodfjupybae	17	13	gators	gator	NNS
work_u6osxdbbyvcabphnodfjupybae	17	14	involved	involve	VBD
work_u6osxdbbyvcabphnodfjupybae	17	15	immediate	immediate	JJ
work_u6osxdbbyvcabphnodfjupybae	17	16	concurrent	concurrent	JJ
work_u6osxdbbyvcabphnodfjupybae	17	17	etoposide	etoposide	NN
work_u6osxdbbyvcabphnodfjupybae	17	18	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	17	19	cisplatin	cisplatin	NN
work_u6osxdbbyvcabphnodfjupybae	17	20	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	17	21	radiotherapy	radiotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	17	22	followed	follow	VBN
work_u6osxdbbyvcabphnodfjupybae	17	23	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	17	24	three	three	CD
work_u6osxdbbyvcabphnodfjupybae	17	25	cycles	cycle	NNS
work_u6osxdbbyvcabphnodfjupybae	17	26	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	17	27	docetaxel.4	docetaxel.4	NN
work_u6osxdbbyvcabphnodfjupybae	17	28	Another	another	DT
work_u6osxdbbyvcabphnodfjupybae	17	29	approach	approach	NN
work_u6osxdbbyvcabphnodfjupybae	17	30	using	use	VBG
work_u6osxdbbyvcabphnodfjupybae	17	31	immediate	immediate	JJ
work_u6osxdbbyvcabphnodfjupybae	17	32	concurrent	concurrent	JJ
work_u6osxdbbyvcabphnodfjupybae	17	33	carboplatin	carboplatin	NNP
work_u6osxdbbyvcabphnodfjupybae	17	34	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	17	35	paclitaxel	paclitaxel	NNP
work_u6osxdbbyvcabphnodfjupybae	17	36	radiation	radiation	NN
work_u6osxdbbyvcabphnodfjupybae	17	37	followed	follow	VBN
work_u6osxdbbyvcabphnodfjupybae	17	38	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	17	39	two	two	CD
work_u6osxdbbyvcabphnodfjupybae	17	40	additional	additional	JJ
work_u6osxdbbyvcabphnodfjupybae	17	41	cycles	cycle	NNS
work_u6osxdbbyvcabphnodfjupybae	17	42	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	17	43	every	every	DT
work_u6osxdbbyvcabphnodfjupybae	17	44	3-week	3-week	CD
work_u6osxdbbyvcabphnodfjupybae	17	45	paclitaxel	paclitaxel	NN
work_u6osxdbbyvcabphnodfjupybae	17	46	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	17	47	carboplatin	carboplatin	NNP
work_u6osxdbbyvcabphnodfjupybae	17	48	was	be	VBD
work_u6osxdbbyvcabphnodfjupybae	17	49	reported	report	VBN
work_u6osxdbbyvcabphnodfjupybae	17	50	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	17	51	Belani	Belani	NNP
work_u6osxdbbyvcabphnodfjupybae	17	52	et	et	NNP
work_u6osxdbbyvcabphnodfjupybae	17	53	al.5	al.5	VBP
work_u6osxdbbyvcabphnodfjupybae	17	54	Data	Data	NNP
work_u6osxdbbyvcabphnodfjupybae	17	55	on	on	IN
work_u6osxdbbyvcabphnodfjupybae	17	56	978	978	CD
work_u6osxdbbyvcabphnodfjupybae	17	57	American	american	JJ
work_u6osxdbbyvcabphnodfjupybae	17	58	medical	medical	JJ
work_u6osxdbbyvcabphnodfjupybae	17	59	oncologists	oncologist	NNS
work_u6osxdbbyvcabphnodfjupybae	17	60	studied	study	VBN
work_u6osxdbbyvcabphnodfjupybae	17	61	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	17	62	investigators	investigator	NNS
work_u6osxdbbyvcabphnodfjupybae	17	63	at	at	IN
work_u6osxdbbyvcabphnodfjupybae	17	64	Network	Network	NNP
work_u6osxdbbyvcabphnodfjupybae	17	65	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	17	66	Medical	Medical	NNP
work_u6osxdbbyvcabphnodfjupybae	17	67	Communications	Communications	NNPS
work_u6osxdbbyvcabphnodfjupybae	17	68	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	17	69	Research	Research	NNP
work_u6osxdbbyvcabphnodfjupybae	17	70	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	17	71	NMCR	NMCR	NNP
work_u6osxdbbyvcabphnodfjupybae	17	72	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	17	73	Analytics	analytic	NNS
work_u6osxdbbyvcabphnodfjupybae	17	74	between	between	IN
work_u6osxdbbyvcabphnodfjupybae	17	75	2005	2005	CD
work_u6osxdbbyvcabphnodfjupybae	17	76	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	17	77	before	before	IN
work_u6osxdbbyvcabphnodfjupybae	17	78	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	17	79	2007	2007	CD
work_u6osxdbbyvcabphnodfjupybae	17	80	Amer-	Amer-	NNP
work_u6osxdbbyvcabphnodfjupybae	17	81	ican	ican	JJ
work_u6osxdbbyvcabphnodfjupybae	17	82	Society	Society	NNP
work_u6osxdbbyvcabphnodfjupybae	17	83	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	17	84	Clinical	Clinical	NNP
work_u6osxdbbyvcabphnodfjupybae	17	85	Oncology	Oncology	NNP
work_u6osxdbbyvcabphnodfjupybae	17	86	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	17	87	ASCO	ASCO	NNP
work_u6osxdbbyvcabphnodfjupybae	17	88	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	17	89	Annual	Annual	NNP
work_u6osxdbbyvcabphnodfjupybae	17	90	Meeting	Meeting	NNP
work_u6osxdbbyvcabphnodfjupybae	17	91	*	*	NFP
work_u6osxdbbyvcabphnodfjupybae	17	92	NMCR	NMCR	NNP
work_u6osxdbbyvcabphnodfjupybae	17	93	Analytics	Analytics	NNP
work_u6osxdbbyvcabphnodfjupybae	17	94	,	,	,
work_u6osxdbbyvcabphnodfjupybae	17	95	Atlanta	Atlanta	NNP
work_u6osxdbbyvcabphnodfjupybae	17	96	,	,	,
work_u6osxdbbyvcabphnodfjupybae	17	97	Georgia	Georgia	NNP
work_u6osxdbbyvcabphnodfjupybae	17	98	;	;	:
work_u6osxdbbyvcabphnodfjupybae	17	99	†Swedish	†Swedish	NNP
work_u6osxdbbyvcabphnodfjupybae	17	100	Cancer	Cancer	NNP
work_u6osxdbbyvcabphnodfjupybae	17	101	Institute	Institute	NNP
work_u6osxdbbyvcabphnodfjupybae	17	102	,	,	,
work_u6osxdbbyvcabphnodfjupybae	17	103	Seattle	Seattle	NNP
work_u6osxdbbyvcabphnodfjupybae	17	104	,	,	,
work_u6osxdbbyvcabphnodfjupybae	17	105	Washington	Washington	NNP
work_u6osxdbbyvcabphnodfjupybae	17	106	;	;	:
work_u6osxdbbyvcabphnodfjupybae	17	107	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	17	108	‡Lineberger	‡Lineberger	NNP
work_u6osxdbbyvcabphnodfjupybae	17	109	Cancer	Cancer	NNP
work_u6osxdbbyvcabphnodfjupybae	17	110	Center	Center	NNP
work_u6osxdbbyvcabphnodfjupybae	17	111	,	,	,
work_u6osxdbbyvcabphnodfjupybae	17	112	University	University	NNP
work_u6osxdbbyvcabphnodfjupybae	17	113	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	17	114	North	North	NNP
work_u6osxdbbyvcabphnodfjupybae	17	115	Caro-	Caro-	NNP
work_u6osxdbbyvcabphnodfjupybae	17	116	lina	lina	NN
work_u6osxdbbyvcabphnodfjupybae	17	117	,	,	,
work_u6osxdbbyvcabphnodfjupybae	17	118	Chapel	Chapel	NNP
work_u6osxdbbyvcabphnodfjupybae	17	119	Hill	Hill	NNP
work_u6osxdbbyvcabphnodfjupybae	17	120	,	,	,
work_u6osxdbbyvcabphnodfjupybae	17	121	North	North	NNP
work_u6osxdbbyvcabphnodfjupybae	17	122	Carolina	Carolina	NNP
work_u6osxdbbyvcabphnodfjupybae	17	123	.	.	.
work_u6osxdbbyvcabphnodfjupybae	18	1	Mark	Mark	NNP
work_u6osxdbbyvcabphnodfjupybae	18	2	R.	R.	NNP
work_u6osxdbbyvcabphnodfjupybae	18	3	Green	Green	NNP
work_u6osxdbbyvcabphnodfjupybae	18	4	,	,	,
work_u6osxdbbyvcabphnodfjupybae	18	5	Laura	Laura	NNP
work_u6osxdbbyvcabphnodfjupybae	18	6	Daniels	Daniels	NNP
work_u6osxdbbyvcabphnodfjupybae	18	7	,	,	,
work_u6osxdbbyvcabphnodfjupybae	18	8	Kristine	Kristine	NNP
work_u6osxdbbyvcabphnodfjupybae	18	9	Lemke	Lemke	NNP
work_u6osxdbbyvcabphnodfjupybae	18	10	,	,	,
work_u6osxdbbyvcabphnodfjupybae	18	11	George	George	NNP
work_u6osxdbbyvcabphnodfjupybae	18	12	Rafferty	Rafferty	NNP
work_u6osxdbbyvcabphnodfjupybae	18	13	,	,	,
work_u6osxdbbyvcabphnodfjupybae	18	14	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	18	15	Lou	Lou	NNP
work_u6osxdbbyvcabphnodfjupybae	18	16	Iovino	Iovino	NNP
work_u6osxdbbyvcabphnodfjupybae	18	17	are	be	VBP
work_u6osxdbbyvcabphnodfjupybae	18	18	employees	employee	NNS
work_u6osxdbbyvcabphnodfjupybae	18	19	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	18	20	NMCR	NMCR	NNP
work_u6osxdbbyvcabphnodfjupybae	18	21	Analytics	Analytics	NNPS
work_u6osxdbbyvcabphnodfjupybae	18	22	,	,	,
work_u6osxdbbyvcabphnodfjupybae	18	23	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	18	24	market	market	NN
work_u6osxdbbyvcabphnodfjupybae	18	25	research	research	NN
work_u6osxdbbyvcabphnodfjupybae	18	26	data	datum	NNS
work_u6osxdbbyvcabphnodfjupybae	18	27	company	company	NN
work_u6osxdbbyvcabphnodfjupybae	18	28	working	work	VBG
work_u6osxdbbyvcabphnodfjupybae	18	29	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	18	30	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	18	31	pharmaceutical	pharmaceutical	JJ
work_u6osxdbbyvcabphnodfjupybae	18	32	space	space	NN
work_u6osxdbbyvcabphnodfjupybae	18	33	.	.	.
work_u6osxdbbyvcabphnodfjupybae	19	1	This	this	DT
work_u6osxdbbyvcabphnodfjupybae	19	2	work	work	NN
work_u6osxdbbyvcabphnodfjupybae	19	3	was	be	VBD
work_u6osxdbbyvcabphnodfjupybae	19	4	done	do	VBN
work_u6osxdbbyvcabphnodfjupybae	19	5	without	without	IN
work_u6osxdbbyvcabphnodfjupybae	19	6	any	any	DT
work_u6osxdbbyvcabphnodfjupybae	19	7	requests	request	NNS
work_u6osxdbbyvcabphnodfjupybae	19	8	or	or	CC
work_u6osxdbbyvcabphnodfjupybae	19	9	special	special	JJ
work_u6osxdbbyvcabphnodfjupybae	19	10	funding	funding	NN
work_u6osxdbbyvcabphnodfjupybae	19	11	from	from	IN
work_u6osxdbbyvcabphnodfjupybae	19	12	any	any	DT
work_u6osxdbbyvcabphnodfjupybae	19	13	pharmaceutical	pharmaceutical	JJ
work_u6osxdbbyvcabphnodfjupybae	19	14	com-	com-	NN
work_u6osxdbbyvcabphnodfjupybae	19	15	pany	pany	NN
work_u6osxdbbyvcabphnodfjupybae	19	16	or	or	CC
work_u6osxdbbyvcabphnodfjupybae	19	17	related	relate	VBN
work_u6osxdbbyvcabphnodfjupybae	19	18	third	third	JJ
work_u6osxdbbyvcabphnodfjupybae	19	19	party	party	NN
work_u6osxdbbyvcabphnodfjupybae	19	20	.	.	.
work_u6osxdbbyvcabphnodfjupybae	20	1	All	all	PDT
work_u6osxdbbyvcabphnodfjupybae	20	2	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	20	3	aforementioned	aforementioned	JJ
work_u6osxdbbyvcabphnodfjupybae	20	4	authors	author	NNS
work_u6osxdbbyvcabphnodfjupybae	20	5	are	be	VBP
work_u6osxdbbyvcabphnodfjupybae	20	6	full	full	JJ
work_u6osxdbbyvcabphnodfjupybae	20	7	time	time	NN
work_u6osxdbbyvcabphnodfjupybae	20	8	employees	employee	NNS
work_u6osxdbbyvcabphnodfjupybae	20	9	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	20	10	NMCR	NMCR	NNP
work_u6osxdbbyvcabphnodfjupybae	20	11	Analytics	Analytics	NNPS
work_u6osxdbbyvcabphnodfjupybae	20	12	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	20	13	none	none	NN
work_u6osxdbbyvcabphnodfjupybae	20	14	has	have	VBZ
work_u6osxdbbyvcabphnodfjupybae	20	15	received	receive	VBN
work_u6osxdbbyvcabphnodfjupybae	20	16	any	any	DT
work_u6osxdbbyvcabphnodfjupybae	20	17	personal	personal	JJ
work_u6osxdbbyvcabphnodfjupybae	20	18	financial	financial	JJ
work_u6osxdbbyvcabphnodfjupybae	20	19	consideration	consideration	NN
work_u6osxdbbyvcabphnodfjupybae	20	20	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	20	21	any	any	DT
work_u6osxdbbyvcabphnodfjupybae	20	22	aspect	aspect	NN
work_u6osxdbbyvcabphnodfjupybae	20	23	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	20	24	this	this	DT
work_u6osxdbbyvcabphnodfjupybae	20	25	work	work	NN
work_u6osxdbbyvcabphnodfjupybae	20	26	.	.	.
work_u6osxdbbyvcabphnodfjupybae	21	1	None	none	NN
work_u6osxdbbyvcabphnodfjupybae	21	2	has	have	VBZ
work_u6osxdbbyvcabphnodfjupybae	21	3	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	21	4	conflict	conflict	NN
work_u6osxdbbyvcabphnodfjupybae	21	5	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	21	6	interest	interest	NN
work_u6osxdbbyvcabphnodfjupybae	21	7	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	21	8	report	report	VB
work_u6osxdbbyvcabphnodfjupybae	21	9	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	21	10	Howard	Howard	NNP
work_u6osxdbbyvcabphnodfjupybae	21	11	West	West	NNP
work_u6osxdbbyvcabphnodfjupybae	21	12	has	have	VBZ
work_u6osxdbbyvcabphnodfjupybae	21	13	no	no	DT
work_u6osxdbbyvcabphnodfjupybae	21	14	conflicts	conflict	NNS
work_u6osxdbbyvcabphnodfjupybae	21	15	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	21	16	report	report	VB
work_u6osxdbbyvcabphnodfjupybae	21	17	concerning	concern	VBG
work_u6osxdbbyvcabphnodfjupybae	21	18	this	this	DT
work_u6osxdbbyvcabphnodfjupybae	21	19	work	work	NN
work_u6osxdbbyvcabphnodfjupybae	21	20	.	.	.
work_u6osxdbbyvcabphnodfjupybae	22	1	Address	address	NN
work_u6osxdbbyvcabphnodfjupybae	22	2	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	22	3	correspondence	correspondence	NN
work_u6osxdbbyvcabphnodfjupybae	22	4	:	:	:
work_u6osxdbbyvcabphnodfjupybae	22	5	Mark	Mark	NNP
work_u6osxdbbyvcabphnodfjupybae	22	6	R.	R.	NNP
work_u6osxdbbyvcabphnodfjupybae	22	7	Green	Green	NNP
work_u6osxdbbyvcabphnodfjupybae	22	8	,	,	,
work_u6osxdbbyvcabphnodfjupybae	22	9	MD	MD	NNP
work_u6osxdbbyvcabphnodfjupybae	22	10	,	,	,
work_u6osxdbbyvcabphnodfjupybae	22	11	NMCR	NMCR	NNP
work_u6osxdbbyvcabphnodfjupybae	22	12	Analytics	Analytics	NNP
work_u6osxdbbyvcabphnodfjupybae	22	13	,	,	,
work_u6osxdbbyvcabphnodfjupybae	22	14	780	780	CD
work_u6osxdbbyvcabphnodfjupybae	22	15	Johnson	Johnson	NNP
work_u6osxdbbyvcabphnodfjupybae	22	16	Ferry	Ferry	NNP
work_u6osxdbbyvcabphnodfjupybae	22	17	Road	Road	NNP
work_u6osxdbbyvcabphnodfjupybae	22	18	,	,	,
work_u6osxdbbyvcabphnodfjupybae	22	19	Suite	Suite	NNP
work_u6osxdbbyvcabphnodfjupybae	22	20	600	600	CD
work_u6osxdbbyvcabphnodfjupybae	22	21	,	,	,
work_u6osxdbbyvcabphnodfjupybae	22	22	Atlanta	Atlanta	NNP
work_u6osxdbbyvcabphnodfjupybae	22	23	,	,	,
work_u6osxdbbyvcabphnodfjupybae	22	24	GA	GA	NNP
work_u6osxdbbyvcabphnodfjupybae	22	25	30342	30342	CD
work_u6osxdbbyvcabphnodfjupybae	22	26	.	.	.
work_u6osxdbbyvcabphnodfjupybae	23	1	E	e	NN
work_u6osxdbbyvcabphnodfjupybae	23	2	-	-	NN
work_u6osxdbbyvcabphnodfjupybae	23	3	mail	mail	NN
work_u6osxdbbyvcabphnodfjupybae	23	4	:	:	:
work_u6osxdbbyvcabphnodfjupybae	23	5	mgreen@	mgreen@	ADD
work_u6osxdbbyvcabphnodfjupybae	23	6	nmcr.com	nmcr.com	ADD
work_u6osxdbbyvcabphnodfjupybae	23	7	Presented	present	VBN
work_u6osxdbbyvcabphnodfjupybae	23	8	at	at	IN
work_u6osxdbbyvcabphnodfjupybae	23	9	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	23	10	2008	2008	CD
work_u6osxdbbyvcabphnodfjupybae	23	11	American	American	NNP
work_u6osxdbbyvcabphnodfjupybae	23	12	Society	Society	NNP
work_u6osxdbbyvcabphnodfjupybae	23	13	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	23	14	Clinical	Clinical	NNP
work_u6osxdbbyvcabphnodfjupybae	23	15	Oncology	Oncology	NNP
work_u6osxdbbyvcabphnodfjupybae	23	16	Annual	Annual	NNP
work_u6osxdbbyvcabphnodfjupybae	23	17	Meeting	Meeting	NNP
work_u6osxdbbyvcabphnodfjupybae	23	18	,	,	,
work_u6osxdbbyvcabphnodfjupybae	23	19	Abstract	Abstract	NNP
work_u6osxdbbyvcabphnodfjupybae	23	20	No	no	NN
work_u6osxdbbyvcabphnodfjupybae	23	21	7579	7579	CD
work_u6osxdbbyvcabphnodfjupybae	23	22	.	.	.
work_u6osxdbbyvcabphnodfjupybae	24	1	Copyright	copyright	NN
work_u6osxdbbyvcabphnodfjupybae	24	2	©	©	NNP
work_u6osxdbbyvcabphnodfjupybae	24	3	2009	2009	CD
work_u6osxdbbyvcabphnodfjupybae	24	4	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	24	5	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	24	6	International	International	NNP
work_u6osxdbbyvcabphnodfjupybae	24	7	Association	Association	NNP
work_u6osxdbbyvcabphnodfjupybae	24	8	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	24	9	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	24	10	Study	Study	NNP
work_u6osxdbbyvcabphnodfjupybae	24	11	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	24	12	Lung	Lung	NNP
work_u6osxdbbyvcabphnodfjupybae	24	13	Cancer	Cancer	NNP
work_u6osxdbbyvcabphnodfjupybae	24	14	ISSN	ISSN	NNP
work_u6osxdbbyvcabphnodfjupybae	24	15	:	:	:
work_u6osxdbbyvcabphnodfjupybae	24	16	1556	1556	CD
work_u6osxdbbyvcabphnodfjupybae	24	17	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	24	18	0864/09/0408	0864/09/0408	NNP
work_u6osxdbbyvcabphnodfjupybae	24	19	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	24	20	0983	0983	CD
work_u6osxdbbyvcabphnodfjupybae	24	21	Journal	Journal	NNP
work_u6osxdbbyvcabphnodfjupybae	24	22	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	24	23	Thoracic	Thoracic	NNP
work_u6osxdbbyvcabphnodfjupybae	24	24	Oncology	Oncology	NNP
work_u6osxdbbyvcabphnodfjupybae	24	25	•	•	NNP
work_u6osxdbbyvcabphnodfjupybae	24	26	Volume	volume	NN
work_u6osxdbbyvcabphnodfjupybae	24	27	4	4	CD
work_u6osxdbbyvcabphnodfjupybae	24	28	,	,	,
work_u6osxdbbyvcabphnodfjupybae	24	29	Number	number	NN
work_u6osxdbbyvcabphnodfjupybae	24	30	8	8	CD
work_u6osxdbbyvcabphnodfjupybae	24	31	,	,	,
work_u6osxdbbyvcabphnodfjupybae	24	32	August	August	NNP
work_u6osxdbbyvcabphnodfjupybae	24	33	2009	2009	CD
work_u6osxdbbyvcabphnodfjupybae	24	34	983	983	CD
work_u6osxdbbyvcabphnodfjupybae	24	35	showed	show	VBD
work_u6osxdbbyvcabphnodfjupybae	24	36	that	that	IN
work_u6osxdbbyvcabphnodfjupybae	24	37	nearly	nearly	RB
work_u6osxdbbyvcabphnodfjupybae	24	38	70	70	CD
work_u6osxdbbyvcabphnodfjupybae	24	39	%	%	NN
work_u6osxdbbyvcabphnodfjupybae	24	40	planned	plan	VBN
work_u6osxdbbyvcabphnodfjupybae	24	41	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	24	42	use	use	VB
work_u6osxdbbyvcabphnodfjupybae	24	43	both	both	DT
work_u6osxdbbyvcabphnodfjupybae	24	44	concurrent	concurrent	JJ
work_u6osxdbbyvcabphnodfjupybae	24	45	che-	che-	NNS
work_u6osxdbbyvcabphnodfjupybae	24	46	moradiation	moradiation	NN
work_u6osxdbbyvcabphnodfjupybae	24	47	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	24	48	consolidation	consolidation	NN
work_u6osxdbbyvcabphnodfjupybae	24	49	chemotherapy	chemotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	24	50	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	24	51	this	this	DT
work_u6osxdbbyvcabphnodfjupybae	24	52	setting.6	setting.6	NN
work_u6osxdbbyvcabphnodfjupybae	24	53	At	at	IN
work_u6osxdbbyvcabphnodfjupybae	24	54	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	24	55	2007	2007	CD
work_u6osxdbbyvcabphnodfjupybae	24	56	ASCO	ASCO	NNP
work_u6osxdbbyvcabphnodfjupybae	24	57	meeting	meeting	NN
work_u6osxdbbyvcabphnodfjupybae	24	58	,	,	,
work_u6osxdbbyvcabphnodfjupybae	24	59	investigators	investigator	NNS
work_u6osxdbbyvcabphnodfjupybae	24	60	from	from	IN
work_u6osxdbbyvcabphnodfjupybae	24	61	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	24	62	Hoosier	Hoosier	NNP
work_u6osxdbbyvcabphnodfjupybae	24	63	Oncology	Oncology	NNP
work_u6osxdbbyvcabphnodfjupybae	24	64	Group7	Group7	NNP
work_u6osxdbbyvcabphnodfjupybae	24	65	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	24	66	HOG	HOG	NNP
work_u6osxdbbyvcabphnodfjupybae	24	67	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	24	68	reported	report	VBD
work_u6osxdbbyvcabphnodfjupybae	24	69	that	that	IN
work_u6osxdbbyvcabphnodfjupybae	24	70	there	there	EX
work_u6osxdbbyvcabphnodfjupybae	24	71	was	be	VBD
work_u6osxdbbyvcabphnodfjupybae	24	72	no	no	DT
work_u6osxdbbyvcabphnodfjupybae	24	73	survival	survival	NN
work_u6osxdbbyvcabphnodfjupybae	24	74	advantage	advantage	NN
work_u6osxdbbyvcabphnodfjupybae	24	75	but	but	CC
work_u6osxdbbyvcabphnodfjupybae	24	76	significant	significant	JJ
work_u6osxdbbyvcabphnodfjupybae	24	77	toxicity	toxicity	NN
work_u6osxdbbyvcabphnodfjupybae	24	78	from	from	IN
work_u6osxdbbyvcabphnodfjupybae	24	79	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	24	80	addition	addition	NN
work_u6osxdbbyvcabphnodfjupybae	24	81	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	24	82	docetaxel	docetaxel	NNP
work_u6osxdbbyvcabphnodfjupybae	24	83	consolidation	consolidation	NN
work_u6osxdbbyvcabphnodfjupybae	24	84	to	to	IN
work_u6osxdbbyvcabphnodfjupybae	24	85	immediate	immediate	JJ
work_u6osxdbbyvcabphnodfjupybae	24	86	radiation	radiation	NN
work_u6osxdbbyvcabphnodfjupybae	24	87	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	24	88	con-	con-	NN
work_u6osxdbbyvcabphnodfjupybae	24	89	current	current	JJ
work_u6osxdbbyvcabphnodfjupybae	24	90	etoposide	etoposide	NN
work_u6osxdbbyvcabphnodfjupybae	24	91	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	24	92	cisplatin	cisplatin	NN
work_u6osxdbbyvcabphnodfjupybae	24	93	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	24	94	Figure	figure	NN
work_u6osxdbbyvcabphnodfjupybae	24	95	1	1	CD
work_u6osxdbbyvcabphnodfjupybae	24	96	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	24	97	.	.	.
work_u6osxdbbyvcabphnodfjupybae	25	1	To	to	TO
work_u6osxdbbyvcabphnodfjupybae	25	2	assess	assess	VB
work_u6osxdbbyvcabphnodfjupybae	25	3	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	25	4	impact	impact	NN
work_u6osxdbbyvcabphnodfjupybae	25	5	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	25	6	these	these	DT
work_u6osxdbbyvcabphnodfjupybae	25	7	data	datum	NNS
work_u6osxdbbyvcabphnodfjupybae	25	8	,	,	,
work_u6osxdbbyvcabphnodfjupybae	25	9	we	-PRON-	PRP
work_u6osxdbbyvcabphnodfjupybae	25	10	documented	document	VBD
work_u6osxdbbyvcabphnodfjupybae	25	11	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	25	12	prescribing	prescribing	NN
work_u6osxdbbyvcabphnodfjupybae	25	13	plans	plan	NNS
work_u6osxdbbyvcabphnodfjupybae	25	14	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	25	15	nonop-	nonop-	JJ
work_u6osxdbbyvcabphnodfjupybae	25	16	erative	erative	JJ
work_u6osxdbbyvcabphnodfjupybae	25	17	therapy	therapy	NN
work_u6osxdbbyvcabphnodfjupybae	25	18	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	25	19	patients	patient	NNS
work_u6osxdbbyvcabphnodfjupybae	25	20	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	25	21	N3	n3	NN
work_u6osxdbbyvcabphnodfjupybae	25	22	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	25	23	IIIB	iiib	NN
work_u6osxdbbyvcabphnodfjupybae	25	24	NSCLC	NSCLC	NNP
work_u6osxdbbyvcabphnodfjupybae	25	25	among	among	IN
work_u6osxdbbyvcabphnodfjupybae	25	26	several	several	JJ
work_u6osxdbbyvcabphnodfjupybae	25	27	hundred	hundred	CD
work_u6osxdbbyvcabphnodfjupybae	25	28	additional	additional	JJ
work_u6osxdbbyvcabphnodfjupybae	25	29	American	american	JJ
work_u6osxdbbyvcabphnodfjupybae	25	30	medical	medical	JJ
work_u6osxdbbyvcabphnodfjupybae	25	31	oncolo-	oncolo-	NN
work_u6osxdbbyvcabphnodfjupybae	25	32	gists	gist	NNS
work_u6osxdbbyvcabphnodfjupybae	25	33	.	.	.
work_u6osxdbbyvcabphnodfjupybae	26	1	Here	here	RB
work_u6osxdbbyvcabphnodfjupybae	26	2	,	,	,
work_u6osxdbbyvcabphnodfjupybae	26	3	we	-PRON-	PRP
work_u6osxdbbyvcabphnodfjupybae	26	4	report	report	VBP
work_u6osxdbbyvcabphnodfjupybae	26	5	those	those	DT
work_u6osxdbbyvcabphnodfjupybae	26	6	prescribing	prescribing	NN
work_u6osxdbbyvcabphnodfjupybae	26	7	plans	plan	NNS
work_u6osxdbbyvcabphnodfjupybae	26	8	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	26	9	discuss	discuss	VB
work_u6osxdbbyvcabphnodfjupybae	26	10	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	26	11	impact	impact	NN
work_u6osxdbbyvcabphnodfjupybae	26	12	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	26	13	new	new	JJ
work_u6osxdbbyvcabphnodfjupybae	26	14	phase	phase	NN
work_u6osxdbbyvcabphnodfjupybae	26	15	III	iii	CD
work_u6osxdbbyvcabphnodfjupybae	26	16	data	datum	NNS
work_u6osxdbbyvcabphnodfjupybae	26	17	on	on	IN
work_u6osxdbbyvcabphnodfjupybae	26	18	treatment	treatment	NN
work_u6osxdbbyvcabphnodfjupybae	26	19	strategies	strategy	NNS
work_u6osxdbbyvcabphnodfjupybae	26	20	planned	plan	VBN
work_u6osxdbbyvcabphnodfjupybae	26	21	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	26	22	patients	patient	NNS
work_u6osxdbbyvcabphnodfjupybae	26	23	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	26	24	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	26	25	IIIB	IIIB	NNP
work_u6osxdbbyvcabphnodfjupybae	26	26	NSCLC	NSCLC	NNP
work_u6osxdbbyvcabphnodfjupybae	26	27	.	.	.
work_u6osxdbbyvcabphnodfjupybae	27	1	METHODS	METHODS	NNP
work_u6osxdbbyvcabphnodfjupybae	27	2	Since	since	IN
work_u6osxdbbyvcabphnodfjupybae	27	3	2005	2005	CD
work_u6osxdbbyvcabphnodfjupybae	27	4	,	,	,
work_u6osxdbbyvcabphnodfjupybae	27	5	NMCR	NMCR	NNP
work_u6osxdbbyvcabphnodfjupybae	27	6	Analytics	Analytics	NNP
work_u6osxdbbyvcabphnodfjupybae	27	7	has	have	VBZ
work_u6osxdbbyvcabphnodfjupybae	27	8	studied	study	VBN
work_u6osxdbbyvcabphnodfjupybae	27	9	prescribing	prescribing	NN
work_u6osxdbbyvcabphnodfjupybae	27	10	plans	plan	NNS
work_u6osxdbbyvcabphnodfjupybae	27	11	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	27	12	American	american	JJ
work_u6osxdbbyvcabphnodfjupybae	27	13	medical	medical	JJ
work_u6osxdbbyvcabphnodfjupybae	27	14	oncologists	oncologist	NNS
work_u6osxdbbyvcabphnodfjupybae	27	15	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	27	16	patients	patient	NNS
work_u6osxdbbyvcabphnodfjupybae	27	17	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	27	18	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	27	19	III	III	NNP
work_u6osxdbbyvcabphnodfjupybae	27	20	NSCLC	NSCLC	NNP
work_u6osxdbbyvcabphnodfjupybae	27	21	using	use	VBG
work_u6osxdbbyvcabphnodfjupybae	27	22	14	14	CD
work_u6osxdbbyvcabphnodfjupybae	27	23	individual	individual	JJ
work_u6osxdbbyvcabphnodfjupybae	27	24	live	live	JJ
work_u6osxdbbyvcabphnodfjupybae	27	25	research	research	NN
work_u6osxdbbyvcabphnodfjupybae	27	26	events	event	NNS
work_u6osxdbbyvcabphnodfjupybae	27	27	.	.	.
work_u6osxdbbyvcabphnodfjupybae	28	1	Physi-	Physi-	NNP
work_u6osxdbbyvcabphnodfjupybae	28	2	cians	cian	NNS
work_u6osxdbbyvcabphnodfjupybae	28	3	participating	participate	VBG
work_u6osxdbbyvcabphnodfjupybae	28	4	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	28	5	these	these	DT
work_u6osxdbbyvcabphnodfjupybae	28	6	research	research	NN
work_u6osxdbbyvcabphnodfjupybae	28	7	programs	program	NNS
work_u6osxdbbyvcabphnodfjupybae	28	8	self	self	NN
work_u6osxdbbyvcabphnodfjupybae	28	9	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	28	10	register	register	VBP
work_u6osxdbbyvcabphnodfjupybae	28	11	through	through	IN
work_u6osxdbbyvcabphnodfjupybae	28	12	direct	direct	JJ
work_u6osxdbbyvcabphnodfjupybae	28	13	invitation	invitation	NN
work_u6osxdbbyvcabphnodfjupybae	28	14	or	or	CC
work_u6osxdbbyvcabphnodfjupybae	28	15	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	28	16	means	mean	NNS
work_u6osxdbbyvcabphnodfjupybae	28	17	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	28	18	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	28	19	NMCR	NMCR	NNP
work_u6osxdbbyvcabphnodfjupybae	28	20	Analytics	Analytics	NNP
work_u6osxdbbyvcabphnodfjupybae	28	21	website	website	NN
work_u6osxdbbyvcabphnodfjupybae	28	22	.	.	.
work_u6osxdbbyvcabphnodfjupybae	29	1	Attendees	attendee	NNS
work_u6osxdbbyvcabphnodfjupybae	29	2	are	be	VBP
work_u6osxdbbyvcabphnodfjupybae	29	3	reimbursed	reimburse	VBN
work_u6osxdbbyvcabphnodfjupybae	29	4	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	29	5	research	research	NN
work_u6osxdbbyvcabphnodfjupybae	29	6	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	29	7	related	relate	VBN
work_u6osxdbbyvcabphnodfjupybae	29	8	ex-	ex-	JJ
work_u6osxdbbyvcabphnodfjupybae	29	9	penses	pense	NNS
work_u6osxdbbyvcabphnodfjupybae	29	10	including	include	VBG
work_u6osxdbbyvcabphnodfjupybae	29	11	any	any	DT
work_u6osxdbbyvcabphnodfjupybae	29	12	travel	travel	NN
work_u6osxdbbyvcabphnodfjupybae	29	13	costs	cost	NNS
work_u6osxdbbyvcabphnodfjupybae	29	14	incurred	incur	VBN
work_u6osxdbbyvcabphnodfjupybae	29	15	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	29	16	specific	specific	JJ
work_u6osxdbbyvcabphnodfjupybae	29	17	out-	out-	NN
work_u6osxdbbyvcabphnodfjupybae	29	18	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	29	19	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	29	20	pocket	pocket	NN
work_u6osxdbbyvcabphnodfjupybae	29	21	expenses	expense	NNS
work_u6osxdbbyvcabphnodfjupybae	29	22	.	.	.
work_u6osxdbbyvcabphnodfjupybae	30	1	Attendees	attendee	NNS
work_u6osxdbbyvcabphnodfjupybae	30	2	do	do	VBP
work_u6osxdbbyvcabphnodfjupybae	30	3	not	not	RB
work_u6osxdbbyvcabphnodfjupybae	30	4	receive	receive	VB
work_u6osxdbbyvcabphnodfjupybae	30	5	additional	additional	JJ
work_u6osxdbbyvcabphnodfjupybae	30	6	pay-	pay-	NNP
work_u6osxdbbyvcabphnodfjupybae	30	7	ments	ment	NNS
work_u6osxdbbyvcabphnodfjupybae	30	8	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	30	9	their	-PRON-	PRP$
work_u6osxdbbyvcabphnodfjupybae	30	10	participation	participation	NN
work_u6osxdbbyvcabphnodfjupybae	30	11	.	.	.
work_u6osxdbbyvcabphnodfjupybae	31	1	Responses	response	NNS
work_u6osxdbbyvcabphnodfjupybae	31	2	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	31	3	research	research	NN
work_u6osxdbbyvcabphnodfjupybae	31	4	queries	query	NNS
work_u6osxdbbyvcabphnodfjupybae	31	5	are	be	VBP
work_u6osxdbbyvcabphnodfjupybae	31	6	treated	treat	VBN
work_u6osxdbbyvcabphnodfjupybae	31	7	confidentially	confidentially	RB
work_u6osxdbbyvcabphnodfjupybae	31	8	,	,	,
work_u6osxdbbyvcabphnodfjupybae	31	9	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	31	10	no	no	DT
work_u6osxdbbyvcabphnodfjupybae	31	11	identifying	identify	VBG
work_u6osxdbbyvcabphnodfjupybae	31	12	information	information	NN
work_u6osxdbbyvcabphnodfjupybae	31	13	about	about	IN
work_u6osxdbbyvcabphnodfjupybae	31	14	individual	individual	JJ
work_u6osxdbbyvcabphnodfjupybae	31	15	participants	participant	NNS
work_u6osxdbbyvcabphnodfjupybae	31	16	is	be	VBZ
work_u6osxdbbyvcabphnodfjupybae	31	17	disclosed	disclose	VBN
work_u6osxdbbyvcabphnodfjupybae	31	18	.	.	.
work_u6osxdbbyvcabphnodfjupybae	32	1	Attendees	attendee	NNS
work_u6osxdbbyvcabphnodfjupybae	32	2	may	may	MD
work_u6osxdbbyvcabphnodfjupybae	32	3	participate	participate	VB
work_u6osxdbbyvcabphnodfjupybae	32	4	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	32	5	only	only	RB
work_u6osxdbbyvcabphnodfjupybae	32	6	one	one	CD
work_u6osxdbbyvcabphnodfjupybae	32	7	lung	lung	NN
work_u6osxdbbyvcabphnodfjupybae	32	8	cancer	cancer	NN
work_u6osxdbbyvcabphnodfjupybae	32	9	research	research	NN
work_u6osxdbbyvcabphnodfjupybae	32	10	event	event	NN
work_u6osxdbbyvcabphnodfjupybae	32	11	within	within	IN
work_u6osxdbbyvcabphnodfjupybae	32	12	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	32	13	calendar	calendar	NN
work_u6osxdbbyvcabphnodfjupybae	32	14	year	year	NN
work_u6osxdbbyvcabphnodfjupybae	32	15	.	.	.
work_u6osxdbbyvcabphnodfjupybae	33	1	Some	some	DT
work_u6osxdbbyvcabphnodfjupybae	33	2	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	33	3	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	33	4	prescribing	prescribing	NN
work_u6osxdbbyvcabphnodfjupybae	33	5	plans	plan	NNS
work_u6osxdbbyvcabphnodfjupybae	33	6	recorded	record	VBN
work_u6osxdbbyvcabphnodfjupybae	33	7	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	33	8	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	33	9	first	first	JJ
work_u6osxdbbyvcabphnodfjupybae	33	10	two	two	CD
work_u6osxdbbyvcabphnodfjupybae	33	11	research	research	NN
work_u6osxdbbyvcabphnodfjupybae	33	12	events	event	NNS
work_u6osxdbbyvcabphnodfjupybae	33	13	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	33	14	2008	2008	CD
work_u6osxdbbyvcabphnodfjupybae	33	15	may	may	MD
work_u6osxdbbyvcabphnodfjupybae	33	16	come	come	VB
work_u6osxdbbyvcabphnodfjupybae	33	17	from	from	IN
work_u6osxdbbyvcabphnodfjupybae	33	18	individuals	individual	NNS
work_u6osxdbbyvcabphnodfjupybae	33	19	also	also	RB
work_u6osxdbbyvcabphnodfjupybae	33	20	included	include	VBN
work_u6osxdbbyvcabphnodfjupybae	33	21	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	33	22	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	33	23	prescribing	prescribing	NN
work_u6osxdbbyvcabphnodfjupybae	33	24	plans	plan	NNS
work_u6osxdbbyvcabphnodfjupybae	33	25	tallied	tally	VBD
work_u6osxdbbyvcabphnodfjupybae	33	26	pre	pre	JJ
work_u6osxdbbyvcabphnodfjupybae	33	27	-	-	NN
work_u6osxdbbyvcabphnodfjupybae	33	28	ASCO	asco	JJ
work_u6osxdbbyvcabphnodfjupybae	33	29	2007	2007	CD
work_u6osxdbbyvcabphnodfjupybae	33	30	or	or	CC
work_u6osxdbbyvcabphnodfjupybae	33	31	post	post	NN
work_u6osxdbbyvcabphnodfjupybae	33	32	-	-	JJ
work_u6osxdbbyvcabphnodfjupybae	33	33	ASCO	asco	JJ
work_u6osxdbbyvcabphnodfjupybae	33	34	2007	2007	CD
work_u6osxdbbyvcabphnodfjupybae	33	35	.	.	.
work_u6osxdbbyvcabphnodfjupybae	34	1	Research	research	NN
work_u6osxdbbyvcabphnodfjupybae	34	2	programs	program	NNS
work_u6osxdbbyvcabphnodfjupybae	34	3	are	be	VBP
work_u6osxdbbyvcabphnodfjupybae	34	4	designed	design	VBN
work_u6osxdbbyvcabphnodfjupybae	34	5	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	34	6	mimic	mimic	VB
work_u6osxdbbyvcabphnodfjupybae	34	7	real	real	JJ
work_u6osxdbbyvcabphnodfjupybae	34	8	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	34	9	life	life	NN
work_u6osxdbbyvcabphnodfjupybae	34	10	clinical	clinical	JJ
work_u6osxdbbyvcabphnodfjupybae	34	11	scenarios	scenario	NNS
work_u6osxdbbyvcabphnodfjupybae	34	12	.	.	.
work_u6osxdbbyvcabphnodfjupybae	35	1	The	the	DT
work_u6osxdbbyvcabphnodfjupybae	35	2	hypothetical	hypothetical	JJ
work_u6osxdbbyvcabphnodfjupybae	35	3	case	case	NN
work_u6osxdbbyvcabphnodfjupybae	35	4	history	history	NN
work_u6osxdbbyvcabphnodfjupybae	35	5	is	be	VBZ
work_u6osxdbbyvcabphnodfjupybae	35	6	projected	project	VBN
work_u6osxdbbyvcabphnodfjupybae	35	7	on	on	IN
work_u6osxdbbyvcabphnodfjupybae	35	8	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	35	9	screen	screen	NN
work_u6osxdbbyvcabphnodfjupybae	35	10	at	at	IN
work_u6osxdbbyvcabphnodfjupybae	35	11	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	35	12	front	front	NN
work_u6osxdbbyvcabphnodfjupybae	35	13	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	35	14	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	35	15	meeting	meeting	NN
work_u6osxdbbyvcabphnodfjupybae	35	16	room	room	NN
work_u6osxdbbyvcabphnodfjupybae	35	17	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	35	18	read	read	VBD
work_u6osxdbbyvcabphnodfjupybae	35	19	aloud	aloud	RB
work_u6osxdbbyvcabphnodfjupybae	35	20	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	35	21	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	35	22	research	research	NN
work_u6osxdbbyvcabphnodfjupybae	35	23	event	event	NN
work_u6osxdbbyvcabphnodfjupybae	35	24	moderator	moderator	NN
work_u6osxdbbyvcabphnodfjupybae	35	25	.	.	.
work_u6osxdbbyvcabphnodfjupybae	36	1	Treatment	treatment	NN
work_u6osxdbbyvcabphnodfjupybae	36	2	plan	plan	NN
work_u6osxdbbyvcabphnodfjupybae	36	3	options	option	NNS
work_u6osxdbbyvcabphnodfjupybae	36	4	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	36	5	up	up	IN
work_u6osxdbbyvcabphnodfjupybae	36	6	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	36	7	10	10	CD
work_u6osxdbbyvcabphnodfjupybae	36	8	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	36	9	are	be	VBP
work_u6osxdbbyvcabphnodfjupybae	36	10	then	then	RB
work_u6osxdbbyvcabphnodfjupybae	36	11	offered	offer	VBN
work_u6osxdbbyvcabphnodfjupybae	36	12	,	,	,
work_u6osxdbbyvcabphnodfjupybae	36	13	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	36	14	physician	physician	NN
work_u6osxdbbyvcabphnodfjupybae	36	15	selections	selection	NNS
work_u6osxdbbyvcabphnodfjupybae	36	16	are	be	VBP
work_u6osxdbbyvcabphnodfjupybae	36	17	acquired	acquire	VBN
work_u6osxdbbyvcabphnodfjupybae	36	18	anonymously	anonymously	RB
work_u6osxdbbyvcabphnodfjupybae	36	19	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	36	20	contemporaneously	contemporaneously	RB
work_u6osxdbbyvcabphnodfjupybae	36	21	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	36	22	keypad	keypad	NNP
work_u6osxdbbyvcabphnodfjupybae	36	23	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	36	24	elec-	elec-	NNP
work_u6osxdbbyvcabphnodfjupybae	36	25	tronic	tronic	NNP
work_u6osxdbbyvcabphnodfjupybae	36	26	data	data	NNP
work_u6osxdbbyvcabphnodfjupybae	36	27	capture	capture	NN
work_u6osxdbbyvcabphnodfjupybae	36	28	before	before	IN
work_u6osxdbbyvcabphnodfjupybae	36	29	any	any	DT
work_u6osxdbbyvcabphnodfjupybae	36	30	discussion	discussion	NN
work_u6osxdbbyvcabphnodfjupybae	36	31	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	36	32	relevant	relevant	JJ
work_u6osxdbbyvcabphnodfjupybae	36	33	data	datum	NNS
work_u6osxdbbyvcabphnodfjupybae	36	34	supporting	support	VBG
work_u6osxdbbyvcabphnodfjupybae	36	35	one	one	CD
work_u6osxdbbyvcabphnodfjupybae	36	36	or	or	CC
work_u6osxdbbyvcabphnodfjupybae	36	37	more	more	JJR
work_u6osxdbbyvcabphnodfjupybae	36	38	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	36	39	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	36	40	possible	possible	JJ
work_u6osxdbbyvcabphnodfjupybae	36	41	prescribing	prescribing	NN
work_u6osxdbbyvcabphnodfjupybae	36	42	plans	plan	NNS
work_u6osxdbbyvcabphnodfjupybae	36	43	offered	offer	VBD
work_u6osxdbbyvcabphnodfjupybae	36	44	.	.	.
work_u6osxdbbyvcabphnodfjupybae	37	1	As	as	RB
work_u6osxdbbyvcabphnodfjupybae	37	2	soon	soon	RB
work_u6osxdbbyvcabphnodfjupybae	37	3	as	as	IN
work_u6osxdbbyvcabphnodfjupybae	37	4	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	37	5	participants	participant	NNS
work_u6osxdbbyvcabphnodfjupybae	37	6	have	have	VBP
work_u6osxdbbyvcabphnodfjupybae	37	7	completed	complete	VBN
work_u6osxdbbyvcabphnodfjupybae	37	8	their	-PRON-	PRP$
work_u6osxdbbyvcabphnodfjupybae	37	9	selection	selection	NN
work_u6osxdbbyvcabphnodfjupybae	37	10	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	37	11	documented	document	VBN
work_u6osxdbbyvcabphnodfjupybae	37	12	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	37	13	real	real	JJ
work_u6osxdbbyvcabphnodfjupybae	37	14	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	37	15	time	time	NN
work_u6osxdbbyvcabphnodfjupybae	37	16	counter	counter	NN
work_u6osxdbbyvcabphnodfjupybae	37	17	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	37	18	responses	response	NNS
work_u6osxdbbyvcabphnodfjupybae	37	19	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	37	20	,	,	,
work_u6osxdbbyvcabphnodfjupybae	37	21	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	37	22	results	result	NNS
work_u6osxdbbyvcabphnodfjupybae	37	23	are	be	VBP
work_u6osxdbbyvcabphnodfjupybae	37	24	tallied	tallied	JJ
work_u6osxdbbyvcabphnodfjupybae	37	25	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	37	26	projected	project	VBN
work_u6osxdbbyvcabphnodfjupybae	37	27	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	37	28	bar	bar	NN
work_u6osxdbbyvcabphnodfjupybae	37	29	graph	graph	NN
work_u6osxdbbyvcabphnodfjupybae	37	30	format	format	NN
work_u6osxdbbyvcabphnodfjupybae	37	31	.	.	.
work_u6osxdbbyvcabphnodfjupybae	38	1	Demographic	demographic	JJ
work_u6osxdbbyvcabphnodfjupybae	38	2	information	information	NN
work_u6osxdbbyvcabphnodfjupybae	38	3	is	be	VBZ
work_u6osxdbbyvcabphnodfjupybae	38	4	collected	collect	VBN
work_u6osxdbbyvcabphnodfjupybae	38	5	from	from	IN
work_u6osxdbbyvcabphnodfjupybae	38	6	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	38	7	partic-	partic-	JJ
work_u6osxdbbyvcabphnodfjupybae	38	8	ipants	ipant	NNS
work_u6osxdbbyvcabphnodfjupybae	38	9	at	at	IN
work_u6osxdbbyvcabphnodfjupybae	38	10	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	38	11	beginning	beginning	NN
work_u6osxdbbyvcabphnodfjupybae	38	12	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	38	13	each	each	DT
work_u6osxdbbyvcabphnodfjupybae	38	14	research	research	NN
work_u6osxdbbyvcabphnodfjupybae	38	15	session	session	NN
work_u6osxdbbyvcabphnodfjupybae	38	16	.	.	.
work_u6osxdbbyvcabphnodfjupybae	39	1	The	the	DT
work_u6osxdbbyvcabphnodfjupybae	39	2	charac-	charac-	JJ
work_u6osxdbbyvcabphnodfjupybae	39	3	teristics	teristic	NNS
work_u6osxdbbyvcabphnodfjupybae	39	4	polled	poll	VBN
work_u6osxdbbyvcabphnodfjupybae	39	5	include	include	VBP
work_u6osxdbbyvcabphnodfjupybae	39	6	practice	practice	NN
work_u6osxdbbyvcabphnodfjupybae	39	7	venue	venue	NN
work_u6osxdbbyvcabphnodfjupybae	39	8	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	39	9	academic	academic	JJ
work_u6osxdbbyvcabphnodfjupybae	39	10	versus	versus	IN
work_u6osxdbbyvcabphnodfjupybae	39	11	com-	com-	NN
work_u6osxdbbyvcabphnodfjupybae	39	12	munity	munity	NN
work_u6osxdbbyvcabphnodfjupybae	39	13	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	39	14	geographic	geographic	JJ
work_u6osxdbbyvcabphnodfjupybae	39	15	region	region	NN
work_u6osxdbbyvcabphnodfjupybae	39	16	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	39	17	,	,	,
work_u6osxdbbyvcabphnodfjupybae	39	18	number	number	NN
work_u6osxdbbyvcabphnodfjupybae	39	19	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	39	20	partners	partner	NNS
work_u6osxdbbyvcabphnodfjupybae	39	21	,	,	,
work_u6osxdbbyvcabphnodfjupybae	39	22	years	year	NNS
work_u6osxdbbyvcabphnodfjupybae	39	23	from	from	IN
work_u6osxdbbyvcabphnodfjupybae	39	24	completion	completion	NN
work_u6osxdbbyvcabphnodfjupybae	39	25	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	39	26	training	training	NN
work_u6osxdbbyvcabphnodfjupybae	39	27	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	39	28	oncology	oncology	NN
work_u6osxdbbyvcabphnodfjupybae	39	29	,	,	,
work_u6osxdbbyvcabphnodfjupybae	39	30	number	number	NN
work_u6osxdbbyvcabphnodfjupybae	39	31	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	39	32	new	new	JJ
work_u6osxdbbyvcabphnodfjupybae	39	33	lung	lung	NN
work_u6osxdbbyvcabphnodfjupybae	39	34	cancer	cancer	NN
work_u6osxdbbyvcabphnodfjupybae	39	35	patients	patient	NNS
work_u6osxdbbyvcabphnodfjupybae	39	36	seen	see	VBN
work_u6osxdbbyvcabphnodfjupybae	39	37	each	each	DT
work_u6osxdbbyvcabphnodfjupybae	39	38	month	month	NN
work_u6osxdbbyvcabphnodfjupybae	39	39	,	,	,
work_u6osxdbbyvcabphnodfjupybae	39	40	sex	sex	NN
work_u6osxdbbyvcabphnodfjupybae	39	41	,	,	,
work_u6osxdbbyvcabphnodfjupybae	39	42	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	39	43	participation	participation	NN
work_u6osxdbbyvcabphnodfjupybae	39	44	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	39	45	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	39	46	group	group	NN
work_u6osxdbbyvcabphnodfjupybae	39	47	purchasing	purchasing	NN
work_u6osxdbbyvcabphnodfjupybae	39	48	organization	organization	NN
work_u6osxdbbyvcabphnodfjupybae	39	49	.	.	.
work_u6osxdbbyvcabphnodfjupybae	40	1	These	these	DT
work_u6osxdbbyvcabphnodfjupybae	40	2	features	feature	NNS
work_u6osxdbbyvcabphnodfjupybae	40	3	are	be	VBP
work_u6osxdbbyvcabphnodfjupybae	40	4	entered	enter	VBN
work_u6osxdbbyvcabphnodfjupybae	40	5	into	into	IN
work_u6osxdbbyvcabphnodfjupybae	40	6	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	40	7	wireless	wireless	JJ
work_u6osxdbbyvcabphnodfjupybae	40	8	keypad	keypad	NN
work_u6osxdbbyvcabphnodfjupybae	40	9	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	40	10	each	each	DT
work_u6osxdbbyvcabphnodfjupybae	40	11	attendee	attendee	NN
work_u6osxdbbyvcabphnodfjupybae	40	12	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	40	13	response	response	NN
work_u6osxdbbyvcabphnodfjupybae	40	14	to	to	IN
work_u6osxdbbyvcabphnodfjupybae	40	15	specific	specific	JJ
work_u6osxdbbyvcabphnodfjupybae	40	16	questions	question	NNS
work_u6osxdbbyvcabphnodfjupybae	40	17	.	.	.
work_u6osxdbbyvcabphnodfjupybae	41	1	This	this	DT
work_u6osxdbbyvcabphnodfjupybae	41	2	information	information	NN
work_u6osxdbbyvcabphnodfjupybae	41	3	then	then	RB
work_u6osxdbbyvcabphnodfjupybae	41	4	gives	give	VBZ
work_u6osxdbbyvcabphnodfjupybae	41	5	each	each	DT
work_u6osxdbbyvcabphnodfjupybae	41	6	keypad	keypad	NN
work_u6osxdbbyvcabphnodfjupybae	41	7	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	41	8	demographic	demographic	JJ
work_u6osxdbbyvcabphnodfjupybae	41	9	character	character	NN
work_u6osxdbbyvcabphnodfjupybae	41	10	that	that	WDT
work_u6osxdbbyvcabphnodfjupybae	41	11	can	can	MD
work_u6osxdbbyvcabphnodfjupybae	41	12	be	be	VB
work_u6osxdbbyvcabphnodfjupybae	41	13	used	use	VBN
work_u6osxdbbyvcabphnodfjupybae	41	14	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	41	15	analyze	analyze	VB
work_u6osxdbbyvcabphnodfjupybae	41	16	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	41	17	re-	re-	JJ
work_u6osxdbbyvcabphnodfjupybae	41	18	spondent	spondent	NN
work_u6osxdbbyvcabphnodfjupybae	41	19	choices	choice	NNS
work_u6osxdbbyvcabphnodfjupybae	41	20	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	41	21	subset	subset	NN
work_u6osxdbbyvcabphnodfjupybae	41	22	while	while	IN
work_u6osxdbbyvcabphnodfjupybae	41	23	maintaining	maintain	VBG
work_u6osxdbbyvcabphnodfjupybae	41	24	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	41	25	anonymity	anonymity	NN
work_u6osxdbbyvcabphnodfjupybae	41	26	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	41	27	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	41	28	individual	individual	JJ
work_u6osxdbbyvcabphnodfjupybae	41	29	participants	participant	NNS
work_u6osxdbbyvcabphnodfjupybae	41	30	.	.	.
work_u6osxdbbyvcabphnodfjupybae	42	1	To	to	TO
work_u6osxdbbyvcabphnodfjupybae	42	2	study	study	VB
work_u6osxdbbyvcabphnodfjupybae	42	3	current	current	JJ
work_u6osxdbbyvcabphnodfjupybae	42	4	approaches	approach	NNS
work_u6osxdbbyvcabphnodfjupybae	42	5	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	42	6	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	42	7	patient	patient	NN
work_u6osxdbbyvcabphnodfjupybae	42	8	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	42	9	N3	n3	NN
work_u6osxdbbyvcabphnodfjupybae	42	10	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	42	11	IIIB	IIIB	NNP
work_u6osxdbbyvcabphnodfjupybae	42	12	NSCLC	NSCLC	NNP
work_u6osxdbbyvcabphnodfjupybae	42	13	,	,	,
work_u6osxdbbyvcabphnodfjupybae	42	14	we	-PRON-	PRP
work_u6osxdbbyvcabphnodfjupybae	42	15	used	use	VBD
work_u6osxdbbyvcabphnodfjupybae	42	16	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	42	17	core	core	NN
work_u6osxdbbyvcabphnodfjupybae	42	18	case	case	NN
work_u6osxdbbyvcabphnodfjupybae	42	19	history	history	NN
work_u6osxdbbyvcabphnodfjupybae	42	20	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	42	21	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	42	22	“	"	``
work_u6osxdbbyvcabphnodfjupybae	42	23	menu	menu	NN
work_u6osxdbbyvcabphnodfjupybae	42	24	”	"	''
work_u6osxdbbyvcabphnodfjupybae	42	25	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	42	26	preset	preset	JJ
work_u6osxdbbyvcabphnodfjupybae	42	27	treatment	treatment	NN
work_u6osxdbbyvcabphnodfjupybae	42	28	plans	plan	NNS
work_u6osxdbbyvcabphnodfjupybae	42	29	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	42	30	Figures	figure	NNS
work_u6osxdbbyvcabphnodfjupybae	42	31	2	2	CD
work_u6osxdbbyvcabphnodfjupybae	42	32	,	,	,
work_u6osxdbbyvcabphnodfjupybae	42	33	3	3	CD
work_u6osxdbbyvcabphnodfjupybae	42	34	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	42	35	.	.	.
work_u6osxdbbyvcabphnodfjupybae	43	1	Oncologists	oncologist	NNS
work_u6osxdbbyvcabphnodfjupybae	43	2	are	be	VBP
work_u6osxdbbyvcabphnodfjupybae	43	3	very	very	RB
work_u6osxdbbyvcabphnodfjupybae	43	4	familiar	familiar	JJ
work_u6osxdbbyvcabphnodfjupybae	43	5	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	43	6	this	this	DT
work_u6osxdbbyvcabphnodfjupybae	43	7	approach	approach	NN
work_u6osxdbbyvcabphnodfjupybae	43	8	.	.	.
work_u6osxdbbyvcabphnodfjupybae	44	1	Case	case	NN
work_u6osxdbbyvcabphnodfjupybae	44	2	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	44	3	based	base	VBN
work_u6osxdbbyvcabphnodfjupybae	44	4	decision	decision	NN
work_u6osxdbbyvcabphnodfjupybae	44	5	making	making	NN
work_u6osxdbbyvcabphnodfjupybae	44	6	is	be	VBZ
work_u6osxdbbyvcabphnodfjupybae	44	7	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	44	8	standard	standard	JJ
work_u6osxdbbyvcabphnodfjupybae	44	9	format	format	NN
work_u6osxdbbyvcabphnodfjupybae	44	10	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	44	11	tumor	tumor	NN
work_u6osxdbbyvcabphnodfjupybae	44	12	board	board	NN
work_u6osxdbbyvcabphnodfjupybae	44	13	or	or	CC
work_u6osxdbbyvcabphnodfjupybae	44	14	clinical	clinical	JJ
work_u6osxdbbyvcabphnodfjupybae	44	15	case	case	NN
work_u6osxdbbyvcabphnodfjupybae	44	16	confer-	confer-	IN
work_u6osxdbbyvcabphnodfjupybae	44	17	ence	ence	NN
work_u6osxdbbyvcabphnodfjupybae	44	18	discussions	discussion	NNS
work_u6osxdbbyvcabphnodfjupybae	44	19	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	44	20	potential	potential	JJ
work_u6osxdbbyvcabphnodfjupybae	44	21	management	management	NN
work_u6osxdbbyvcabphnodfjupybae	44	22	options	option	NNS
work_u6osxdbbyvcabphnodfjupybae	44	23	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	44	24	indi-	indi-	NNP
work_u6osxdbbyvcabphnodfjupybae	44	25	vidual	vidual	JJ
work_u6osxdbbyvcabphnodfjupybae	44	26	patients	patient	NNS
work_u6osxdbbyvcabphnodfjupybae	44	27	.	.	.
work_u6osxdbbyvcabphnodfjupybae	45	1	Although	although	IN
work_u6osxdbbyvcabphnodfjupybae	45	2	this	this	DT
work_u6osxdbbyvcabphnodfjupybae	45	3	format	format	NN
work_u6osxdbbyvcabphnodfjupybae	45	4	can	can	MD
work_u6osxdbbyvcabphnodfjupybae	45	5	not	not	RB
work_u6osxdbbyvcabphnodfjupybae	45	6	encompass	encompass	VB
work_u6osxdbbyvcabphnodfjupybae	45	7	all	all	DT
work_u6osxdbbyvcabphnodfjupybae	45	8	possible	possible	JJ
work_u6osxdbbyvcabphnodfjupybae	45	9	treatment	treatment	NN
work_u6osxdbbyvcabphnodfjupybae	45	10	plans	plan	NNS
work_u6osxdbbyvcabphnodfjupybae	45	11	among	among	IN
work_u6osxdbbyvcabphnodfjupybae	45	12	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	45	13	options	option	NNS
work_u6osxdbbyvcabphnodfjupybae	45	14	offered	offer	VBN
work_u6osxdbbyvcabphnodfjupybae	45	15	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	45	16	�	�	NNP
work_u6osxdbbyvcabphnodfjupybae	45	17	10	10	CD
work_u6osxdbbyvcabphnodfjupybae	45	18	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	45	19	,	,	,
work_u6osxdbbyvcabphnodfjupybae	45	20	we	-PRON-	PRP
work_u6osxdbbyvcabphnodfjupybae	45	21	include	include	VBP
work_u6osxdbbyvcabphnodfjupybae	45	22	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	45	23	broad	broad	JJ
work_u6osxdbbyvcabphnodfjupybae	45	24	range	range	NN
work_u6osxdbbyvcabphnodfjupybae	45	25	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	45	26	relevant	relevant	JJ
work_u6osxdbbyvcabphnodfjupybae	45	27	options	option	NNS
work_u6osxdbbyvcabphnodfjupybae	45	28	including	include	VBG
work_u6osxdbbyvcabphnodfjupybae	45	29	all	all	DT
work_u6osxdbbyvcabphnodfjupybae	45	30	relevant	relevant	JJ
work_u6osxdbbyvcabphnodfjupybae	45	31	evidence	evidence	NN
work_u6osxdbbyvcabphnodfjupybae	45	32	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	45	33	based	base	VBN
work_u6osxdbbyvcabphnodfjupybae	45	34	strategies	strategy	NNS
work_u6osxdbbyvcabphnodfjupybae	45	35	.	.	.
work_u6osxdbbyvcabphnodfjupybae	46	1	An	an	DT
work_u6osxdbbyvcabphnodfjupybae	46	2	option	option	NN
work_u6osxdbbyvcabphnodfjupybae	46	3	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	46	4	“	"	``
work_u6osxdbbyvcabphnodfjupybae	46	5	other	other	JJ
work_u6osxdbbyvcabphnodfjupybae	46	6	”	"	''
work_u6osxdbbyvcabphnodfjupybae	46	7	is	be	VBZ
work_u6osxdbbyvcabphnodfjupybae	46	8	also	also	RB
work_u6osxdbbyvcabphnodfjupybae	46	9	included	include	VBN
work_u6osxdbbyvcabphnodfjupybae	46	10	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	46	11	avoid	avoid	VB
work_u6osxdbbyvcabphnodfjupybae	46	12	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	46	13	forced	force	VBN
work_u6osxdbbyvcabphnodfjupybae	46	14	choice	choice	NN
work_u6osxdbbyvcabphnodfjupybae	46	15	.	.	.
work_u6osxdbbyvcabphnodfjupybae	47	1	Not	not	RB
work_u6osxdbbyvcabphnodfjupybae	47	2	all	all	DT
work_u6osxdbbyvcabphnodfjupybae	47	3	attendees	attendee	NNS
work_u6osxdbbyvcabphnodfjupybae	47	4	respond	respond	VBP
work_u6osxdbbyvcabphnodfjupybae	47	5	to	to	IN
work_u6osxdbbyvcabphnodfjupybae	47	6	every	every	DT
work_u6osxdbbyvcabphnodfjupybae	47	7	research	research	NN
work_u6osxdbbyvcabphnodfjupybae	47	8	question	question	NN
work_u6osxdbbyvcabphnodfjupybae	47	9	posed	pose	VBN
work_u6osxdbbyvcabphnodfjupybae	47	10	,	,	,
work_u6osxdbbyvcabphnodfjupybae	47	11	but	but	CC
work_u6osxdbbyvcabphnodfjupybae	47	12	overall	overall	JJ
work_u6osxdbbyvcabphnodfjupybae	47	13	participation	participation	NN
work_u6osxdbbyvcabphnodfjupybae	47	14	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	47	15	more	more	JJR
work_u6osxdbbyvcabphnodfjupybae	47	16	than	than	IN
work_u6osxdbbyvcabphnodfjupybae	47	17	80	80	CD
work_u6osxdbbyvcabphnodfjupybae	47	18	%	%	NN
work_u6osxdbbyvcabphnodfjupybae	47	19	is	be	VBZ
work_u6osxdbbyvcabphnodfjupybae	47	20	achieved	achieve	VBN
work_u6osxdbbyvcabphnodfjupybae	47	21	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	47	22	each	each	DT
work_u6osxdbbyvcabphnodfjupybae	47	23	question	question	NN
work_u6osxdbbyvcabphnodfjupybae	47	24	.	.	.
work_u6osxdbbyvcabphnodfjupybae	48	1	FIGURE	FIGURE	NNP
work_u6osxdbbyvcabphnodfjupybae	48	2	1	1	CD
work_u6osxdbbyvcabphnodfjupybae	48	3	.	.	.
work_u6osxdbbyvcabphnodfjupybae	49	1	Schema	Schema	NNP
work_u6osxdbbyvcabphnodfjupybae	49	2	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	49	3	Hoosier	Hoosier	NNP
work_u6osxdbbyvcabphnodfjupybae	49	4	Oncology	Oncology	NNP
work_u6osxdbbyvcabphnodfjupybae	49	5	Group	Group	NNP
work_u6osxdbbyvcabphnodfjupybae	49	6	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	49	7	HOG	HOG	NNP
work_u6osxdbbyvcabphnodfjupybae	49	8	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	49	9	trial	trial	NN
work_u6osxdbbyvcabphnodfjupybae	49	10	evaluating	evaluate	VBG
work_u6osxdbbyvcabphnodfjupybae	49	11	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	49	12	role	role	NN
work_u6osxdbbyvcabphnodfjupybae	49	13	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	49	14	docetaxel	docetaxel	NNP
work_u6osxdbbyvcabphnodfjupybae	49	15	consolidation	consolidation	NN
work_u6osxdbbyvcabphnodfjupybae	49	16	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	49	17	pa-	pa-	NN
work_u6osxdbbyvcabphnodfjupybae	49	18	tients	tient	NNS
work_u6osxdbbyvcabphnodfjupybae	49	19	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	49	20	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	49	21	new	new	JJ
work_u6osxdbbyvcabphnodfjupybae	49	22	diagnosis	diagnosis	NN
work_u6osxdbbyvcabphnodfjupybae	49	23	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	49	24	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	49	25	III	iii	CD
work_u6osxdbbyvcabphnodfjupybae	49	26	non	non	JJ
work_u6osxdbbyvcabphnodfjupybae	49	27	-	-	JJ
work_u6osxdbbyvcabphnodfjupybae	49	28	small	small	JJ
work_u6osxdbbyvcabphnodfjupybae	49	29	cell	cell	NN
work_u6osxdbbyvcabphnodfjupybae	49	30	lung	lung	NN
work_u6osxdbbyvcabphnodfjupybae	49	31	cancer	cancer	NN
work_u6osxdbbyvcabphnodfjupybae	49	32	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	49	33	NSCLC	NSCLC	NNP
work_u6osxdbbyvcabphnodfjupybae	49	34	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	49	35	.	.	.
work_u6osxdbbyvcabphnodfjupybae	50	1	A	a	DT
work_u6osxdbbyvcabphnodfjupybae	50	2	66-year	66-year	CD
work_u6osxdbbyvcabphnodfjupybae	50	3	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	50	4	old	old	JJ
work_u6osxdbbyvcabphnodfjupybae	50	5	former	former	JJ
work_u6osxdbbyvcabphnodfjupybae	50	6	smoker	smoker	NN
work_u6osxdbbyvcabphnodfjupybae	50	7	has	have	VBZ
work_u6osxdbbyvcabphnodfjupybae	50	8	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	50	9	progressive	progressive	JJ
work_u6osxdbbyvcabphnodfjupybae	50	10	cough	cough	NN
work_u6osxdbbyvcabphnodfjupybae	50	11	.	.	.
work_u6osxdbbyvcabphnodfjupybae	51	1	After	after	IN
work_u6osxdbbyvcabphnodfjupybae	51	2	an	an	DT
work_u6osxdbbyvcabphnodfjupybae	51	3	episode	episode	NN
work_u6osxdbbyvcabphnodfjupybae	51	4	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	51	5	hemoptysis	hemoptysis	NN
work_u6osxdbbyvcabphnodfjupybae	51	6	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	51	7	actually	actually	RB
work_u6osxdbbyvcabphnodfjupybae	51	8	only	only	RB
work_u6osxdbbyvcabphnodfjupybae	51	9	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	51	10	small	small	JJ
work_u6osxdbbyvcabphnodfjupybae	51	11	amount	amount	NN
work_u6osxdbbyvcabphnodfjupybae	51	12	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	51	13	bloody	bloody	JJ
work_u6osxdbbyvcabphnodfjupybae	51	14	sputum	sputum	NN
work_u6osxdbbyvcabphnodfjupybae	51	15	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	51	16	he	-PRON-	PRP
work_u6osxdbbyvcabphnodfjupybae	51	17	is	be	VBZ
work_u6osxdbbyvcabphnodfjupybae	51	18	seen	see	VBN
work_u6osxdbbyvcabphnodfjupybae	51	19	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	51	20	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	51	21	ER	ER	NNP
work_u6osxdbbyvcabphnodfjupybae	51	22	where	where	WRB
work_u6osxdbbyvcabphnodfjupybae	51	23	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	51	24	chest	chest	NN
work_u6osxdbbyvcabphnodfjupybae	51	25	x	x	NN
work_u6osxdbbyvcabphnodfjupybae	51	26	-	-	NN
work_u6osxdbbyvcabphnodfjupybae	51	27	ray	ray	NN
work_u6osxdbbyvcabphnodfjupybae	51	28	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	51	29	chest	chest	NN
work_u6osxdbbyvcabphnodfjupybae	51	30	CT	CT	NNP
work_u6osxdbbyvcabphnodfjupybae	51	31	are	be	VBP
work_u6osxdbbyvcabphnodfjupybae	51	32	done	do	VBN
work_u6osxdbbyvcabphnodfjupybae	51	33	.	.	.
work_u6osxdbbyvcabphnodfjupybae	52	1	There	there	EX
work_u6osxdbbyvcabphnodfjupybae	52	2	is	be	VBZ
work_u6osxdbbyvcabphnodfjupybae	52	3	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	52	4	partially	partially	RB
work_u6osxdbbyvcabphnodfjupybae	52	5	cavitated	cavitate	VBN
work_u6osxdbbyvcabphnodfjupybae	52	6	,	,	,
work_u6osxdbbyvcabphnodfjupybae	52	7	medially	medially	RB
work_u6osxdbbyvcabphnodfjupybae	52	8	located	locate	VBN
work_u6osxdbbyvcabphnodfjupybae	52	9	,	,	,
work_u6osxdbbyvcabphnodfjupybae	52	10	RUL	RUL	NNP
work_u6osxdbbyvcabphnodfjupybae	52	11	mass	mass	NN
work_u6osxdbbyvcabphnodfjupybae	52	12	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	52	13	enlarged	enlarged	JJ
work_u6osxdbbyvcabphnodfjupybae	52	14	hilar	hilar	NNP
work_u6osxdbbyvcabphnodfjupybae	52	15	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	52	16	N2	N2	NNP
work_u6osxdbbyvcabphnodfjupybae	52	17	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	52	18	N3	N3	NNP
work_u6osxdbbyvcabphnodfjupybae	52	19	mediastinal	mediastinal	JJ
work_u6osxdbbyvcabphnodfjupybae	52	20	nodes	node	NNS
work_u6osxdbbyvcabphnodfjupybae	52	21	.	.	.
work_u6osxdbbyvcabphnodfjupybae	53	1	A	a	DT
work_u6osxdbbyvcabphnodfjupybae	53	2	pulmonary	pulmonary	JJ
work_u6osxdbbyvcabphnodfjupybae	53	3	medicine	medicine	NN
work_u6osxdbbyvcabphnodfjupybae	53	4	physician	physician	NN
work_u6osxdbbyvcabphnodfjupybae	53	5	sees	see	VBZ
work_u6osxdbbyvcabphnodfjupybae	53	6	him	-PRON-	PRP
work_u6osxdbbyvcabphnodfjupybae	53	7	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	53	8	arranges	arrange	VBZ
work_u6osxdbbyvcabphnodfjupybae	53	9	an	an	DT
work_u6osxdbbyvcabphnodfjupybae	53	10	urgent	urgent	JJ
work_u6osxdbbyvcabphnodfjupybae	53	11	bronchoscopy	bronchoscopy	NN
work_u6osxdbbyvcabphnodfjupybae	53	12	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	53	13	TBB	TBB	NNP
work_u6osxdbbyvcabphnodfjupybae	53	14	specimen	specimen	VBZ
work_u6osxdbbyvcabphnodfjupybae	53	15	positive	positive	JJ
work_u6osxdbbyvcabphnodfjupybae	53	16	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	53	17	NSCLC	NSCLC	NNP
work_u6osxdbbyvcabphnodfjupybae	53	18	NOS	NOS	NNP
work_u6osxdbbyvcabphnodfjupybae	53	19	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	53	20	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	53	21	Wang	Wang	NNP
work_u6osxdbbyvcabphnodfjupybae	53	22	needle	needle	NN
work_u6osxdbbyvcabphnodfjupybae	53	23	aspiration	aspiration	NN
work_u6osxdbbyvcabphnodfjupybae	53	24	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	53	25	subcarinal	subcarinal	JJ
work_u6osxdbbyvcabphnodfjupybae	53	26	nodes	node	NNS
work_u6osxdbbyvcabphnodfjupybae	53	27	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	53	28	also	also	RB
work_u6osxdbbyvcabphnodfjupybae	53	29	+	+	NNS
work_u6osxdbbyvcabphnodfjupybae	53	30	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	53	31	tumor	tumor	NN
work_u6osxdbbyvcabphnodfjupybae	53	32	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	53	33	.	.	.
work_u6osxdbbyvcabphnodfjupybae	54	1	A	a	DT
work_u6osxdbbyvcabphnodfjupybae	54	2	PET	PET	NNP
work_u6osxdbbyvcabphnodfjupybae	54	3	scan	scan	NN
work_u6osxdbbyvcabphnodfjupybae	54	4	is	be	VBZ
work_u6osxdbbyvcabphnodfjupybae	54	5	positive	positive	JJ
work_u6osxdbbyvcabphnodfjupybae	54	6	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	54	7	these	these	DT
work_u6osxdbbyvcabphnodfjupybae	54	8	areas	area	NNS
work_u6osxdbbyvcabphnodfjupybae	54	9	as	as	RB
work_u6osxdbbyvcabphnodfjupybae	54	10	well	well	RB
work_u6osxdbbyvcabphnodfjupybae	54	11	as	as	IN
work_u6osxdbbyvcabphnodfjupybae	54	12	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	54	13	right	right	JJ
work_u6osxdbbyvcabphnodfjupybae	54	14	hilum	hilum	NN
work_u6osxdbbyvcabphnodfjupybae	54	15	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	54	16	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	54	17	right	right	NN
work_u6osxdbbyvcabphnodfjupybae	54	18	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	54	19	left	leave	VBD
work_u6osxdbbyvcabphnodfjupybae	54	20	paratracheal	paratracheal	NN
work_u6osxdbbyvcabphnodfjupybae	54	21	areas	area	NNS
work_u6osxdbbyvcabphnodfjupybae	54	22	.	.	.
work_u6osxdbbyvcabphnodfjupybae	55	1	A	a	DT
work_u6osxdbbyvcabphnodfjupybae	55	2	head	head	NN
work_u6osxdbbyvcabphnodfjupybae	55	3	MRI	MRI	NNP
work_u6osxdbbyvcabphnodfjupybae	55	4	is	be	VBZ
work_u6osxdbbyvcabphnodfjupybae	55	5	negative	negative	JJ
work_u6osxdbbyvcabphnodfjupybae	55	6	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	55	7	metastatic	metastatic	JJ
work_u6osxdbbyvcabphnodfjupybae	55	8	disease	disease	NN
work_u6osxdbbyvcabphnodfjupybae	55	9	.	.	.
work_u6osxdbbyvcabphnodfjupybae	56	1	FIGURE	FIGURE	NNP
work_u6osxdbbyvcabphnodfjupybae	56	2	2	2	CD
work_u6osxdbbyvcabphnodfjupybae	56	3	.	.	.
work_u6osxdbbyvcabphnodfjupybae	57	1	Case	case	NN
work_u6osxdbbyvcabphnodfjupybae	57	2	scenario	scenario	NN
work_u6osxdbbyvcabphnodfjupybae	57	3	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	57	4	assessing	assess	VBG
work_u6osxdbbyvcabphnodfjupybae	57	5	prescribing	prescribing	NN
work_u6osxdbbyvcabphnodfjupybae	57	6	plans	plan	NNS
work_u6osxdbbyvcabphnodfjupybae	57	7	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	57	8	American	american	JJ
work_u6osxdbbyvcabphnodfjupybae	57	9	medical	medical	JJ
work_u6osxdbbyvcabphnodfjupybae	57	10	oncologists	oncologist	NNS
work_u6osxdbbyvcabphnodfjupybae	57	11	.	.	.
work_u6osxdbbyvcabphnodfjupybae	58	1	No	no	DT
work_u6osxdbbyvcabphnodfjupybae	58	2	changes	change	NNS
work_u6osxdbbyvcabphnodfjupybae	58	3	were	be	VBD
work_u6osxdbbyvcabphnodfjupybae	58	4	made	make	VBN
work_u6osxdbbyvcabphnodfjupybae	58	5	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	58	6	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	58	7	case	case	NN
work_u6osxdbbyvcabphnodfjupybae	58	8	scenario	scenario	NN
work_u6osxdbbyvcabphnodfjupybae	58	9	during	during	IN
work_u6osxdbbyvcabphnodfjupybae	58	10	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	58	11	entire	entire	JJ
work_u6osxdbbyvcabphnodfjupybae	58	12	period	period	NN
work_u6osxdbbyvcabphnodfjupybae	58	13	reported	report	VBD
work_u6osxdbbyvcabphnodfjupybae	58	14	.	.	.
work_u6osxdbbyvcabphnodfjupybae	59	1	1	1	LS
work_u6osxdbbyvcabphnodfjupybae	59	2	.	.	.
work_u6osxdbbyvcabphnodfjupybae	60	1	Immediate	Immediate	NNP
work_u6osxdbbyvcabphnodfjupybae	60	2	TRT	TRT	NNP
work_u6osxdbbyvcabphnodfjupybae	60	3	followed	follow	VBD
work_u6osxdbbyvcabphnodfjupybae	60	4	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	60	5	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	60	6	f	f	NNP
work_u6osxdbbyvcabphnodfjupybae	60	7	/	/	SYM
work_u6osxdbbyvcabphnodfjupybae	60	8	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	60	9	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	60	10	CT	CT	NNP
work_u6osxdbbyvcabphnodfjupybae	60	11	2	2	CD
work_u6osxdbbyvcabphnodfjupybae	60	12	.	.	.
work_u6osxdbbyvcabphnodfjupybae	61	1	Induction	Induction	NNP
work_u6osxdbbyvcabphnodfjupybae	61	2	CT	CT	NNP
work_u6osxdbbyvcabphnodfjupybae	61	3	f	f	NNP
work_u6osxdbbyvcabphnodfjupybae	61	4	/	/	SYM
work_u6osxdbbyvcabphnodfjupybae	61	5	byTRT	byTRT	NNP
work_u6osxdbbyvcabphnodfjupybae	61	6	3	3	CD
work_u6osxdbbyvcabphnodfjupybae	61	7	.	.	.
work_u6osxdbbyvcabphnodfjupybae	62	1	2	2	CD
work_u6osxdbbyvcabphnodfjupybae	62	2	cycles	cycle	NNS
work_u6osxdbbyvcabphnodfjupybae	62	3	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	62	4	induction	induction	NN
work_u6osxdbbyvcabphnodfjupybae	62	5	CT	CT	NNP
work_u6osxdbbyvcabphnodfjupybae	62	6	f	f	NNP
work_u6osxdbbyvcabphnodfjupybae	62	7	/	/	SYM
work_u6osxdbbyvcabphnodfjupybae	62	8	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	62	9	CT	CT	NNP
work_u6osxdbbyvcabphnodfjupybae	62	10	/	/	SYM
work_u6osxdbbyvcabphnodfjupybae	62	11	TRT	TRT	NNP
work_u6osxdbbyvcabphnodfjupybae	62	12	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	62	13	same	same	JJ
work_u6osxdbbyvcabphnodfjupybae	62	14	drugs	drug	NNS
work_u6osxdbbyvcabphnodfjupybae	62	15	as	as	IN
work_u6osxdbbyvcabphnodfjupybae	62	16	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	62	17	induction	induction	NN
work_u6osxdbbyvcabphnodfjupybae	62	18	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	62	19	4	4	CD
work_u6osxdbbyvcabphnodfjupybae	62	20	.	.	.
work_u6osxdbbyvcabphnodfjupybae	63	1	CT	CT	NNP
work_u6osxdbbyvcabphnodfjupybae	63	2	/	/	SYM
work_u6osxdbbyvcabphnodfjupybae	63	3	TRT	TRT	NNP
work_u6osxdbbyvcabphnodfjupybae	63	4	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	63	5	no	no	DT
work_u6osxdbbyvcabphnodfjupybae	63	6	induction	induction	NN
work_u6osxdbbyvcabphnodfjupybae	63	7	or	or	CC
work_u6osxdbbyvcabphnodfjupybae	63	8	consolidation	consolidation	NN
work_u6osxdbbyvcabphnodfjupybae	63	9	CT	CT	NNP
work_u6osxdbbyvcabphnodfjupybae	63	10	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	63	11	5	5	CD
work_u6osxdbbyvcabphnodfjupybae	63	12	.	.	.
work_u6osxdbbyvcabphnodfjupybae	64	1	CT	CT	NNP
work_u6osxdbbyvcabphnodfjupybae	64	2	/	/	SYM
work_u6osxdbbyvcabphnodfjupybae	64	3	TRT	TRT	NNP
work_u6osxdbbyvcabphnodfjupybae	64	4	f	f	NNP
work_u6osxdbbyvcabphnodfjupybae	64	5	/	/	SYM
work_u6osxdbbyvcabphnodfjupybae	64	6	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	64	7	2	2	CD
work_u6osxdbbyvcabphnodfjupybae	64	8	added	add	VBN
work_u6osxdbbyvcabphnodfjupybae	64	9	cycles	cycle	NNS
work_u6osxdbbyvcabphnodfjupybae	64	10	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	64	11	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	64	12	same	same	JJ
work_u6osxdbbyvcabphnodfjupybae	64	13	CT	CT	NNP
work_u6osxdbbyvcabphnodfjupybae	64	14	used	use	VBN
work_u6osxdbbyvcabphnodfjupybae	64	15	during	during	IN
work_u6osxdbbyvcabphnodfjupybae	64	16	radiation	radiation	NN
work_u6osxdbbyvcabphnodfjupybae	64	17	6	6	CD
work_u6osxdbbyvcabphnodfjupybae	64	18	.	.	.
work_u6osxdbbyvcabphnodfjupybae	65	1	CT	CT	NNP
work_u6osxdbbyvcabphnodfjupybae	65	2	/	/	SYM
work_u6osxdbbyvcabphnodfjupybae	65	3	TRT	TRT	NNP
work_u6osxdbbyvcabphnodfjupybae	65	4	f	f	NNP
work_u6osxdbbyvcabphnodfjupybae	65	5	/	/	SYM
work_u6osxdbbyvcabphnodfjupybae	65	6	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	65	7	3	3	CD
work_u6osxdbbyvcabphnodfjupybae	65	8	doses	dose	NNS
work_u6osxdbbyvcabphnodfjupybae	65	9	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	65	10	docetaxel	docetaxel	NNP
work_u6osxdbbyvcabphnodfjupybae	65	11	7	7	CD
work_u6osxdbbyvcabphnodfjupybae	65	12	.	.	.
work_u6osxdbbyvcabphnodfjupybae	66	1	CT	CT	NNP
work_u6osxdbbyvcabphnodfjupybae	66	2	/	/	SYM
work_u6osxdbbyvcabphnodfjupybae	66	3	TRT	TRT	NNP
work_u6osxdbbyvcabphnodfjupybae	66	4	f	f	NNP
work_u6osxdbbyvcabphnodfjupybae	66	5	/	/	SYM
work_u6osxdbbyvcabphnodfjupybae	66	6	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	66	7	3	3	CD
work_u6osxdbbyvcabphnodfjupybae	66	8	doses	dose	NNS
work_u6osxdbbyvcabphnodfjupybae	66	9	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	66	10	docetaxel	docetaxel	NNP
work_u6osxdbbyvcabphnodfjupybae	66	11	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	66	12	then	then	RB
work_u6osxdbbyvcabphnodfjupybae	66	13	single	single	JJ
work_u6osxdbbyvcabphnodfjupybae	66	14	agent	agent	NN
work_u6osxdbbyvcabphnodfjupybae	66	15	erlotinib	erlotinib	NNP
work_u6osxdbbyvcabphnodfjupybae	66	16	.	.	.
work_u6osxdbbyvcabphnodfjupybae	67	1	8	8	LS
work_u6osxdbbyvcabphnodfjupybae	67	2	.	.	.
work_u6osxdbbyvcabphnodfjupybae	68	1	CT	CT	NNP
work_u6osxdbbyvcabphnodfjupybae	68	2	alone	alone	RB
work_u6osxdbbyvcabphnodfjupybae	68	3	9	9	CD
work_u6osxdbbyvcabphnodfjupybae	68	4	.	.	.
work_u6osxdbbyvcabphnodfjupybae	69	1	Other	other	JJ
work_u6osxdbbyvcabphnodfjupybae	69	2	TRT	TRT	NNP
work_u6osxdbbyvcabphnodfjupybae	69	3	=	=	SYM
work_u6osxdbbyvcabphnodfjupybae	69	4	Thoracic	Thoracic	NNP
work_u6osxdbbyvcabphnodfjupybae	69	5	radiotherapy	radiotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	69	6	;	;	:
work_u6osxdbbyvcabphnodfjupybae	69	7	CT	CT	NNP
work_u6osxdbbyvcabphnodfjupybae	69	8	=	=	SYM
work_u6osxdbbyvcabphnodfjupybae	69	9	Chemotherapy	Chemotherapy	NNP
work_u6osxdbbyvcabphnodfjupybae	69	10	;	;	:
work_u6osxdbbyvcabphnodfjupybae	69	11	CT	CT	NNP
work_u6osxdbbyvcabphnodfjupybae	69	12	/	/	SYM
work_u6osxdbbyvcabphnodfjupybae	69	13	TRT	TRT	NNP
work_u6osxdbbyvcabphnodfjupybae	69	14	=	=	SYM
work_u6osxdbbyvcabphnodfjupybae	69	15	concurrent	concurrent	JJ
work_u6osxdbbyvcabphnodfjupybae	69	16	chemoradiotherapy	chemoradiotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	69	17	FIGURE	FIGURE	NNP
work_u6osxdbbyvcabphnodfjupybae	69	18	3	3	CD
work_u6osxdbbyvcabphnodfjupybae	69	19	.	.	.
work_u6osxdbbyvcabphnodfjupybae	70	1	Prescribing	prescribing	NN
work_u6osxdbbyvcabphnodfjupybae	70	2	plans	plan	NNS
work_u6osxdbbyvcabphnodfjupybae	70	3	offered	offer	VBD
work_u6osxdbbyvcabphnodfjupybae	70	4	as	as	IN
work_u6osxdbbyvcabphnodfjupybae	70	5	selection	selection	NN
work_u6osxdbbyvcabphnodfjupybae	70	6	options	option	NNS
work_u6osxdbbyvcabphnodfjupybae	70	7	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	70	8	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	70	9	research	research	NN
work_u6osxdbbyvcabphnodfjupybae	70	10	study	study	NN
work_u6osxdbbyvcabphnodfjupybae	70	11	participants	participant	NNS
work_u6osxdbbyvcabphnodfjupybae	70	12	.	.	.
work_u6osxdbbyvcabphnodfjupybae	71	1	The	the	DT
work_u6osxdbbyvcabphnodfjupybae	71	2	option	option	NN
work_u6osxdbbyvcabphnodfjupybae	71	3	“	"	``
work_u6osxdbbyvcabphnodfjupybae	71	4	other	other	JJ
work_u6osxdbbyvcabphnodfjupybae	71	5	”	"	''
work_u6osxdbbyvcabphnodfjupybae	71	6	is	be	VBZ
work_u6osxdbbyvcabphnodfjupybae	71	7	rou-	rou-	RB
work_u6osxdbbyvcabphnodfjupybae	71	8	tinely	tinely	RB
work_u6osxdbbyvcabphnodfjupybae	71	9	included	include	VBN
work_u6osxdbbyvcabphnodfjupybae	71	10	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	71	11	avoid	avoid	VB
work_u6osxdbbyvcabphnodfjupybae	71	12	driving	drive	VBG
work_u6osxdbbyvcabphnodfjupybae	71	13	research	research	NN
work_u6osxdbbyvcabphnodfjupybae	71	14	participants	participant	NNS
work_u6osxdbbyvcabphnodfjupybae	71	15	to	to	IN
work_u6osxdbbyvcabphnodfjupybae	71	16	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	71	17	“	"	``
work_u6osxdbbyvcabphnodfjupybae	71	18	forced	force	VBN
work_u6osxdbbyvcabphnodfjupybae	71	19	choice	choice	NN
work_u6osxdbbyvcabphnodfjupybae	71	20	”	"	''
work_u6osxdbbyvcabphnodfjupybae	71	21	selection	selection	NN
work_u6osxdbbyvcabphnodfjupybae	71	22	.	.	.
work_u6osxdbbyvcabphnodfjupybae	72	1	Green	Green	NNP
work_u6osxdbbyvcabphnodfjupybae	72	2	et	et	FW
work_u6osxdbbyvcabphnodfjupybae	72	3	al	al	NNP
work_u6osxdbbyvcabphnodfjupybae	72	4	.	.	.
work_u6osxdbbyvcabphnodfjupybae	73	1	Journal	Journal	NNP
work_u6osxdbbyvcabphnodfjupybae	73	2	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	73	3	Thoracic	Thoracic	NNP
work_u6osxdbbyvcabphnodfjupybae	73	4	Oncology	Oncology	NNP
work_u6osxdbbyvcabphnodfjupybae	73	5	•	•	NNP
work_u6osxdbbyvcabphnodfjupybae	73	6	Volume	volume	NN
work_u6osxdbbyvcabphnodfjupybae	73	7	4	4	CD
work_u6osxdbbyvcabphnodfjupybae	73	8	,	,	,
work_u6osxdbbyvcabphnodfjupybae	73	9	Number	number	NN
work_u6osxdbbyvcabphnodfjupybae	73	10	8	8	CD
work_u6osxdbbyvcabphnodfjupybae	73	11	,	,	,
work_u6osxdbbyvcabphnodfjupybae	73	12	August	August	NNP
work_u6osxdbbyvcabphnodfjupybae	73	13	2009	2009	CD
work_u6osxdbbyvcabphnodfjupybae	73	14	Copyright	copyright	NN
work_u6osxdbbyvcabphnodfjupybae	73	15	©	©	NNP
work_u6osxdbbyvcabphnodfjupybae	73	16	2009	2009	CD
work_u6osxdbbyvcabphnodfjupybae	73	17	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	73	18	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	73	19	International	International	NNP
work_u6osxdbbyvcabphnodfjupybae	73	20	Association	Association	NNP
work_u6osxdbbyvcabphnodfjupybae	73	21	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	73	22	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	73	23	Study	Study	NNP
work_u6osxdbbyvcabphnodfjupybae	73	24	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	73	25	Lung	Lung	NNP
work_u6osxdbbyvcabphnodfjupybae	73	26	Cancer984	Cancer984	NNP
work_u6osxdbbyvcabphnodfjupybae	73	27	RESULTS	RESULTS	NNP
work_u6osxdbbyvcabphnodfjupybae	73	28	Between	between	IN
work_u6osxdbbyvcabphnodfjupybae	73	29	March	March	NNP
work_u6osxdbbyvcabphnodfjupybae	73	30	2005	2005	CD
work_u6osxdbbyvcabphnodfjupybae	73	31	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	73	32	May	May	NNP
work_u6osxdbbyvcabphnodfjupybae	73	33	2007	2007	CD
work_u6osxdbbyvcabphnodfjupybae	73	34	,	,	,
work_u6osxdbbyvcabphnodfjupybae	73	35	978	978	CD
work_u6osxdbbyvcabphnodfjupybae	73	36	medical	medical	JJ
work_u6osxdbbyvcabphnodfjupybae	73	37	oncologists	oncologist	NNS
work_u6osxdbbyvcabphnodfjupybae	73	38	participated	participate	VBD
work_u6osxdbbyvcabphnodfjupybae	73	39	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	73	40	12	12	CD
work_u6osxdbbyvcabphnodfjupybae	73	41	live	live	JJ
work_u6osxdbbyvcabphnodfjupybae	73	42	research	research	NN
work_u6osxdbbyvcabphnodfjupybae	73	43	events	event	NNS
work_u6osxdbbyvcabphnodfjupybae	73	44	studying	study	VBG
work_u6osxdbbyvcabphnodfjupybae	73	45	prescribing	prescribing	NN
work_u6osxdbbyvcabphnodfjupybae	73	46	plans	plan	NNS
work_u6osxdbbyvcabphnodfjupybae	73	47	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	73	48	different	different	JJ
work_u6osxdbbyvcabphnodfjupybae	73	49	clinical	clinical	JJ
work_u6osxdbbyvcabphnodfjupybae	73	50	settings	setting	NNS
work_u6osxdbbyvcabphnodfjupybae	73	51	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	73	52	lung	lung	NN
work_u6osxdbbyvcabphnodfjupybae	73	53	cancer	cancer	NN
work_u6osxdbbyvcabphnodfjupybae	73	54	.	.	.
work_u6osxdbbyvcabphnodfjupybae	74	1	These	these	DT
work_u6osxdbbyvcabphnodfjupybae	74	2	individuals	individual	NNS
work_u6osxdbbyvcabphnodfjupybae	74	3	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	74	4	those	those	DT
work_u6osxdbbyvcabphnodfjupybae	74	5	queried	query	VBN
work_u6osxdbbyvcabphnodfjupybae	74	6	after	after	IN
work_u6osxdbbyvcabphnodfjupybae	74	7	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	74	8	2007	2007	CD
work_u6osxdbbyvcabphnodfjupybae	74	9	ASCO	ASCO	NNP
work_u6osxdbbyvcabphnodfjupybae	74	10	meeting	meeting	NN
work_u6osxdbbyvcabphnodfjupybae	74	11	were	be	VBD
work_u6osxdbbyvcabphnodfjupybae	74	12	�	�	NNP
work_u6osxdbbyvcabphnodfjupybae	74	13	80	80	CD
work_u6osxdbbyvcabphnodfjupybae	74	14	%	%	NN
work_u6osxdbbyvcabphnodfjupybae	74	15	self	self	NN
work_u6osxdbbyvcabphnodfjupybae	74	16	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	74	17	identified	identify	VBN
work_u6osxdbbyvcabphnodfjupybae	74	18	as	as	IN
work_u6osxdbbyvcabphnodfjupybae	74	19	“	"	``
work_u6osxdbbyvcabphnodfjupybae	74	20	community	community	NN
work_u6osxdbbyvcabphnodfjupybae	74	21	based	base	VBN
work_u6osxdbbyvcabphnodfjupybae	74	22	”	"	''
work_u6osxdbbyvcabphnodfjupybae	74	23	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	74	24	displayed	display	VBD
work_u6osxdbbyvcabphnodfjupybae	74	25	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	74	26	geographic	geographic	JJ
work_u6osxdbbyvcabphnodfjupybae	74	27	spread	spread	NN
work_u6osxdbbyvcabphnodfjupybae	74	28	reflective	reflective	JJ
work_u6osxdbbyvcabphnodfjupybae	74	29	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	74	30	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	74	31	broad	broad	JJ
work_u6osxdbbyvcabphnodfjupybae	74	32	American	American	NNP
work_u6osxdbbyvcabphnodfjupybae	74	33	Oncology	Oncology	NNP
work_u6osxdbbyvcabphnodfjupybae	74	34	workforce	workforce	NN
work_u6osxdbbyvcabphnodfjupybae	74	35	.	.	.
work_u6osxdbbyvcabphnodfjupybae	75	1	Less	Less	JJR
work_u6osxdbbyvcabphnodfjupybae	75	2	than	than	IN
work_u6osxdbbyvcabphnodfjupybae	75	3	25	25	CD
work_u6osxdbbyvcabphnodfjupybae	75	4	%	%	NN
work_u6osxdbbyvcabphnodfjupybae	75	5	were	be	VBD
work_u6osxdbbyvcabphnodfjupybae	75	6	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	75	7	solo	solo	NN
work_u6osxdbbyvcabphnodfjupybae	75	8	practice	practice	NN
work_u6osxdbbyvcabphnodfjupybae	75	9	,	,	,
work_u6osxdbbyvcabphnodfjupybae	75	10	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	75	11	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	75	12	majority	majority	NN
work_u6osxdbbyvcabphnodfjupybae	75	13	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	75	14	all	all	DT
work_u6osxdbbyvcabphnodfjupybae	75	15	respondents	respondent	NNS
work_u6osxdbbyvcabphnodfjupybae	75	16	were	be	VBD
work_u6osxdbbyvcabphnodfjupybae	75	17	more	more	JJR
work_u6osxdbbyvcabphnodfjupybae	75	18	than	than	IN
work_u6osxdbbyvcabphnodfjupybae	75	19	10	10	CD
work_u6osxdbbyvcabphnodfjupybae	75	20	years	year	NNS
work_u6osxdbbyvcabphnodfjupybae	75	21	out	out	IN
work_u6osxdbbyvcabphnodfjupybae	75	22	from	from	IN
work_u6osxdbbyvcabphnodfjupybae	75	23	completion	completion	NN
work_u6osxdbbyvcabphnodfjupybae	75	24	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	75	25	their	-PRON-	PRP$
work_u6osxdbbyvcabphnodfjupybae	75	26	oncology	oncology	NN
work_u6osxdbbyvcabphnodfjupybae	75	27	training	training	NN
work_u6osxdbbyvcabphnodfjupybae	75	28	.	.	.
work_u6osxdbbyvcabphnodfjupybae	76	1	In	in	IN
work_u6osxdbbyvcabphnodfjupybae	76	2	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	76	3	assessment	assessment	NN
work_u6osxdbbyvcabphnodfjupybae	76	4	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	76	5	prescribing	prescribing	NN
work_u6osxdbbyvcabphnodfjupybae	76	6	plans	plan	NNS
work_u6osxdbbyvcabphnodfjupybae	76	7	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	76	8	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	76	9	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	76	10	IIIB	IIIB	NNP
work_u6osxdbbyvcabphnodfjupybae	76	11	setting	setting	NN
work_u6osxdbbyvcabphnodfjupybae	76	12	,	,	,
work_u6osxdbbyvcabphnodfjupybae	76	13	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	76	14	substantial	substantial	JJ
work_u6osxdbbyvcabphnodfjupybae	76	15	majority	majority	NN
work_u6osxdbbyvcabphnodfjupybae	76	16	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	76	17	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	76	18	978	978	CD
work_u6osxdbbyvcabphnodfjupybae	76	19	responding	respond	VBG
work_u6osxdbbyvcabphnodfjupybae	76	20	physi-	physi-	NN
work_u6osxdbbyvcabphnodfjupybae	76	21	cians	cian	NNS
work_u6osxdbbyvcabphnodfjupybae	76	22	planned	plan	VBD
work_u6osxdbbyvcabphnodfjupybae	76	23	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	76	24	use	use	VB
work_u6osxdbbyvcabphnodfjupybae	76	25	concurrent	concurrent	JJ
work_u6osxdbbyvcabphnodfjupybae	76	26	chemoradiotherapy	chemoradiotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	76	27	followed	follow	VBN
work_u6osxdbbyvcabphnodfjupybae	76	28	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	76	29	additional	additional	JJ
work_u6osxdbbyvcabphnodfjupybae	76	30	chemotherapy	chemotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	76	31	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	76	32	Figure	figure	NN
work_u6osxdbbyvcabphnodfjupybae	76	33	4	4	CD
work_u6osxdbbyvcabphnodfjupybae	76	34	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	76	35	.	.	.
work_u6osxdbbyvcabphnodfjupybae	77	1	For	for	IN
work_u6osxdbbyvcabphnodfjupybae	77	2	47	47	CD
work_u6osxdbbyvcabphnodfjupybae	77	3	%	%	NN
work_u6osxdbbyvcabphnodfjupybae	77	4	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	77	5	physi-	physi-	JJ
work_u6osxdbbyvcabphnodfjupybae	77	6	cians	cians	NNPS
work_u6osxdbbyvcabphnodfjupybae	77	7	,	,	,
work_u6osxdbbyvcabphnodfjupybae	77	8	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	77	9	planned	plan	VBN
work_u6osxdbbyvcabphnodfjupybae	77	10	therapy	therapy	NN
work_u6osxdbbyvcabphnodfjupybae	77	11	was	be	VBD
work_u6osxdbbyvcabphnodfjupybae	77	12	immediate	immediate	JJ
work_u6osxdbbyvcabphnodfjupybae	77	13	chemoradiation	chemoradiation	NN
work_u6osxdbbyvcabphnodfjupybae	77	14	followed	follow	VBN
work_u6osxdbbyvcabphnodfjupybae	77	15	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	77	16	three	three	CD
work_u6osxdbbyvcabphnodfjupybae	77	17	doses	dose	NNS
work_u6osxdbbyvcabphnodfjupybae	77	18	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	77	19	docetaxel	docetaxel	NNP
work_u6osxdbbyvcabphnodfjupybae	77	20	consolidation	consolidation	NN
work_u6osxdbbyvcabphnodfjupybae	77	21	.	.	.
work_u6osxdbbyvcabphnodfjupybae	78	1	For	for	IN
work_u6osxdbbyvcabphnodfjupybae	78	2	3	3	CD
work_u6osxdbbyvcabphnodfjupybae	78	3	%	%	NN
work_u6osxdbbyvcabphnodfjupybae	78	4	,	,	,
work_u6osxdbbyvcabphnodfjupybae	78	5	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	78	6	plan	plan	NN
work_u6osxdbbyvcabphnodfjupybae	78	7	included	include	VBD
work_u6osxdbbyvcabphnodfjupybae	78	8	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	78	9	same	same	JJ
work_u6osxdbbyvcabphnodfjupybae	78	10	chemoradiation	chemoradiation	NN
work_u6osxdbbyvcabphnodfjupybae	78	11	followed	follow	VBN
work_u6osxdbbyvcabphnodfjupybae	78	12	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	78	13	three	three	CD
work_u6osxdbbyvcabphnodfjupybae	78	14	doses	dose	NNS
work_u6osxdbbyvcabphnodfjupybae	78	15	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	78	16	docetaxel	docetaxel	NNP
work_u6osxdbbyvcabphnodfjupybae	78	17	consolidation	consolidation	NN
work_u6osxdbbyvcabphnodfjupybae	78	18	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	78	19	then	then	RB
work_u6osxdbbyvcabphnodfjupybae	78	20	additional	additional	JJ
work_u6osxdbbyvcabphnodfjupybae	78	21	mainte-	mainte-	XX
work_u6osxdbbyvcabphnodfjupybae	78	22	nance	nance	NN
work_u6osxdbbyvcabphnodfjupybae	78	23	therapy	therapy	NN
work_u6osxdbbyvcabphnodfjupybae	78	24	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	78	25	an	an	DT
work_u6osxdbbyvcabphnodfjupybae	78	26	oral	oral	JJ
work_u6osxdbbyvcabphnodfjupybae	78	27	antiepidermal	antiepidermal	JJ
work_u6osxdbbyvcabphnodfjupybae	78	28	growth	growth	NN
work_u6osxdbbyvcabphnodfjupybae	78	29	factor	factor	NN
work_u6osxdbbyvcabphnodfjupybae	78	30	re-	re-	RB
work_u6osxdbbyvcabphnodfjupybae	78	31	ceptor	ceptor	NN
work_u6osxdbbyvcabphnodfjupybae	78	32	tyrosine	tyrosine	NN
work_u6osxdbbyvcabphnodfjupybae	78	33	kinase	kinase	NN
work_u6osxdbbyvcabphnodfjupybae	78	34	inhibitor	inhibitor	NN
work_u6osxdbbyvcabphnodfjupybae	78	35	.	.	.
work_u6osxdbbyvcabphnodfjupybae	79	1	An	an	DT
work_u6osxdbbyvcabphnodfjupybae	79	2	additional	additional	JJ
work_u6osxdbbyvcabphnodfjupybae	79	3	17	17	CD
work_u6osxdbbyvcabphnodfjupybae	79	4	%	%	NN
work_u6osxdbbyvcabphnodfjupybae	79	5	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	79	6	re-	re-	JJ
work_u6osxdbbyvcabphnodfjupybae	79	7	spondents	spondent	NNS
work_u6osxdbbyvcabphnodfjupybae	79	8	favored	favor	VBD
work_u6osxdbbyvcabphnodfjupybae	79	9	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	79	10	use	use	NN
work_u6osxdbbyvcabphnodfjupybae	79	11	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	79	12	immediate	immediate	JJ
work_u6osxdbbyvcabphnodfjupybae	79	13	chemoradiotherapy	chemoradiotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	79	14	followed	follow	VBN
work_u6osxdbbyvcabphnodfjupybae	79	15	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	79	16	two	two	CD
work_u6osxdbbyvcabphnodfjupybae	79	17	additional	additional	JJ
work_u6osxdbbyvcabphnodfjupybae	79	18	cycles	cycle	NNS
work_u6osxdbbyvcabphnodfjupybae	79	19	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	79	20	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	79	21	same	same	JJ
work_u6osxdbbyvcabphnodfjupybae	79	22	chemotherapy	chemotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	79	23	used	use	VBN
work_u6osxdbbyvcabphnodfjupybae	79	24	during	during	IN
work_u6osxdbbyvcabphnodfjupybae	79	25	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	79	26	concurrent	concurrent	JJ
work_u6osxdbbyvcabphnodfjupybae	79	27	phase	phase	NN
work_u6osxdbbyvcabphnodfjupybae	79	28	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	79	29	treatment	treatment	NN
work_u6osxdbbyvcabphnodfjupybae	79	30	.	.	.
work_u6osxdbbyvcabphnodfjupybae	80	1	In	in	IN
work_u6osxdbbyvcabphnodfjupybae	80	2	2007	2007	CD
work_u6osxdbbyvcabphnodfjupybae	80	3	,	,	,
work_u6osxdbbyvcabphnodfjupybae	80	4	we	-PRON-	PRP
work_u6osxdbbyvcabphnodfjupybae	80	5	studied	study	VBD
work_u6osxdbbyvcabphnodfjupybae	80	6	an	an	DT
work_u6osxdbbyvcabphnodfjupybae	80	7	additional	additional	JJ
work_u6osxdbbyvcabphnodfjupybae	80	8	427	427	CD
work_u6osxdbbyvcabphnodfjupybae	80	9	physicians	physician	NNS
work_u6osxdbbyvcabphnodfjupybae	80	10	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	80	11	pre-	pre-	RB
work_u6osxdbbyvcabphnodfjupybae	80	12	set	set	VBN
work_u6osxdbbyvcabphnodfjupybae	80	13	participation	participation	NN
work_u6osxdbbyvcabphnodfjupybae	80	14	goal	goal	NN
work_u6osxdbbyvcabphnodfjupybae	80	15	�	�	NNP
work_u6osxdbbyvcabphnodfjupybae	80	16	400	400	CD
work_u6osxdbbyvcabphnodfjupybae	80	17	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	80	18	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	80	19	five	five	CD
work_u6osxdbbyvcabphnodfjupybae	80	20	live	live	JJ
work_u6osxdbbyvcabphnodfjupybae	80	21	research	research	NN
work_u6osxdbbyvcabphnodfjupybae	80	22	events	event	NNS
work_u6osxdbbyvcabphnodfjupybae	80	23	held	hold	VBN
work_u6osxdbbyvcabphnodfjupybae	80	24	between	between	IN
work_u6osxdbbyvcabphnodfjupybae	80	25	March	March	NNP
work_u6osxdbbyvcabphnodfjupybae	80	26	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	80	27	September	September	NNP
work_u6osxdbbyvcabphnodfjupybae	80	28	.	.	.
work_u6osxdbbyvcabphnodfjupybae	81	1	Demographic	demographic	JJ
work_u6osxdbbyvcabphnodfjupybae	81	2	characteristics	characteristic	NNS
work_u6osxdbbyvcabphnodfjupybae	81	3	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	81	4	these	these	DT
work_u6osxdbbyvcabphnodfjupybae	81	5	research	research	NN
work_u6osxdbbyvcabphnodfjupybae	81	6	participants	participant	NNS
work_u6osxdbbyvcabphnodfjupybae	81	7	were	be	VBD
work_u6osxdbbyvcabphnodfjupybae	81	8	similar	similar	JJ
work_u6osxdbbyvcabphnodfjupybae	81	9	to	to	IN
work_u6osxdbbyvcabphnodfjupybae	81	10	those	those	DT
work_u6osxdbbyvcabphnodfjupybae	81	11	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	81	12	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	81	13	earlier	early	JJR
work_u6osxdbbyvcabphnodfjupybae	81	14	987	987	CD
work_u6osxdbbyvcabphnodfjupybae	81	15	physician	physician	NN
work_u6osxdbbyvcabphnodfjupybae	81	16	cohort	cohort	NN
work_u6osxdbbyvcabphnodfjupybae	81	17	.	.	.
work_u6osxdbbyvcabphnodfjupybae	82	1	These	these	DT
work_u6osxdbbyvcabphnodfjupybae	82	2	research	research	NN
work_u6osxdbbyvcabphnodfjupybae	82	3	events	event	NNS
work_u6osxdbbyvcabphnodfjupybae	82	4	again	again	RB
work_u6osxdbbyvcabphnodfjupybae	82	5	used	use	VBD
work_u6osxdbbyvcabphnodfjupybae	82	6	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	82	7	same	same	JJ
work_u6osxdbbyvcabphnodfjupybae	82	8	clinical	clinical	JJ
work_u6osxdbbyvcabphnodfjupybae	82	9	scenario	scenario	NN
work_u6osxdbbyvcabphnodfjupybae	82	10	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	82	11	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	82	12	IIIB	IIIB	NNP
work_u6osxdbbyvcabphnodfjupybae	82	13	disease	disease	NN
work_u6osxdbbyvcabphnodfjupybae	82	14	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	82	15	offered	offer	VBD
work_u6osxdbbyvcabphnodfjupybae	82	16	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	82	17	same	same	JJ
work_u6osxdbbyvcabphnodfjupybae	82	18	panel	panel	NN
work_u6osxdbbyvcabphnodfjupybae	82	19	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	82	20	therapy	therapy	NN
work_u6osxdbbyvcabphnodfjupybae	82	21	options	option	NNS
work_u6osxdbbyvcabphnodfjupybae	82	22	.	.	.
work_u6osxdbbyvcabphnodfjupybae	83	1	In	in	IN
work_u6osxdbbyvcabphnodfjupybae	83	2	Figure	Figure	NNP
work_u6osxdbbyvcabphnodfjupybae	83	3	5	5	CD
work_u6osxdbbyvcabphnodfjupybae	83	4	,	,	,
work_u6osxdbbyvcabphnodfjupybae	83	5	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	83	6	aggregate	aggregate	JJ
work_u6osxdbbyvcabphnodfjupybae	83	7	findings	finding	NNS
work_u6osxdbbyvcabphnodfjupybae	83	8	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	83	9	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	83	10	five	five	CD
work_u6osxdbbyvcabphnodfjupybae	83	11	research	research	NN
work_u6osxdbbyvcabphnodfjupybae	83	12	events	event	NNS
work_u6osxdbbyvcabphnodfjupybae	83	13	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	83	14	2007	2007	CD
work_u6osxdbbyvcabphnodfjupybae	83	15	are	be	VBP
work_u6osxdbbyvcabphnodfjupybae	83	16	shown	show	VBN
work_u6osxdbbyvcabphnodfjupybae	83	17	,	,	,
work_u6osxdbbyvcabphnodfjupybae	83	18	whereas	whereas	IN
work_u6osxdbbyvcabphnodfjupybae	83	19	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	83	20	Figure	Figure	NNP
work_u6osxdbbyvcabphnodfjupybae	83	21	6	6	CD
work_u6osxdbbyvcabphnodfjupybae	83	22	,	,	,
work_u6osxdbbyvcabphnodfjupybae	83	23	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	83	24	data	datum	NNS
work_u6osxdbbyvcabphnodfjupybae	83	25	are	be	VBP
work_u6osxdbbyvcabphnodfjupybae	83	26	broken	break	VBN
work_u6osxdbbyvcabphnodfjupybae	83	27	down	down	RP
work_u6osxdbbyvcabphnodfjupybae	83	28	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	83	29	pre	pre	JJ
work_u6osxdbbyvcabphnodfjupybae	83	30	-	-	NN
work_u6osxdbbyvcabphnodfjupybae	83	31	ASCO	asco	JJ
work_u6osxdbbyvcabphnodfjupybae	83	32	2007	2007	CD
work_u6osxdbbyvcabphnodfjupybae	83	33	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	83	34	post	post	JJ
work_u6osxdbbyvcabphnodfjupybae	83	35	-	-	JJ
work_u6osxdbbyvcabphnodfjupybae	83	36	ASCO	asco	JJ
work_u6osxdbbyvcabphnodfjupybae	83	37	2007	2007	CD
work_u6osxdbbyvcabphnodfjupybae	83	38	.	.	.
work_u6osxdbbyvcabphnodfjupybae	84	1	The	the	DT
work_u6osxdbbyvcabphnodfjupybae	84	2	aggregate	aggregate	JJ
work_u6osxdbbyvcabphnodfjupybae	84	3	data	datum	NNS
work_u6osxdbbyvcabphnodfjupybae	84	4	do	do	VBP
work_u6osxdbbyvcabphnodfjupybae	84	5	show	show	VB
work_u6osxdbbyvcabphnodfjupybae	84	6	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	84	7	shift	shift	NN
work_u6osxdbbyvcabphnodfjupybae	84	8	away	away	RB
work_u6osxdbbyvcabphnodfjupybae	84	9	from	from	IN
work_u6osxdbbyvcabphnodfjupybae	84	10	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	84	11	use	use	NN
work_u6osxdbbyvcabphnodfjupybae	84	12	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	84	13	immediate	immediate	JJ
work_u6osxdbbyvcabphnodfjupybae	84	14	chemoradio-	chemoradio-	NN
work_u6osxdbbyvcabphnodfjupybae	84	15	therapy	therapy	NN
work_u6osxdbbyvcabphnodfjupybae	84	16	followed	follow	VBN
work_u6osxdbbyvcabphnodfjupybae	84	17	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	84	18	docetaxel	docetaxel	NNP
work_u6osxdbbyvcabphnodfjupybae	84	19	consolidation	consolidation	NNP
work_u6osxdbbyvcabphnodfjupybae	84	20	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	84	21	38	38	CD
work_u6osxdbbyvcabphnodfjupybae	84	22	%	%	NN
work_u6osxdbbyvcabphnodfjupybae	84	23	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	84	24	,	,	,
work_u6osxdbbyvcabphnodfjupybae	84	25	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	84	26	rise	rise	NN
work_u6osxdbbyvcabphnodfjupybae	84	27	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	84	28	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	84	29	use	use	NN
work_u6osxdbbyvcabphnodfjupybae	84	30	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	84	31	immediate	immediate	JJ
work_u6osxdbbyvcabphnodfjupybae	84	32	concurrent	concurrent	JJ
work_u6osxdbbyvcabphnodfjupybae	84	33	chemoradiotherapy	chemoradiotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	84	34	alone	alone	RB
work_u6osxdbbyvcabphnodfjupybae	84	35	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	84	36	20	20	CD
work_u6osxdbbyvcabphnodfjupybae	84	37	%	%	NN
work_u6osxdbbyvcabphnodfjupybae	84	38	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	84	39	,	,	,
work_u6osxdbbyvcabphnodfjupybae	84	40	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	84	41	stable	stable	JJ
work_u6osxdbbyvcabphnodfjupybae	84	42	plans	plan	NNS
work_u6osxdbbyvcabphnodfjupybae	84	43	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	84	44	use	use	NN
work_u6osxdbbyvcabphnodfjupybae	84	45	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	84	46	immediate	immediate	JJ
work_u6osxdbbyvcabphnodfjupybae	84	47	concurrent	concurrent	JJ
work_u6osxdbbyvcabphnodfjupybae	84	48	chemoradiation	chemoradiation	NN
work_u6osxdbbyvcabphnodfjupybae	84	49	followed	follow	VBN
work_u6osxdbbyvcabphnodfjupybae	84	50	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	84	51	two	two	CD
work_u6osxdbbyvcabphnodfjupybae	84	52	additional	additional	JJ
work_u6osxdbbyvcabphnodfjupybae	84	53	cycles	cycle	NNS
work_u6osxdbbyvcabphnodfjupybae	84	54	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	84	55	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	84	56	same	same	JJ
work_u6osxdbbyvcabphnodfjupybae	84	57	chemotherapy	chemotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	84	58	that	that	WDT
work_u6osxdbbyvcabphnodfjupybae	84	59	was	be	VBD
work_u6osxdbbyvcabphnodfjupybae	84	60	used	use	VBN
work_u6osxdbbyvcabphnodfjupybae	84	61	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	84	62	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	84	63	concurrent	concurrent	JJ
work_u6osxdbbyvcabphnodfjupybae	84	64	phase	phase	NN
work_u6osxdbbyvcabphnodfjupybae	84	65	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	84	66	therapy	therapy	NN
work_u6osxdbbyvcabphnodfjupybae	84	67	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	84	68	19	19	CD
work_u6osxdbbyvcabphnodfjupybae	84	69	%	%	NN
work_u6osxdbbyvcabphnodfjupybae	84	70	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	84	71	.	.	.
work_u6osxdbbyvcabphnodfjupybae	85	1	However	however	RB
work_u6osxdbbyvcabphnodfjupybae	85	2	,	,	,
work_u6osxdbbyvcabphnodfjupybae	85	3	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	85	4	aggregate	aggregate	JJ
work_u6osxdbbyvcabphnodfjupybae	85	5	data	datum	NNS
work_u6osxdbbyvcabphnodfjupybae	85	6	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	85	7	Figure	Figure	NNP
work_u6osxdbbyvcabphnodfjupybae	85	8	5	5	CD
work_u6osxdbbyvcabphnodfjupybae	85	9	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	85	10	ob-	ob-	CD
work_u6osxdbbyvcabphnodfjupybae	85	11	scure	scure	VB
work_u6osxdbbyvcabphnodfjupybae	85	12	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	85	13	more	more	RBR
work_u6osxdbbyvcabphnodfjupybae	85	14	dramatic	dramatic	JJ
work_u6osxdbbyvcabphnodfjupybae	85	15	time	time	NN
work_u6osxdbbyvcabphnodfjupybae	85	16	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	85	17	dependent	dependent	JJ
work_u6osxdbbyvcabphnodfjupybae	85	18	movement	movement	NN
work_u6osxdbbyvcabphnodfjupybae	85	19	away	away	RB
work_u6osxdbbyvcabphnodfjupybae	85	20	from	from	IN
work_u6osxdbbyvcabphnodfjupybae	85	21	docetaxel	docetaxel	NNP
work_u6osxdbbyvcabphnodfjupybae	85	22	consolidation	consolidation	NN
work_u6osxdbbyvcabphnodfjupybae	85	23	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	85	24	45	45	CD
work_u6osxdbbyvcabphnodfjupybae	85	25	%	%	NN
work_u6osxdbbyvcabphnodfjupybae	85	26	3	3	CD
work_u6osxdbbyvcabphnodfjupybae	85	27	27	27	CD
work_u6osxdbbyvcabphnodfjupybae	85	28	%	%	NN
work_u6osxdbbyvcabphnodfjupybae	85	29	;	;	:
work_u6osxdbbyvcabphnodfjupybae	85	30	�	�	NNP
work_u6osxdbbyvcabphnodfjupybae	85	31	2	2	CD
work_u6osxdbbyvcabphnodfjupybae	85	32	p	p	NN
work_u6osxdbbyvcabphnodfjupybae	85	33	�	�	NNP
work_u6osxdbbyvcabphnodfjupybae	85	34	0.0002	0.0002	CD
work_u6osxdbbyvcabphnodfjupybae	85	35	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	85	36	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	85	37	toward	toward	IN
work_u6osxdbbyvcabphnodfjupybae	85	38	immediate	immediate	JJ
work_u6osxdbbyvcabphnodfjupybae	85	39	concurrent	concurrent	JJ
work_u6osxdbbyvcabphnodfjupybae	85	40	chemoradiotherapy	chemoradiotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	85	41	without	without	IN
work_u6osxdbbyvcabphnodfjupybae	85	42	consolidation	consolidation	NN
work_u6osxdbbyvcabphnodfjupybae	85	43	,	,	,
work_u6osxdbbyvcabphnodfjupybae	85	44	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	85	45	strategies	strategy	NNS
work_u6osxdbbyvcabphnodfjupybae	85	46	compared	compare	VBN
work_u6osxdbbyvcabphnodfjupybae	85	47	directly	directly	RB
work_u6osxdbbyvcabphnodfjupybae	85	48	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	85	49	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	85	50	HOG	hog	NN
work_u6osxdbbyvcabphnodfjupybae	85	51	phase	phase	NN
work_u6osxdbbyvcabphnodfjupybae	85	52	III	iii	CD
work_u6osxdbbyvcabphnodfjupybae	85	53	trial	trial	NN
work_u6osxdbbyvcabphnodfjupybae	85	54	.	.	.
work_u6osxdbbyvcabphnodfjupybae	86	1	In	in	IN
work_u6osxdbbyvcabphnodfjupybae	86	2	Figure	Figure	NNP
work_u6osxdbbyvcabphnodfjupybae	86	3	7	7	CD
work_u6osxdbbyvcabphnodfjupybae	86	4	,	,	,
work_u6osxdbbyvcabphnodfjupybae	86	5	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	86	6	2007	2007	CD
work_u6osxdbbyvcabphnodfjupybae	86	7	data	datum	NNS
work_u6osxdbbyvcabphnodfjupybae	86	8	from	from	IN
work_u6osxdbbyvcabphnodfjupybae	86	9	each	each	DT
work_u6osxdbbyvcabphnodfjupybae	86	10	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	86	11	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	86	12	five	five	CD
work_u6osxdbbyvcabphnodfjupybae	86	13	research	research	NN
work_u6osxdbbyvcabphnodfjupybae	86	14	events	event	NNS
work_u6osxdbbyvcabphnodfjupybae	86	15	are	be	VBP
work_u6osxdbbyvcabphnodfjupybae	86	16	displayed	display	VBN
work_u6osxdbbyvcabphnodfjupybae	86	17	individually	individually	RB
work_u6osxdbbyvcabphnodfjupybae	86	18	.	.	.
work_u6osxdbbyvcabphnodfjupybae	87	1	Presenting	present	VBG
work_u6osxdbbyvcabphnodfjupybae	87	2	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	87	3	data	datum	NNS
work_u6osxdbbyvcabphnodfjupybae	87	4	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	87	5	this	this	DT
work_u6osxdbbyvcabphnodfjupybae	87	6	fashion	fashion	NN
work_u6osxdbbyvcabphnodfjupybae	87	7	further	far	RBR
work_u6osxdbbyvcabphnodfjupybae	87	8	highlights	highlight	VBZ
work_u6osxdbbyvcabphnodfjupybae	87	9	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	87	10	change	change	NN
work_u6osxdbbyvcabphnodfjupybae	87	11	driven	drive	VBN
work_u6osxdbbyvcabphnodfjupybae	87	12	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	87	13	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	87	14	2007	2007	CD
work_u6osxdbbyvcabphnodfjupybae	87	15	ASCO	ASCO	NNP
work_u6osxdbbyvcabphnodfjupybae	87	16	presentation	presentation	NN
work_u6osxdbbyvcabphnodfjupybae	87	17	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	87	18	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	87	19	HOG	HOG	NNP
work_u6osxdbbyvcabphnodfjupybae	87	20	trial	trial	NN
work_u6osxdbbyvcabphnodfjupybae	87	21	data	datum	NNS
work_u6osxdbbyvcabphnodfjupybae	87	22	.	.	.
work_u6osxdbbyvcabphnodfjupybae	88	1	Immediately	immediately	RB
work_u6osxdbbyvcabphnodfjupybae	88	2	after	after	IN
work_u6osxdbbyvcabphnodfjupybae	88	3	ASCO	ASCO	NNP
work_u6osxdbbyvcabphnodfjupybae	88	4	2007	2007	CD
work_u6osxdbbyvcabphnodfjupybae	88	5	,	,	,
work_u6osxdbbyvcabphnodfjupybae	88	6	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	88	7	shift	shift	NN
work_u6osxdbbyvcabphnodfjupybae	88	8	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	88	9	prescribing	prescribing	NN
work_u6osxdbbyvcabphnodfjupybae	88	10	plans	plan	NNS
work_u6osxdbbyvcabphnodfjupybae	88	11	occurred	occur	VBD
work_u6osxdbbyvcabphnodfjupybae	88	12	.	.	.
work_u6osxdbbyvcabphnodfjupybae	89	1	Its	-PRON-	PRP$
work_u6osxdbbyvcabphnodfjupybae	89	2	dura-	dura-	JJ
work_u6osxdbbyvcabphnodfjupybae	89	3	bility	bility	NN
work_u6osxdbbyvcabphnodfjupybae	89	4	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	89	5	further	further	JJ
work_u6osxdbbyvcabphnodfjupybae	89	6	amplification	amplification	NN
work_u6osxdbbyvcabphnodfjupybae	89	7	are	be	VBP
work_u6osxdbbyvcabphnodfjupybae	89	8	evident	evident	JJ
work_u6osxdbbyvcabphnodfjupybae	89	9	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	89	10	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	89	11	data	datum	NNS
work_u6osxdbbyvcabphnodfjupybae	89	12	from	from	IN
work_u6osxdbbyvcabphnodfjupybae	89	13	late	late	JJ
work_u6osxdbbyvcabphnodfjupybae	89	14	September	September	NNP
work_u6osxdbbyvcabphnodfjupybae	89	15	.	.	.
work_u6osxdbbyvcabphnodfjupybae	90	1	After	after	IN
work_u6osxdbbyvcabphnodfjupybae	90	2	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	90	3	acquisition	acquisition	NN
work_u6osxdbbyvcabphnodfjupybae	90	4	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	90	5	these	these	DT
work_u6osxdbbyvcabphnodfjupybae	90	6	data	datum	NNS
work_u6osxdbbyvcabphnodfjupybae	90	7	,	,	,
work_u6osxdbbyvcabphnodfjupybae	90	8	we	-PRON-	PRP
work_u6osxdbbyvcabphnodfjupybae	90	9	con-	con-	VBP
work_u6osxdbbyvcabphnodfjupybae	90	10	tinued	tinue	VBD
work_u6osxdbbyvcabphnodfjupybae	90	11	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	90	12	monitor	monitor	VB
work_u6osxdbbyvcabphnodfjupybae	90	13	prescribing	prescribing	NN
work_u6osxdbbyvcabphnodfjupybae	90	14	plans	plan	NNS
work_u6osxdbbyvcabphnodfjupybae	90	15	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	90	16	2008	2008	CD
work_u6osxdbbyvcabphnodfjupybae	90	17	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	90	18	Table	table	NN
work_u6osxdbbyvcabphnodfjupybae	90	19	1	1	CD
work_u6osxdbbyvcabphnodfjupybae	90	20	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	90	21	.	.	.
work_u6osxdbbyvcabphnodfjupybae	91	1	In	in	IN
work_u6osxdbbyvcabphnodfjupybae	91	2	two	two	CD
work_u6osxdbbyvcabphnodfjupybae	91	3	research	research	NN
work_u6osxdbbyvcabphnodfjupybae	91	4	events	event	NNS
work_u6osxdbbyvcabphnodfjupybae	91	5	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	91	6	February	February	NNP
work_u6osxdbbyvcabphnodfjupybae	91	7	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	91	8	April	April	NNP
work_u6osxdbbyvcabphnodfjupybae	91	9	2008	2008	CD
work_u6osxdbbyvcabphnodfjupybae	91	10	,	,	,
work_u6osxdbbyvcabphnodfjupybae	91	11	plans	plan	NNS
work_u6osxdbbyvcabphnodfjupybae	91	12	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	91	13	use	use	NN
work_u6osxdbbyvcabphnodfjupybae	91	14	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	91	15	FIGURE	FIGURE	NNP
work_u6osxdbbyvcabphnodfjupybae	91	16	4	4	CD
work_u6osxdbbyvcabphnodfjupybae	91	17	.	.	.
work_u6osxdbbyvcabphnodfjupybae	92	1	Prescribing	prescribing	NN
work_u6osxdbbyvcabphnodfjupybae	92	2	plans	plan	NNS
work_u6osxdbbyvcabphnodfjupybae	92	3	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	92	4	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	92	5	patient	patient	NN
work_u6osxdbbyvcabphnodfjupybae	92	6	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	92	7	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	92	8	new	new	JJ
work_u6osxdbbyvcabphnodfjupybae	92	9	diag-	diag-	NN
work_u6osxdbbyvcabphnodfjupybae	92	10	nosis	nosis	NN
work_u6osxdbbyvcabphnodfjupybae	92	11	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	92	12	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	92	13	IIIB	IIIB	NNP
work_u6osxdbbyvcabphnodfjupybae	92	14	non	non	JJ
work_u6osxdbbyvcabphnodfjupybae	92	15	-	-	JJ
work_u6osxdbbyvcabphnodfjupybae	92	16	small	small	JJ
work_u6osxdbbyvcabphnodfjupybae	92	17	cell	cell	NN
work_u6osxdbbyvcabphnodfjupybae	92	18	lung	lung	NN
work_u6osxdbbyvcabphnodfjupybae	92	19	cancer	cancer	NN
work_u6osxdbbyvcabphnodfjupybae	92	20	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	92	21	NSCLC	NSCLC	NNP
work_u6osxdbbyvcabphnodfjupybae	92	22	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	92	23	as-	as-	NN
work_u6osxdbbyvcabphnodfjupybae	92	24	sessed	sesse	VBD
work_u6osxdbbyvcabphnodfjupybae	92	25	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	92	26	987	987	CD
work_u6osxdbbyvcabphnodfjupybae	92	27	American	american	JJ
work_u6osxdbbyvcabphnodfjupybae	92	28	medical	medical	JJ
work_u6osxdbbyvcabphnodfjupybae	92	29	oncologists	oncologist	NNS
work_u6osxdbbyvcabphnodfjupybae	92	30	who	who	WP
work_u6osxdbbyvcabphnodfjupybae	92	31	partici-	partici-	VBD
work_u6osxdbbyvcabphnodfjupybae	92	32	pated	pat	VBD
work_u6osxdbbyvcabphnodfjupybae	92	33	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	92	34	Network	Network	NNP
work_u6osxdbbyvcabphnodfjupybae	92	35	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	92	36	Medical	Medical	NNP
work_u6osxdbbyvcabphnodfjupybae	92	37	Communications	Communications	NNPS
work_u6osxdbbyvcabphnodfjupybae	92	38	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	92	39	Research	Research	NNP
work_u6osxdbbyvcabphnodfjupybae	92	40	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	92	41	NMCR	NMCR	NNP
work_u6osxdbbyvcabphnodfjupybae	92	42	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	92	43	live	live	VBP
work_u6osxdbbyvcabphnodfjupybae	92	44	research	research	NN
work_u6osxdbbyvcabphnodfjupybae	92	45	events	event	NNS
work_u6osxdbbyvcabphnodfjupybae	92	46	between	between	IN
work_u6osxdbbyvcabphnodfjupybae	92	47	March	March	NNP
work_u6osxdbbyvcabphnodfjupybae	92	48	2005	2005	CD
work_u6osxdbbyvcabphnodfjupybae	92	49	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	92	50	May	May	NNP
work_u6osxdbbyvcabphnodfjupybae	92	51	2007	2007	CD
work_u6osxdbbyvcabphnodfjupybae	92	52	.	.	.
work_u6osxdbbyvcabphnodfjupybae	93	1	FIGURE	FIGURE	NNP
work_u6osxdbbyvcabphnodfjupybae	93	2	5	5	CD
work_u6osxdbbyvcabphnodfjupybae	93	3	.	.	.
work_u6osxdbbyvcabphnodfjupybae	94	1	Prescribing	prescribing	NN
work_u6osxdbbyvcabphnodfjupybae	94	2	plans	plan	NNS
work_u6osxdbbyvcabphnodfjupybae	94	3	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	94	4	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	94	5	patient	patient	NN
work_u6osxdbbyvcabphnodfjupybae	94	6	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	94	7	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	94	8	new	new	JJ
work_u6osxdbbyvcabphnodfjupybae	94	9	diag-	diag-	NN
work_u6osxdbbyvcabphnodfjupybae	94	10	nosis	nosis	NN
work_u6osxdbbyvcabphnodfjupybae	94	11	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	94	12	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	94	13	IIIB	IIIB	NNP
work_u6osxdbbyvcabphnodfjupybae	94	14	non	non	JJ
work_u6osxdbbyvcabphnodfjupybae	94	15	-	-	JJ
work_u6osxdbbyvcabphnodfjupybae	94	16	small	small	JJ
work_u6osxdbbyvcabphnodfjupybae	94	17	cell	cell	NN
work_u6osxdbbyvcabphnodfjupybae	94	18	lung	lung	NN
work_u6osxdbbyvcabphnodfjupybae	94	19	cancer	cancer	NN
work_u6osxdbbyvcabphnodfjupybae	94	20	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	94	21	NSCLC	NSCLC	NNP
work_u6osxdbbyvcabphnodfjupybae	94	22	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	94	23	as-	as-	NN
work_u6osxdbbyvcabphnodfjupybae	94	24	sessed	sesse	VBD
work_u6osxdbbyvcabphnodfjupybae	94	25	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	94	26	427	427	CD
work_u6osxdbbyvcabphnodfjupybae	94	27	American	american	JJ
work_u6osxdbbyvcabphnodfjupybae	94	28	medical	medical	JJ
work_u6osxdbbyvcabphnodfjupybae	94	29	oncologists	oncologist	NNS
work_u6osxdbbyvcabphnodfjupybae	94	30	who	who	WP
work_u6osxdbbyvcabphnodfjupybae	94	31	partici-	partici-	VBD
work_u6osxdbbyvcabphnodfjupybae	94	32	pated	pat	VBD
work_u6osxdbbyvcabphnodfjupybae	94	33	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	94	34	Network	Network	NNP
work_u6osxdbbyvcabphnodfjupybae	94	35	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	94	36	Medical	Medical	NNP
work_u6osxdbbyvcabphnodfjupybae	94	37	Communications	Communications	NNPS
work_u6osxdbbyvcabphnodfjupybae	94	38	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	94	39	Research	Research	NNP
work_u6osxdbbyvcabphnodfjupybae	94	40	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	94	41	NMCR	NMCR	NNP
work_u6osxdbbyvcabphnodfjupybae	94	42	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	94	43	live	live	VBP
work_u6osxdbbyvcabphnodfjupybae	94	44	research	research	NN
work_u6osxdbbyvcabphnodfjupybae	94	45	events	event	NNS
work_u6osxdbbyvcabphnodfjupybae	94	46	between	between	IN
work_u6osxdbbyvcabphnodfjupybae	94	47	March	March	NNP
work_u6osxdbbyvcabphnodfjupybae	94	48	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	94	49	September	September	NNP
work_u6osxdbbyvcabphnodfjupybae	94	50	2007	2007	CD
work_u6osxdbbyvcabphnodfjupybae	94	51	.	.	.
work_u6osxdbbyvcabphnodfjupybae	95	1	FIGURE	FIGURE	NNP
work_u6osxdbbyvcabphnodfjupybae	95	2	6	6	CD
work_u6osxdbbyvcabphnodfjupybae	95	3	.	.	.
work_u6osxdbbyvcabphnodfjupybae	96	1	Prescribing	prescribing	NN
work_u6osxdbbyvcabphnodfjupybae	96	2	plans	plan	NNS
work_u6osxdbbyvcabphnodfjupybae	96	3	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	96	4	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	96	5	patient	patient	NN
work_u6osxdbbyvcabphnodfjupybae	96	6	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	96	7	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	96	8	new	new	JJ
work_u6osxdbbyvcabphnodfjupybae	96	9	diag-	diag-	NN
work_u6osxdbbyvcabphnodfjupybae	96	10	nosis	nosis	NN
work_u6osxdbbyvcabphnodfjupybae	96	11	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	96	12	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	96	13	IIIB	IIIB	NNP
work_u6osxdbbyvcabphnodfjupybae	96	14	non	non	JJ
work_u6osxdbbyvcabphnodfjupybae	96	15	-	-	JJ
work_u6osxdbbyvcabphnodfjupybae	96	16	small	small	JJ
work_u6osxdbbyvcabphnodfjupybae	96	17	cell	cell	NN
work_u6osxdbbyvcabphnodfjupybae	96	18	lung	lung	NN
work_u6osxdbbyvcabphnodfjupybae	96	19	cancer	cancer	NN
work_u6osxdbbyvcabphnodfjupybae	96	20	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	96	21	NSCLC	NSCLC	NNP
work_u6osxdbbyvcabphnodfjupybae	96	22	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	96	23	as-	as-	NN
work_u6osxdbbyvcabphnodfjupybae	96	24	sessed	sesse	VBD
work_u6osxdbbyvcabphnodfjupybae	96	25	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	96	26	427	427	CD
work_u6osxdbbyvcabphnodfjupybae	96	27	American	american	JJ
work_u6osxdbbyvcabphnodfjupybae	96	28	medical	medical	JJ
work_u6osxdbbyvcabphnodfjupybae	96	29	oncologists	oncologist	NNS
work_u6osxdbbyvcabphnodfjupybae	96	30	who	who	WP
work_u6osxdbbyvcabphnodfjupybae	96	31	partici-	partici-	VBD
work_u6osxdbbyvcabphnodfjupybae	96	32	pated	pat	VBD
work_u6osxdbbyvcabphnodfjupybae	96	33	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	96	34	Network	Network	NNP
work_u6osxdbbyvcabphnodfjupybae	96	35	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	96	36	Medical	Medical	NNP
work_u6osxdbbyvcabphnodfjupybae	96	37	Communications	Communications	NNPS
work_u6osxdbbyvcabphnodfjupybae	96	38	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	96	39	Research	Research	NNP
work_u6osxdbbyvcabphnodfjupybae	96	40	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	96	41	NMCR	NMCR	NNP
work_u6osxdbbyvcabphnodfjupybae	96	42	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	96	43	live	live	VBP
work_u6osxdbbyvcabphnodfjupybae	96	44	research	research	NN
work_u6osxdbbyvcabphnodfjupybae	96	45	events	event	NNS
work_u6osxdbbyvcabphnodfjupybae	96	46	between	between	IN
work_u6osxdbbyvcabphnodfjupybae	96	47	March	March	NNP
work_u6osxdbbyvcabphnodfjupybae	96	48	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	96	49	September	September	NNP
work_u6osxdbbyvcabphnodfjupybae	96	50	2007	2007	CD
work_u6osxdbbyvcabphnodfjupybae	96	51	.	.	.
work_u6osxdbbyvcabphnodfjupybae	97	1	Prescribing	prescribing	NN
work_u6osxdbbyvcabphnodfjupybae	97	2	plans	plan	NNS
work_u6osxdbbyvcabphnodfjupybae	97	3	shown	show	VBN
work_u6osxdbbyvcabphnodfjupybae	97	4	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	97	5	two	two	CD
work_u6osxdbbyvcabphnodfjupybae	97	6	time	time	NN
work_u6osxdbbyvcabphnodfjupybae	97	7	frames	frame	NNS
work_u6osxdbbyvcabphnodfjupybae	97	8	,	,	,
work_u6osxdbbyvcabphnodfjupybae	97	9	before	before	RB
work_u6osxdbbyvcabphnodfjupybae	97	10	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	97	11	after	after	IN
work_u6osxdbbyvcabphnodfjupybae	97	12	American	American	NNP
work_u6osxdbbyvcabphnodfjupybae	97	13	Society	Society	NNP
work_u6osxdbbyvcabphnodfjupybae	97	14	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	97	15	Clinical	Clinical	NNP
work_u6osxdbbyvcabphnodfjupybae	97	16	Oncology	Oncology	NNP
work_u6osxdbbyvcabphnodfjupybae	97	17	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	97	18	ASCO	ASCO	NNP
work_u6osxdbbyvcabphnodfjupybae	97	19	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	97	20	2007	2007	CD
work_u6osxdbbyvcabphnodfjupybae	97	21	.	.	.
work_u6osxdbbyvcabphnodfjupybae	98	1	Choices	choice	NNS
work_u6osxdbbyvcabphnodfjupybae	98	2	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	98	3	“	"	``
work_u6osxdbbyvcabphnodfjupybae	98	4	radiation	radiation	NN
work_u6osxdbbyvcabphnodfjupybae	98	5	followed	follow	VBN
work_u6osxdbbyvcabphnodfjupybae	98	6	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	98	7	chemotherapy	chemotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	98	8	,	,	,
work_u6osxdbbyvcabphnodfjupybae	98	9	”	"	''
work_u6osxdbbyvcabphnodfjupybae	98	10	“	"	``
work_u6osxdbbyvcabphnodfjupybae	98	11	chemotherapy	chemotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	98	12	alone	alone	RB
work_u6osxdbbyvcabphnodfjupybae	98	13	,	,	,
work_u6osxdbbyvcabphnodfjupybae	98	14	”	"	''
work_u6osxdbbyvcabphnodfjupybae	98	15	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	98	16	“	"	``
work_u6osxdbbyvcabphnodfjupybae	98	17	other	other	JJ
work_u6osxdbbyvcabphnodfjupybae	98	18	,	,	,
work_u6osxdbbyvcabphnodfjupybae	98	19	”	"	''
work_u6osxdbbyvcabphnodfjupybae	98	20	totaling	total	VBG
work_u6osxdbbyvcabphnodfjupybae	98	21	3	3	CD
work_u6osxdbbyvcabphnodfjupybae	98	22	%	%	NN
work_u6osxdbbyvcabphnodfjupybae	98	23	are	be	VBP
work_u6osxdbbyvcabphnodfjupybae	98	24	not	not	RB
work_u6osxdbbyvcabphnodfjupybae	98	25	shown	show	VBN
work_u6osxdbbyvcabphnodfjupybae	98	26	here	here	RB
work_u6osxdbbyvcabphnodfjupybae	98	27	.	.	.
work_u6osxdbbyvcabphnodfjupybae	99	1	Journal	Journal	NNP
work_u6osxdbbyvcabphnodfjupybae	99	2	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	99	3	Thoracic	Thoracic	NNP
work_u6osxdbbyvcabphnodfjupybae	99	4	Oncology	Oncology	NNP
work_u6osxdbbyvcabphnodfjupybae	99	5	•	•	NNP
work_u6osxdbbyvcabphnodfjupybae	99	6	Volume	volume	NN
work_u6osxdbbyvcabphnodfjupybae	99	7	4	4	CD
work_u6osxdbbyvcabphnodfjupybae	99	8	,	,	,
work_u6osxdbbyvcabphnodfjupybae	99	9	Number	number	NN
work_u6osxdbbyvcabphnodfjupybae	99	10	8	8	CD
work_u6osxdbbyvcabphnodfjupybae	99	11	,	,	,
work_u6osxdbbyvcabphnodfjupybae	99	12	August	August	NNP
work_u6osxdbbyvcabphnodfjupybae	99	13	2009	2009	CD
work_u6osxdbbyvcabphnodfjupybae	99	14	Impact	Impact	NNP
work_u6osxdbbyvcabphnodfjupybae	99	15	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	99	16	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	99	17	ASCO	ASCO	NNP
work_u6osxdbbyvcabphnodfjupybae	99	18	2007	2007	CD
work_u6osxdbbyvcabphnodfjupybae	99	19	Presentation	Presentation	NNP
work_u6osxdbbyvcabphnodfjupybae	99	20	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	99	21	HOG	HOG	NNP
work_u6osxdbbyvcabphnodfjupybae	99	22	Lun	Lun	NNP
work_u6osxdbbyvcabphnodfjupybae	99	23	01	01	CD
work_u6osxdbbyvcabphnodfjupybae	99	24	-	-	SYM
work_u6osxdbbyvcabphnodfjupybae	99	25	24	24	CD
work_u6osxdbbyvcabphnodfjupybae	99	26	/	/	SYM
work_u6osxdbbyvcabphnodfjupybae	99	27	USO-023	uso-023	CD
work_u6osxdbbyvcabphnodfjupybae	99	28	Copyright	copyright	NN
work_u6osxdbbyvcabphnodfjupybae	99	29	©	©	NN
work_u6osxdbbyvcabphnodfjupybae	99	30	2009	2009	CD
work_u6osxdbbyvcabphnodfjupybae	99	31	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	99	32	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	99	33	International	International	NNP
work_u6osxdbbyvcabphnodfjupybae	99	34	Association	Association	NNP
work_u6osxdbbyvcabphnodfjupybae	99	35	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	99	36	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	99	37	Study	Study	NNP
work_u6osxdbbyvcabphnodfjupybae	99	38	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	99	39	Lung	Lung	NNP
work_u6osxdbbyvcabphnodfjupybae	99	40	Cancer	Cancer	NNP
work_u6osxdbbyvcabphnodfjupybae	99	41	985	985	CD
work_u6osxdbbyvcabphnodfjupybae	99	42	consolidation	consolidation	NN
work_u6osxdbbyvcabphnodfjupybae	99	43	docetaxel	docetaxel	NNP
work_u6osxdbbyvcabphnodfjupybae	99	44	have	have	VBP
work_u6osxdbbyvcabphnodfjupybae	99	45	fallen	fall	VBN
work_u6osxdbbyvcabphnodfjupybae	99	46	to	to	IN
work_u6osxdbbyvcabphnodfjupybae	99	47	less	less	JJR
work_u6osxdbbyvcabphnodfjupybae	99	48	than	than	IN
work_u6osxdbbyvcabphnodfjupybae	99	49	20	20	CD
work_u6osxdbbyvcabphnodfjupybae	99	50	%	%	NN
work_u6osxdbbyvcabphnodfjupybae	99	51	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	99	52	research	research	NN
work_u6osxdbbyvcabphnodfjupybae	99	53	respondents	respondent	NNS
work_u6osxdbbyvcabphnodfjupybae	99	54	.	.	.
work_u6osxdbbyvcabphnodfjupybae	100	1	The	the	DT
work_u6osxdbbyvcabphnodfjupybae	100	2	largest	large	JJS
work_u6osxdbbyvcabphnodfjupybae	100	3	single	single	JJ
work_u6osxdbbyvcabphnodfjupybae	100	4	group	group	NN
work_u6osxdbbyvcabphnodfjupybae	100	5	now	now	RB
work_u6osxdbbyvcabphnodfjupybae	100	6	plans	plan	VBZ
work_u6osxdbbyvcabphnodfjupybae	100	7	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	100	8	use	use	VB
work_u6osxdbbyvcabphnodfjupybae	100	9	immediate	immediate	JJ
work_u6osxdbbyvcabphnodfjupybae	100	10	concurrent	concurrent	JJ
work_u6osxdbbyvcabphnodfjupybae	100	11	chemoradiotherapy	chemoradiotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	100	12	without	without	IN
work_u6osxdbbyvcabphnodfjupybae	100	13	either	either	DT
work_u6osxdbbyvcabphnodfjupybae	100	14	induction	induction	NN
work_u6osxdbbyvcabphnodfjupybae	100	15	or	or	CC
work_u6osxdbbyvcabphnodfjupybae	100	16	consolidation	consolidation	NN
work_u6osxdbbyvcabphnodfjupybae	100	17	.	.	.
work_u6osxdbbyvcabphnodfjupybae	101	1	However	however	RB
work_u6osxdbbyvcabphnodfjupybae	101	2	,	,	,
work_u6osxdbbyvcabphnodfjupybae	101	3	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	101	4	ambiva-	ambiva-	JJ
work_u6osxdbbyvcabphnodfjupybae	101	5	lence	lence	NN
work_u6osxdbbyvcabphnodfjupybae	101	6	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	101	7	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	101	8	treating	treat	VBG
work_u6osxdbbyvcabphnodfjupybae	101	9	oncology	oncology	NN
work_u6osxdbbyvcabphnodfjupybae	101	10	community	community	NN
work_u6osxdbbyvcabphnodfjupybae	101	11	is	be	VBZ
work_u6osxdbbyvcabphnodfjupybae	101	12	clear	clear	JJ
work_u6osxdbbyvcabphnodfjupybae	101	13	,	,	,
work_u6osxdbbyvcabphnodfjupybae	101	14	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	101	15	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	101	16	majority	majority	NN
work_u6osxdbbyvcabphnodfjupybae	101	17	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	101	18	all	all	DT
work_u6osxdbbyvcabphnodfjupybae	101	19	respondents	respondent	NNS
work_u6osxdbbyvcabphnodfjupybae	101	20	planning	plan	VBG
work_u6osxdbbyvcabphnodfjupybae	101	21	some	some	DT
work_u6osxdbbyvcabphnodfjupybae	101	22	treatment	treatment	NN
work_u6osxdbbyvcabphnodfjupybae	101	23	strat-	strat-	NN
work_u6osxdbbyvcabphnodfjupybae	101	24	egy	egy	NN
work_u6osxdbbyvcabphnodfjupybae	101	25	that	that	WDT
work_u6osxdbbyvcabphnodfjupybae	101	26	includes	include	VBZ
work_u6osxdbbyvcabphnodfjupybae	101	27	more	more	JJR
work_u6osxdbbyvcabphnodfjupybae	101	28	than	than	IN
work_u6osxdbbyvcabphnodfjupybae	101	29	just	just	RB
work_u6osxdbbyvcabphnodfjupybae	101	30	two	two	CD
work_u6osxdbbyvcabphnodfjupybae	101	31	cycles	cycle	NNS
work_u6osxdbbyvcabphnodfjupybae	101	32	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	101	33	or	or	CC
work_u6osxdbbyvcabphnodfjupybae	101	34	equivalent	equivalent	JJ
work_u6osxdbbyvcabphnodfjupybae	101	35	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	101	36	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	101	37	chemotherapy	chemotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	101	38	during	during	IN
work_u6osxdbbyvcabphnodfjupybae	101	39	radiation	radiation	NN
work_u6osxdbbyvcabphnodfjupybae	101	40	as	as	IN
work_u6osxdbbyvcabphnodfjupybae	101	41	total	total	JJ
work_u6osxdbbyvcabphnodfjupybae	101	42	therapy	therapy	NN
work_u6osxdbbyvcabphnodfjupybae	101	43	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	101	44	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	101	45	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	101	46	IIIB	IIIB	NNP
work_u6osxdbbyvcabphnodfjupybae	101	47	setting	setting	NN
work_u6osxdbbyvcabphnodfjupybae	101	48	.	.	.
work_u6osxdbbyvcabphnodfjupybae	102	1	DISCUSSION	DISCUSSION	NNP
work_u6osxdbbyvcabphnodfjupybae	102	2	Individuals	individual	NNS
work_u6osxdbbyvcabphnodfjupybae	102	3	diagnosed	diagnose	VBD
work_u6osxdbbyvcabphnodfjupybae	102	4	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	102	5	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	102	6	contralateral	contralateral	JJ
work_u6osxdbbyvcabphnodfjupybae	102	7	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	102	8	mediastinal	mediastinal	JJ
work_u6osxdbbyvcabphnodfjupybae	102	9	,	,	,
work_u6osxdbbyvcabphnodfjupybae	102	10	N3	n3	NN
work_u6osxdbbyvcabphnodfjupybae	102	11	,	,	,
work_u6osxdbbyvcabphnodfjupybae	102	12	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	102	13	IIIB	IIIB	NNP
work_u6osxdbbyvcabphnodfjupybae	102	14	NSCLC	NSCLC	NNP
work_u6osxdbbyvcabphnodfjupybae	102	15	are	be	VBP
work_u6osxdbbyvcabphnodfjupybae	102	16	seeking	seek	VBG
work_u6osxdbbyvcabphnodfjupybae	102	17	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	102	18	best	good	JJS
work_u6osxdbbyvcabphnodfjupybae	102	19	therapy	therapy	NN
work_u6osxdbbyvcabphnodfjupybae	102	20	option	option	NN
work_u6osxdbbyvcabphnodfjupybae	102	21	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	102	22	provide	provide	VB
work_u6osxdbbyvcabphnodfjupybae	102	23	them	-PRON-	PRP
work_u6osxdbbyvcabphnodfjupybae	102	24	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	102	25	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	102	26	longest	long	JJS
work_u6osxdbbyvcabphnodfjupybae	102	27	duration	duration	NN
work_u6osxdbbyvcabphnodfjupybae	102	28	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	102	29	quality	quality	NN
work_u6osxdbbyvcabphnodfjupybae	102	30	life	life	NN
work_u6osxdbbyvcabphnodfjupybae	102	31	.	.	.
work_u6osxdbbyvcabphnodfjupybae	103	1	They	-PRON-	PRP
work_u6osxdbbyvcabphnodfjupybae	103	2	recognize	recognize	VBP
work_u6osxdbbyvcabphnodfjupybae	103	3	that	that	IN
work_u6osxdbbyvcabphnodfjupybae	103	4	there	there	EX
work_u6osxdbbyvcabphnodfjupybae	103	5	may	may	MD
work_u6osxdbbyvcabphnodfjupybae	103	6	be	be	VB
work_u6osxdbbyvcabphnodfjupybae	103	7	some	some	DT
work_u6osxdbbyvcabphnodfjupybae	103	8	individual	individual	JJ
work_u6osxdbbyvcabphnodfjupybae	103	9	potential	potential	NN
work_u6osxdbbyvcabphnodfjupybae	103	10	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	103	11	achieve	achieve	VB
work_u6osxdbbyvcabphnodfjupybae	103	12	long	long	JJ
work_u6osxdbbyvcabphnodfjupybae	103	13	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	103	14	term	term	NN
work_u6osxdbbyvcabphnodfjupybae	103	15	disease	disease	NN
work_u6osxdbbyvcabphnodfjupybae	103	16	control	control	NN
work_u6osxdbbyvcabphnodfjupybae	103	17	,	,	,
work_u6osxdbbyvcabphnodfjupybae	103	18	although	although	IN
work_u6osxdbbyvcabphnodfjupybae	103	19	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	103	20	best	good	JJS
work_u6osxdbbyvcabphnodfjupybae	103	21	strategy	strategy	NN
work_u6osxdbbyvcabphnodfjupybae	103	22	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	103	23	optimizing	optimize	VBG
work_u6osxdbbyvcabphnodfjupybae	103	24	this	this	DT
work_u6osxdbbyvcabphnodfjupybae	103	25	goal	goal	NN
work_u6osxdbbyvcabphnodfjupybae	103	26	is	be	VBZ
work_u6osxdbbyvcabphnodfjupybae	103	27	unclear	unclear	JJ
work_u6osxdbbyvcabphnodfjupybae	103	28	.	.	.
work_u6osxdbbyvcabphnodfjupybae	104	1	For	for	IN
work_u6osxdbbyvcabphnodfjupybae	104	2	fit	fit	JJ
work_u6osxdbbyvcabphnodfjupybae	104	3	individuals	individual	NNS
work_u6osxdbbyvcabphnodfjupybae	104	4	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	104	5	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	104	6	diagnosis	diagnosis	NN
work_u6osxdbbyvcabphnodfjupybae	104	7	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	104	8	N3	n3	NN
work_u6osxdbbyvcabphnodfjupybae	104	9	,	,	,
work_u6osxdbbyvcabphnodfjupybae	104	10	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	104	11	IIIB	IIIB	NNP
work_u6osxdbbyvcabphnodfjupybae	104	12	NSCLC	NSCLC	NNP
work_u6osxdbbyvcabphnodfjupybae	104	13	,	,	,
work_u6osxdbbyvcabphnodfjupybae	104	14	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	104	15	treatment	treatment	NN
work_u6osxdbbyvcabphnodfjupybae	104	16	recom-	recom-	JJ
work_u6osxdbbyvcabphnodfjupybae	104	17	mendations	mendation	NNS
work_u6osxdbbyvcabphnodfjupybae	104	18	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	104	19	American	american	JJ
work_u6osxdbbyvcabphnodfjupybae	104	20	medical	medical	JJ
work_u6osxdbbyvcabphnodfjupybae	104	21	oncologists	oncologist	NNS
work_u6osxdbbyvcabphnodfjupybae	104	22	almost	almost	RB
work_u6osxdbbyvcabphnodfjupybae	104	23	always	always	RB
work_u6osxdbbyvcabphnodfjupybae	104	24	involve	involve	VBP
work_u6osxdbbyvcabphnodfjupybae	104	25	both	both	DT
work_u6osxdbbyvcabphnodfjupybae	104	26	chemotherapy	chemotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	104	27	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	104	28	radiation	radiation	NN
work_u6osxdbbyvcabphnodfjupybae	104	29	.	.	.
work_u6osxdbbyvcabphnodfjupybae	105	1	These	these	DT
work_u6osxdbbyvcabphnodfjupybae	105	2	two	two	CD
work_u6osxdbbyvcabphnodfjupybae	105	3	modal-	modal-	NN
work_u6osxdbbyvcabphnodfjupybae	105	4	ities	itie	NNS
work_u6osxdbbyvcabphnodfjupybae	105	5	are	be	VBP
work_u6osxdbbyvcabphnodfjupybae	105	6	designed	design	VBN
work_u6osxdbbyvcabphnodfjupybae	105	7	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	105	8	both	both	DT
work_u6osxdbbyvcabphnodfjupybae	105	9	maximize	maximize	VB
work_u6osxdbbyvcabphnodfjupybae	105	10	control	control	NN
work_u6osxdbbyvcabphnodfjupybae	105	11	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	105	12	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	105	13	macro-	macro-	JJ
work_u6osxdbbyvcabphnodfjupybae	105	14	scopic	scopic	NNP
work_u6osxdbbyvcabphnodfjupybae	105	15	locoregional	locoregional	JJ
work_u6osxdbbyvcabphnodfjupybae	105	16	disease	disease	NN
work_u6osxdbbyvcabphnodfjupybae	105	17	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	105	18	eradicate	eradicate	VB
work_u6osxdbbyvcabphnodfjupybae	105	19	micrometastatic	micrometastatic	JJ
work_u6osxdbbyvcabphnodfjupybae	105	20	foci	foci	NN
work_u6osxdbbyvcabphnodfjupybae	105	21	that	that	WDT
work_u6osxdbbyvcabphnodfjupybae	105	22	are	be	VBP
work_u6osxdbbyvcabphnodfjupybae	105	23	also	also	RB
work_u6osxdbbyvcabphnodfjupybae	105	24	highly	highly	RB
work_u6osxdbbyvcabphnodfjupybae	105	25	likely	likely	JJ
work_u6osxdbbyvcabphnodfjupybae	105	26	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	105	27	be	be	VB
work_u6osxdbbyvcabphnodfjupybae	105	28	present	present	JJ
work_u6osxdbbyvcabphnodfjupybae	105	29	.	.	.
work_u6osxdbbyvcabphnodfjupybae	106	1	Currently	currently	RB
work_u6osxdbbyvcabphnodfjupybae	106	2	,	,	,
work_u6osxdbbyvcabphnodfjupybae	106	3	phase	phase	NN
work_u6osxdbbyvcabphnodfjupybae	106	4	III	iii	CD
work_u6osxdbbyvcabphnodfjupybae	106	5	trial	trial	NN
work_u6osxdbbyvcabphnodfjupybae	106	6	data	datum	NNS
work_u6osxdbbyvcabphnodfjupybae	106	7	from	from	IN
work_u6osxdbbyvcabphnodfjupybae	106	8	numerous	numerous	JJ
work_u6osxdbbyvcabphnodfjupybae	106	9	sources	source	NNS
work_u6osxdbbyvcabphnodfjupybae	106	10	suggest	suggest	VBP
work_u6osxdbbyvcabphnodfjupybae	106	11	that	that	IN
work_u6osxdbbyvcabphnodfjupybae	106	12	use	use	NN
work_u6osxdbbyvcabphnodfjupybae	106	13	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	106	14	concurrent	concurrent	JJ
work_u6osxdbbyvcabphnodfjupybae	106	15	chemoradiotherapy	chemoradiotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	106	16	can	can	MD
work_u6osxdbbyvcabphnodfjupybae	106	17	increase	increase	VB
work_u6osxdbbyvcabphnodfjupybae	106	18	overall	overall	JJ
work_u6osxdbbyvcabphnodfjupybae	106	19	survival	survival	NN
work_u6osxdbbyvcabphnodfjupybae	106	20	when	when	WRB
work_u6osxdbbyvcabphnodfjupybae	106	21	compared	compare	VBN
work_u6osxdbbyvcabphnodfjupybae	106	22	directly	directly	RB
work_u6osxdbbyvcabphnodfjupybae	106	23	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	106	24	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	106	25	same	same	JJ
work_u6osxdbbyvcabphnodfjupybae	106	26	therapies	therapy	NNS
work_u6osxdbbyvcabphnodfjupybae	106	27	given	give	VBN
work_u6osxdbbyvcabphnodfjupybae	106	28	se-	se-	XX
work_u6osxdbbyvcabphnodfjupybae	106	29	quentially	quentially	RB
work_u6osxdbbyvcabphnodfjupybae	106	30	.	.	.
work_u6osxdbbyvcabphnodfjupybae	107	1	The	the	DT
work_u6osxdbbyvcabphnodfjupybae	107	2	survival	survival	NN
work_u6osxdbbyvcabphnodfjupybae	107	3	advantage	advantage	NN
work_u6osxdbbyvcabphnodfjupybae	107	4	is	be	VBZ
work_u6osxdbbyvcabphnodfjupybae	107	5	modest	modest	JJ
work_u6osxdbbyvcabphnodfjupybae	107	6	however	however	RB
work_u6osxdbbyvcabphnodfjupybae	107	7	,	,	,
work_u6osxdbbyvcabphnodfjupybae	107	8	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	107	9	there	there	EX
work_u6osxdbbyvcabphnodfjupybae	107	10	are	be	VBP
work_u6osxdbbyvcabphnodfjupybae	107	11	additional	additional	JJ
work_u6osxdbbyvcabphnodfjupybae	107	12	toxicities	toxicity	NNS
work_u6osxdbbyvcabphnodfjupybae	107	13	associated	associate	VBN
work_u6osxdbbyvcabphnodfjupybae	107	14	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	107	15	concurrent	concurrent	JJ
work_u6osxdbbyvcabphnodfjupybae	107	16	rather	rather	RB
work_u6osxdbbyvcabphnodfjupybae	107	17	than	than	IN
work_u6osxdbbyvcabphnodfjupybae	107	18	sequential	sequential	JJ
work_u6osxdbbyvcabphnodfjupybae	107	19	management.2	management.2	PDT
work_u6osxdbbyvcabphnodfjupybae	107	20	The	the	DT
work_u6osxdbbyvcabphnodfjupybae	107	21	potential	potential	NN
work_u6osxdbbyvcabphnodfjupybae	107	22	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	107	23	chemotherapy	chemotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	107	24	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	107	25	effectively	effectively	RB
work_u6osxdbbyvcabphnodfjupybae	107	26	eradicate	eradicate	VB
work_u6osxdbbyvcabphnodfjupybae	107	27	micrometastases	micrometastase	NNS
work_u6osxdbbyvcabphnodfjupybae	107	28	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	107	29	improve	improve	VB
work_u6osxdbbyvcabphnodfjupybae	107	30	survival	survival	NN
work_u6osxdbbyvcabphnodfjupybae	107	31	when	when	WRB
work_u6osxdbbyvcabphnodfjupybae	107	32	used	use	VBN
work_u6osxdbbyvcabphnodfjupybae	107	33	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	107	34	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	107	35	adjuvant	adjuvant	JJ
work_u6osxdbbyvcabphnodfjupybae	107	36	setting	setting	NN
work_u6osxdbbyvcabphnodfjupybae	107	37	has	have	VBZ
work_u6osxdbbyvcabphnodfjupybae	107	38	been	be	VBN
work_u6osxdbbyvcabphnodfjupybae	107	39	demonstrated	demonstrate	VBN
work_u6osxdbbyvcabphnodfjupybae	107	40	among	among	IN
work_u6osxdbbyvcabphnodfjupybae	107	41	patients	patient	NNS
work_u6osxdbbyvcabphnodfjupybae	107	42	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	107	43	many	many	JJ
work_u6osxdbbyvcabphnodfjupybae	107	44	different	different	JJ
work_u6osxdbbyvcabphnodfjupybae	107	45	types	type	NNS
work_u6osxdbbyvcabphnodfjupybae	107	46	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	107	47	solid	solid	JJ
work_u6osxdbbyvcabphnodfjupybae	107	48	tumors	tumor	NNS
work_u6osxdbbyvcabphnodfjupybae	107	49	including	include	VBG
work_u6osxdbbyvcabphnodfjupybae	107	50	NSCLC.8	nsclc.8	NN
work_u6osxdbbyvcabphnodfjupybae	107	51	In	in	IN
work_u6osxdbbyvcabphnodfjupybae	107	52	almost	almost	RB
work_u6osxdbbyvcabphnodfjupybae	107	53	all	all	PDT
work_u6osxdbbyvcabphnodfjupybae	107	54	these	these	DT
work_u6osxdbbyvcabphnodfjupybae	107	55	settings	setting	NNS
work_u6osxdbbyvcabphnodfjupybae	107	56	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	107	57	testis	testis	NNP
work_u6osxdbbyvcabphnodfjupybae	107	58	cancer	cancer	NN
work_u6osxdbbyvcabphnodfjupybae	107	59	being	be	VBG
work_u6osxdbbyvcabphnodfjupybae	107	60	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	107	61	notable	notable	JJ
work_u6osxdbbyvcabphnodfjupybae	107	62	solid	solid	JJ
work_u6osxdbbyvcabphnodfjupybae	107	63	tumor	tumor	NN
work_u6osxdbbyvcabphnodfjupybae	107	64	exception	exception	NN
work_u6osxdbbyvcabphnodfjupybae	107	65	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	107	66	,	,	,
work_u6osxdbbyvcabphnodfjupybae	107	67	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	107	68	adjuvant	adjuvant	JJ
work_u6osxdbbyvcabphnodfjupybae	107	69	chemotherapy	chemotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	107	70	prescription	prescription	NN
work_u6osxdbbyvcabphnodfjupybae	107	71	has	have	VBZ
work_u6osxdbbyvcabphnodfjupybae	107	72	included	include	VBN
work_u6osxdbbyvcabphnodfjupybae	107	73	more	more	JJR
work_u6osxdbbyvcabphnodfjupybae	107	74	than	than	IN
work_u6osxdbbyvcabphnodfjupybae	107	75	two	two	CD
work_u6osxdbbyvcabphnodfjupybae	107	76	cycles	cycle	NNS
work_u6osxdbbyvcabphnodfjupybae	107	77	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	107	78	chemotherapy	chemotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	107	79	.	.	.
work_u6osxdbbyvcabphnodfjupybae	108	1	Thus	thus	RB
work_u6osxdbbyvcabphnodfjupybae	108	2	,	,	,
work_u6osxdbbyvcabphnodfjupybae	108	3	when	when	WRB
work_u6osxdbbyvcabphnodfjupybae	108	4	approaching	approach	VBG
work_u6osxdbbyvcabphnodfjupybae	108	5	an	an	DT
work_u6osxdbbyvcabphnodfjupybae	108	6	individual	individual	NN
work_u6osxdbbyvcabphnodfjupybae	108	7	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	108	8	more	more	JJR
work_u6osxdbbyvcabphnodfjupybae	108	9	disease	disease	NN
work_u6osxdbbyvcabphnodfjupybae	108	10	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	108	11	e.g.	e.g.	RB
work_u6osxdbbyvcabphnodfjupybae	108	12	,	,	,
work_u6osxdbbyvcabphnodfjupybae	108	13	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	108	14	IIIB	IIIB	NNP
work_u6osxdbbyvcabphnodfjupybae	108	15	NSCLC	NSCLC	NNP
work_u6osxdbbyvcabphnodfjupybae	108	16	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	108	17	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	108	18	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	108	19	expectation	expectation	NN
work_u6osxdbbyvcabphnodfjupybae	108	20	that	that	IN
work_u6osxdbbyvcabphnodfjupybae	108	21	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	108	22	burden	burden	NN
work_u6osxdbbyvcabphnodfjupybae	108	23	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	108	24	micrometastatic	micrometastatic	JJ
work_u6osxdbbyvcabphnodfjupybae	108	25	disease	disease	NN
work_u6osxdbbyvcabphnodfjupybae	108	26	is	be	VBZ
work_u6osxdbbyvcabphnodfjupybae	108	27	likely	likely	JJ
work_u6osxdbbyvcabphnodfjupybae	108	28	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	108	29	be	be	VB
work_u6osxdbbyvcabphnodfjupybae	108	30	at	at	IN
work_u6osxdbbyvcabphnodfjupybae	108	31	least	least	JJS
work_u6osxdbbyvcabphnodfjupybae	108	32	as	as	RB
work_u6osxdbbyvcabphnodfjupybae	108	33	great	great	JJ
work_u6osxdbbyvcabphnodfjupybae	108	34	if	if	IN
work_u6osxdbbyvcabphnodfjupybae	108	35	not	not	RB
work_u6osxdbbyvcabphnodfjupybae	108	36	greater	great	JJR
work_u6osxdbbyvcabphnodfjupybae	108	37	than	than	IN
work_u6osxdbbyvcabphnodfjupybae	108	38	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	108	39	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	108	40	traditional	traditional	JJ
work_u6osxdbbyvcabphnodfjupybae	108	41	adjuvant	adjuvant	JJ
work_u6osxdbbyvcabphnodfjupybae	108	42	setting	setting	NN
work_u6osxdbbyvcabphnodfjupybae	108	43	,	,	,
work_u6osxdbbyvcabphnodfjupybae	108	44	investigators	investigator	NNS
work_u6osxdbbyvcabphnodfjupybae	108	45	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	108	46	treating	treat	VBG
work_u6osxdbbyvcabphnodfjupybae	108	47	physicians	physician	NNS
work_u6osxdbbyvcabphnodfjupybae	108	48	have	have	VBP
work_u6osxdbbyvcabphnodfjupybae	108	49	tended	tend	VBN
work_u6osxdbbyvcabphnodfjupybae	108	50	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	108	51	favor	favor	VB
work_u6osxdbbyvcabphnodfjupybae	108	52	strategies	strategy	NNS
work_u6osxdbbyvcabphnodfjupybae	108	53	using	use	VBG
work_u6osxdbbyvcabphnodfjupybae	108	54	more	more	JJR
work_u6osxdbbyvcabphnodfjupybae	108	55	than	than	IN
work_u6osxdbbyvcabphnodfjupybae	108	56	two	two	CD
work_u6osxdbbyvcabphnodfjupybae	108	57	cycles	cycle	NNS
work_u6osxdbbyvcabphnodfjupybae	108	58	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	108	59	chemotherapy	chemotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	108	60	as	as	IN
work_u6osxdbbyvcabphnodfjupybae	108	61	part	part	NN
work_u6osxdbbyvcabphnodfjupybae	108	62	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	108	63	definitive	definitive	JJ
work_u6osxdbbyvcabphnodfjupybae	108	64	management.2	management.2	NNP
work_u6osxdbbyvcabphnodfjupybae	108	65	Yet	yet	CC
work_u6osxdbbyvcabphnodfjupybae	108	66	,	,	,
work_u6osxdbbyvcabphnodfjupybae	108	67	no	no	DT
work_u6osxdbbyvcabphnodfjupybae	108	68	randomized	randomized	JJ
work_u6osxdbbyvcabphnodfjupybae	108	69	phase	phase	NN
work_u6osxdbbyvcabphnodfjupybae	108	70	III	iii	CD
work_u6osxdbbyvcabphnodfjupybae	108	71	data	datum	NNS
work_u6osxdbbyvcabphnodfjupybae	108	72	are	be	VBP
work_u6osxdbbyvcabphnodfjupybae	108	73	avail-	avail-	JJ
work_u6osxdbbyvcabphnodfjupybae	108	74	able	able	JJ
work_u6osxdbbyvcabphnodfjupybae	108	75	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	108	76	endorse	endorse	VB
work_u6osxdbbyvcabphnodfjupybae	108	77	this	this	DT
work_u6osxdbbyvcabphnodfjupybae	108	78	approach	approach	NN
work_u6osxdbbyvcabphnodfjupybae	108	79	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	108	80	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	108	81	III	iii	CD
work_u6osxdbbyvcabphnodfjupybae	108	82	NSCLC	NSCLC	NNP
work_u6osxdbbyvcabphnodfjupybae	108	83	.	.	.
work_u6osxdbbyvcabphnodfjupybae	109	1	However	however	RB
work_u6osxdbbyvcabphnodfjupybae	109	2	,	,	,
work_u6osxdbbyvcabphnodfjupybae	109	3	as	as	IN
work_u6osxdbbyvcabphnodfjupybae	109	4	demonstrated	demonstrate	VBN
work_u6osxdbbyvcabphnodfjupybae	109	5	here	here	RB
work_u6osxdbbyvcabphnodfjupybae	109	6	,	,	,
work_u6osxdbbyvcabphnodfjupybae	109	7	before	before	IN
work_u6osxdbbyvcabphnodfjupybae	109	8	ASCO	ASCO	NNP
work_u6osxdbbyvcabphnodfjupybae	109	9	2007	2007	CD
work_u6osxdbbyvcabphnodfjupybae	109	10	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	109	11	use	use	NN
work_u6osxdbbyvcabphnodfjupybae	109	12	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	109	13	more	more	JJR
work_u6osxdbbyvcabphnodfjupybae	109	14	than	than	IN
work_u6osxdbbyvcabphnodfjupybae	109	15	two	two	CD
work_u6osxdbbyvcabphnodfjupybae	109	16	cycles	cycle	NNS
work_u6osxdbbyvcabphnodfjupybae	109	17	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	109	18	chemotherapy	chemotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	109	19	was	be	VBD
work_u6osxdbbyvcabphnodfjupybae	109	20	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	109	21	overwhelming	overwhelming	JJ
work_u6osxdbbyvcabphnodfjupybae	109	22	plan	plan	NN
work_u6osxdbbyvcabphnodfjupybae	109	23	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	109	24	American	american	JJ
work_u6osxdbbyvcabphnodfjupybae	109	25	medical	medical	JJ
work_u6osxdbbyvcabphnodfjupybae	109	26	oncologists	oncologist	NNS
work_u6osxdbbyvcabphnodfjupybae	109	27	treating	treat	VBG
work_u6osxdbbyvcabphnodfjupybae	109	28	patients	patient	NNS
work_u6osxdbbyvcabphnodfjupybae	109	29	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	109	30	N3	n3	NN
work_u6osxdbbyvcabphnodfjupybae	109	31	,	,	,
work_u6osxdbbyvcabphnodfjupybae	109	32	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	109	33	IIIB	IIIB	NNP
work_u6osxdbbyvcabphnodfjupybae	109	34	disease	disease	NN
work_u6osxdbbyvcabphnodfjupybae	109	35	.	.	.
work_u6osxdbbyvcabphnodfjupybae	110	1	For	for	IN
work_u6osxdbbyvcabphnodfjupybae	110	2	nearly	nearly	RB
work_u6osxdbbyvcabphnodfjupybae	110	3	70	70	CD
work_u6osxdbbyvcabphnodfjupybae	110	4	%	%	NN
work_u6osxdbbyvcabphnodfjupybae	110	5	,	,	,
work_u6osxdbbyvcabphnodfjupybae	110	6	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	110	7	additional	additional	JJ
work_u6osxdbbyvcabphnodfjupybae	110	8	chemother-	chemother-	NN
work_u6osxdbbyvcabphnodfjupybae	110	9	apy	apy	NNP
work_u6osxdbbyvcabphnodfjupybae	110	10	was	be	VBD
work_u6osxdbbyvcabphnodfjupybae	110	11	planned	plan	VBN
work_u6osxdbbyvcabphnodfjupybae	110	12	as	as	IN
work_u6osxdbbyvcabphnodfjupybae	110	13	consolidation	consolidation	NN
work_u6osxdbbyvcabphnodfjupybae	110	14	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	110	15	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	110	16	most	most	JJS
work_u6osxdbbyvcabphnodfjupybae	110	17	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	110	18	those	those	DT
work_u6osxdbbyvcabphnodfjupybae	110	19	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	110	20	consolidation	consolidation	NN
work_u6osxdbbyvcabphnodfjupybae	110	21	involved	involve	VBD
work_u6osxdbbyvcabphnodfjupybae	110	22	use	use	NN
work_u6osxdbbyvcabphnodfjupybae	110	23	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	110	24	single	single	JJ
work_u6osxdbbyvcabphnodfjupybae	110	25	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	110	26	agent	agent	NN
work_u6osxdbbyvcabphnodfjupybae	110	27	docetaxel	docetaxel	NNP
work_u6osxdbbyvcabphnodfjupybae	110	28	.	.	.
work_u6osxdbbyvcabphnodfjupybae	111	1	This	this	DT
work_u6osxdbbyvcabphnodfjupybae	111	2	approach	approach	NN
work_u6osxdbbyvcabphnodfjupybae	111	3	was	be	VBD
work_u6osxdbbyvcabphnodfjupybae	111	4	supported	support	VBN
work_u6osxdbbyvcabphnodfjupybae	111	5	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	111	6	impressive	impressive	JJ
work_u6osxdbbyvcabphnodfjupybae	111	7	multiinstitutional	multiinstitutional	JJ
work_u6osxdbbyvcabphnodfjupybae	111	8	phase	phase	NN
work_u6osxdbbyvcabphnodfjupybae	111	9	II	ii	CD
work_u6osxdbbyvcabphnodfjupybae	111	10	data	datum	NNS
work_u6osxdbbyvcabphnodfjupybae	111	11	provided	provide	VBN
work_u6osxdbbyvcabphnodfjupybae	111	12	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	111	13	investigators	investigator	NNS
work_u6osxdbbyvcabphnodfjupybae	111	14	from	from	IN
work_u6osxdbbyvcabphnodfjupybae	111	15	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	111	16	SWOG	swog	NN
work_u6osxdbbyvcabphnodfjupybae	111	17	.	.	.
work_u6osxdbbyvcabphnodfjupybae	112	1	In	in	IN
work_u6osxdbbyvcabphnodfjupybae	112	2	their	-PRON-	PRP$
work_u6osxdbbyvcabphnodfjupybae	112	3	phase	phase	NN
work_u6osxdbbyvcabphnodfjupybae	112	4	II	ii	CD
work_u6osxdbbyvcabphnodfjupybae	112	5	work	work	NN
work_u6osxdbbyvcabphnodfjupybae	112	6	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	112	7	SWOG	swog	NN
work_u6osxdbbyvcabphnodfjupybae	112	8	9504),4	9504),4	VB
work_u6osxdbbyvcabphnodfjupybae	112	9	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	112	10	median	median	JJ
work_u6osxdbbyvcabphnodfjupybae	112	11	survival	survival	NN
work_u6osxdbbyvcabphnodfjupybae	112	12	achieved	achieve	VBN
work_u6osxdbbyvcabphnodfjupybae	112	13	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	112	14	immediate	immediate	JJ
work_u6osxdbbyvcabphnodfjupybae	112	15	concurrent	concurrent	JJ
work_u6osxdbbyvcabphnodfjupybae	112	16	etoposide	etoposide	NN
work_u6osxdbbyvcabphnodfjupybae	112	17	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	112	18	cisplatin	cisplatin	NN
work_u6osxdbbyvcabphnodfjupybae	112	19	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	112	20	thoracic	thoracic	NN
work_u6osxdbbyvcabphnodfjupybae	112	21	radiation	radiation	NN
work_u6osxdbbyvcabphnodfjupybae	112	22	followed	follow	VBN
work_u6osxdbbyvcabphnodfjupybae	112	23	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	112	24	three	three	CD
work_u6osxdbbyvcabphnodfjupybae	112	25	cycles	cycle	NNS
work_u6osxdbbyvcabphnodfjupybae	112	26	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	112	27	docetaxel	docetaxel	NNP
work_u6osxdbbyvcabphnodfjupybae	112	28	consolidation	consolidation	NN
work_u6osxdbbyvcabphnodfjupybae	112	29	was	be	VBD
work_u6osxdbbyvcabphnodfjupybae	112	30	26	26	CD
work_u6osxdbbyvcabphnodfjupybae	112	31	months	month	NNS
work_u6osxdbbyvcabphnodfjupybae	112	32	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	112	33	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	112	34	3-	3-	NNPS
work_u6osxdbbyvcabphnodfjupybae	112	35	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	112	36	5-year	5-year	CD
work_u6osxdbbyvcabphnodfjupybae	112	37	survival	survival	NN
work_u6osxdbbyvcabphnodfjupybae	112	38	rates	rate	NNS
work_u6osxdbbyvcabphnodfjupybae	112	39	were	be	VBD
work_u6osxdbbyvcabphnodfjupybae	112	40	40	40	CD
work_u6osxdbbyvcabphnodfjupybae	112	41	%	%	NN
work_u6osxdbbyvcabphnodfjupybae	112	42	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	112	43	29	29	CD
work_u6osxdbbyvcabphnodfjupybae	112	44	%	%	NN
work_u6osxdbbyvcabphnodfjupybae	112	45	,	,	,
work_u6osxdbbyvcabphnodfjupybae	112	46	respectively.4	respectively.4	VBN
work_u6osxdbbyvcabphnodfjupybae	112	47	In	in	IN
work_u6osxdbbyvcabphnodfjupybae	112	48	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	112	49	previous	previous	JJ
work_u6osxdbbyvcabphnodfjupybae	112	50	SWOG	swog	NN
work_u6osxdbbyvcabphnodfjupybae	112	51	study	study	NN
work_u6osxdbbyvcabphnodfjupybae	112	52	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	112	53	patients	patient	NNS
work_u6osxdbbyvcabphnodfjupybae	112	54	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	112	55	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	112	56	III	iii	CD
work_u6osxdbbyvcabphnodfjupybae	112	57	disease	disease	NN
work_u6osxdbbyvcabphnodfjupybae	112	58	using	use	VBG
work_u6osxdbbyvcabphnodfjupybae	112	59	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	112	60	same	same	JJ
work_u6osxdbbyvcabphnodfjupybae	112	61	initial	initial	JJ
work_u6osxdbbyvcabphnodfjupybae	112	62	chemoradiotherapy	chemoradiotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	112	63	but	but	CC
work_u6osxdbbyvcabphnodfjupybae	112	64	followed	follow	VBN
work_u6osxdbbyvcabphnodfjupybae	112	65	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	112	66	consolidation	consolidation	NN
work_u6osxdbbyvcabphnodfjupybae	112	67	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	112	68	two	two	CD
work_u6osxdbbyvcabphnodfjupybae	112	69	added	add	VBN
work_u6osxdbbyvcabphnodfjupybae	112	70	cycles	cycle	NNS
work_u6osxdbbyvcabphnodfjupybae	112	71	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	112	72	etoposide	etoposide	NN
work_u6osxdbbyvcabphnodfjupybae	112	73	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	112	74	cisplatin	cisplatin	NN
work_u6osxdbbyvcabphnodfjupybae	112	75	,	,	,
work_u6osxdbbyvcabphnodfjupybae	112	76	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	112	77	median	median	JJ
work_u6osxdbbyvcabphnodfjupybae	112	78	survival	survival	NN
work_u6osxdbbyvcabphnodfjupybae	112	79	was	be	VBD
work_u6osxdbbyvcabphnodfjupybae	112	80	15	15	CD
work_u6osxdbbyvcabphnodfjupybae	112	81	months	month	NNS
work_u6osxdbbyvcabphnodfjupybae	112	82	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	112	83	3-	3-	NNPS
work_u6osxdbbyvcabphnodfjupybae	112	84	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	112	85	5-year	5-year	CD
work_u6osxdbbyvcabphnodfjupybae	112	86	survival	survival	NN
work_u6osxdbbyvcabphnodfjupybae	112	87	rates	rate	NNS
work_u6osxdbbyvcabphnodfjupybae	112	88	were	be	VBD
work_u6osxdbbyvcabphnodfjupybae	112	89	17%.9	17%.9	CD
work_u6osxdbbyvcabphnodfjupybae	112	90	These	these	DT
work_u6osxdbbyvcabphnodfjupybae	112	91	phase	phase	NN
work_u6osxdbbyvcabphnodfjupybae	112	92	II	ii	CD
work_u6osxdbbyvcabphnodfjupybae	112	93	findings	finding	NNS
work_u6osxdbbyvcabphnodfjupybae	112	94	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	112	95	informal	informal	JJ
work_u6osxdbbyvcabphnodfjupybae	112	96	comparison	comparison	NN
work_u6osxdbbyvcabphnodfjupybae	112	97	generated	generate	VBD
work_u6osxdbbyvcabphnodfjupybae	112	98	major	major	JJ
work_u6osxdbbyvcabphnodfjupybae	112	99	enthusiasm	enthusiasm	NN
work_u6osxdbbyvcabphnodfjupybae	112	100	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	112	101	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	112	102	SWOG	swog	NN
work_u6osxdbbyvcabphnodfjupybae	112	103	9504	9504	CD
work_u6osxdbbyvcabphnodfjupybae	112	104	approach	approach	NN
work_u6osxdbbyvcabphnodfjupybae	112	105	.	.	.
work_u6osxdbbyvcabphnodfjupybae	113	1	After	after	IN
work_u6osxdbbyvcabphnodfjupybae	113	2	lengthy	lengthy	JJ
work_u6osxdbbyvcabphnodfjupybae	113	3	discussions	discussion	NNS
work_u6osxdbbyvcabphnodfjupybae	113	4	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	113	5	representatives	representative	NNS
work_u6osxdbbyvcabphnodfjupybae	113	6	from	from	IN
work_u6osxdbbyvcabphnodfjupybae	113	7	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	113	8	National	National	NNP
work_u6osxdbbyvcabphnodfjupybae	113	9	Cancer	Cancer	NNP
work_u6osxdbbyvcabphnodfjupybae	113	10	Institute	Institute	NNP
work_u6osxdbbyvcabphnodfjupybae	113	11	’s	’s	POS
work_u6osxdbbyvcabphnodfjupybae	113	12	Cancer	Cancer	NNP
work_u6osxdbbyvcabphnodfjupybae	113	13	Therapy	Therapy	NNP
work_u6osxdbbyvcabphnodfjupybae	113	14	Evaluation	Evaluation	NNP
work_u6osxdbbyvcabphnodfjupybae	113	15	Program	Program	NNP
work_u6osxdbbyvcabphnodfjupybae	113	16	,	,	,
work_u6osxdbbyvcabphnodfjupybae	113	17	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	113	18	follow	follow	NN
work_u6osxdbbyvcabphnodfjupybae	113	19	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	113	20	up	up	NN
work_u6osxdbbyvcabphnodfjupybae	113	21	phase	phase	NN
work_u6osxdbbyvcabphnodfjupybae	113	22	III	iii	CD
work_u6osxdbbyvcabphnodfjupybae	113	23	trial	trial	NN
work_u6osxdbbyvcabphnodfjupybae	113	24	proposed	propose	VBN
work_u6osxdbbyvcabphnodfjupybae	113	25	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	113	26	SWOG	swog	NN
work_u6osxdbbyvcabphnodfjupybae	113	27	investigators	investigator	NNS
work_u6osxdbbyvcabphnodfjupybae	113	28	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	113	29	confirm	confirm	VB
work_u6osxdbbyvcabphnodfjupybae	113	30	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	113	31	benefit	benefit	NN
work_u6osxdbbyvcabphnodfjupybae	113	32	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	113	33	consolidation	consolidation	NN
work_u6osxdbbyvcabphnodfjupybae	113	34	docetaxel	docetaxel	NNP
work_u6osxdbbyvcabphnodfjupybae	113	35	that	that	WDT
work_u6osxdbbyvcabphnodfjupybae	113	36	was	be	VBD
work_u6osxdbbyvcabphnodfjupybae	113	37	im-	im-	RB
work_u6osxdbbyvcabphnodfjupybae	113	38	plied	ply	VBN
work_u6osxdbbyvcabphnodfjupybae	113	39	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	113	40	their	-PRON-	PRP$
work_u6osxdbbyvcabphnodfjupybae	113	41	sequential	sequential	JJ
work_u6osxdbbyvcabphnodfjupybae	113	42	phase	phase	NN
work_u6osxdbbyvcabphnodfjupybae	113	43	II	ii	CD
work_u6osxdbbyvcabphnodfjupybae	113	44	trials	trial	NNS
work_u6osxdbbyvcabphnodfjupybae	113	45	was	be	VBD
work_u6osxdbbyvcabphnodfjupybae	113	46	not	not	RB
work_u6osxdbbyvcabphnodfjupybae	113	47	approved	approve	VBN
work_u6osxdbbyvcabphnodfjupybae	113	48	.	.	.
work_u6osxdbbyvcabphnodfjupybae	114	1	Instead	instead	RB
work_u6osxdbbyvcabphnodfjupybae	114	2	,	,	,
work_u6osxdbbyvcabphnodfjupybae	114	3	an	an	DT
work_u6osxdbbyvcabphnodfjupybae	114	4	alternative	alternative	JJ
work_u6osxdbbyvcabphnodfjupybae	114	5	design	design	NN
work_u6osxdbbyvcabphnodfjupybae	114	6	that	that	WDT
work_u6osxdbbyvcabphnodfjupybae	114	7	presumed	presume	VBD
work_u6osxdbbyvcabphnodfjupybae	114	8	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	114	9	benefit	benefit	NN
work_u6osxdbbyvcabphnodfjupybae	114	10	from	from	IN
work_u6osxdbbyvcabphnodfjupybae	114	11	consolidation	consolidation	NN
work_u6osxdbbyvcabphnodfjupybae	114	12	docetaxel	docetaxel	NNS
work_u6osxdbbyvcabphnodfjupybae	114	13	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	114	14	tested	test	VBD
work_u6osxdbbyvcabphnodfjupybae	114	15	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	114	16	value	value	NN
work_u6osxdbbyvcabphnodfjupybae	114	17	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	114	18	maintenance	maintenance	NN
work_u6osxdbbyvcabphnodfjupybae	114	19	gefitinib	gefitinib	JJ
work_u6osxdbbyvcabphnodfjupybae	114	20	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	114	21	SWOG	SWOG	NNP
work_u6osxdbbyvcabphnodfjupybae	114	22	S0023	S0023	NNP
work_u6osxdbbyvcabphnodfjupybae	114	23	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	114	24	was	be	VBD
work_u6osxdbbyvcabphnodfjupybae	114	25	moved	move	VBN
work_u6osxdbbyvcabphnodfjupybae	114	26	forward.10	forward.10	NNP
work_u6osxdbbyvcabphnodfjupybae	114	27	At	at	IN
work_u6osxdbbyvcabphnodfjupybae	114	28	ASCO	ASCO	NNP
work_u6osxdbbyvcabphnodfjupybae	114	29	2007	2007	CD
work_u6osxdbbyvcabphnodfjupybae	114	30	,	,	,
work_u6osxdbbyvcabphnodfjupybae	114	31	findings	finding	NNS
work_u6osxdbbyvcabphnodfjupybae	114	32	from	from	IN
work_u6osxdbbyvcabphnodfjupybae	114	33	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	114	34	HOG	hog	NN
work_u6osxdbbyvcabphnodfjupybae	114	35	phase	phase	NN
work_u6osxdbbyvcabphnodfjupybae	114	36	III	iii	CD
work_u6osxdbbyvcabphnodfjupybae	114	37	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	114	38	albeit	albeit	IN
work_u6osxdbbyvcabphnodfjupybae	114	39	modest	modest	JJ
work_u6osxdbbyvcabphnodfjupybae	114	40	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	114	41	size	size	NN
work_u6osxdbbyvcabphnodfjupybae	114	42	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	114	43	trial	trial	NN
work_u6osxdbbyvcabphnodfjupybae	114	44	testing	test	VBG
work_u6osxdbbyvcabphnodfjupybae	114	45	immediate	immediate	JJ
work_u6osxdbbyvcabphnodfjupybae	114	46	concurrent	concurrent	JJ
work_u6osxdbbyvcabphnodfjupybae	114	47	FIGURE	FIGURE	NNP
work_u6osxdbbyvcabphnodfjupybae	114	48	7	7	CD
work_u6osxdbbyvcabphnodfjupybae	114	49	.	.	.
work_u6osxdbbyvcabphnodfjupybae	115	1	Prescribing	prescribing	NN
work_u6osxdbbyvcabphnodfjupybae	115	2	plans	plan	NNS
work_u6osxdbbyvcabphnodfjupybae	115	3	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	115	4	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	115	5	patient	patient	NN
work_u6osxdbbyvcabphnodfjupybae	115	6	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	115	7	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	115	8	new	new	JJ
work_u6osxdbbyvcabphnodfjupybae	115	9	diag-	diag-	NN
work_u6osxdbbyvcabphnodfjupybae	115	10	nosis	nosis	NN
work_u6osxdbbyvcabphnodfjupybae	115	11	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	115	12	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	115	13	IIIB	IIIB	NNP
work_u6osxdbbyvcabphnodfjupybae	115	14	non	non	JJ
work_u6osxdbbyvcabphnodfjupybae	115	15	-	-	JJ
work_u6osxdbbyvcabphnodfjupybae	115	16	small	small	JJ
work_u6osxdbbyvcabphnodfjupybae	115	17	cell	cell	NN
work_u6osxdbbyvcabphnodfjupybae	115	18	lung	lung	NN
work_u6osxdbbyvcabphnodfjupybae	115	19	cancer	cancer	NN
work_u6osxdbbyvcabphnodfjupybae	115	20	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	115	21	NSCLC	NSCLC	NNP
work_u6osxdbbyvcabphnodfjupybae	115	22	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	115	23	as-	as-	NN
work_u6osxdbbyvcabphnodfjupybae	115	24	sessed	sesse	VBD
work_u6osxdbbyvcabphnodfjupybae	115	25	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	115	26	427	427	CD
work_u6osxdbbyvcabphnodfjupybae	115	27	American	american	JJ
work_u6osxdbbyvcabphnodfjupybae	115	28	medical	medical	JJ
work_u6osxdbbyvcabphnodfjupybae	115	29	oncologists	oncologist	NNS
work_u6osxdbbyvcabphnodfjupybae	115	30	who	who	WP
work_u6osxdbbyvcabphnodfjupybae	115	31	partici-	partici-	VBD
work_u6osxdbbyvcabphnodfjupybae	115	32	pated	pat	VBD
work_u6osxdbbyvcabphnodfjupybae	115	33	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	115	34	Network	Network	NNP
work_u6osxdbbyvcabphnodfjupybae	115	35	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	115	36	Medical	Medical	NNP
work_u6osxdbbyvcabphnodfjupybae	115	37	Communications	Communications	NNPS
work_u6osxdbbyvcabphnodfjupybae	115	38	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	115	39	Research	Research	NNP
work_u6osxdbbyvcabphnodfjupybae	115	40	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	115	41	NMCR	NMCR	NNP
work_u6osxdbbyvcabphnodfjupybae	115	42	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	115	43	live	live	VBP
work_u6osxdbbyvcabphnodfjupybae	115	44	research	research	NN
work_u6osxdbbyvcabphnodfjupybae	115	45	events	event	NNS
work_u6osxdbbyvcabphnodfjupybae	115	46	between	between	IN
work_u6osxdbbyvcabphnodfjupybae	115	47	March	March	NNP
work_u6osxdbbyvcabphnodfjupybae	115	48	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	115	49	September	September	NNP
work_u6osxdbbyvcabphnodfjupybae	115	50	2007	2007	CD
work_u6osxdbbyvcabphnodfjupybae	115	51	.	.	.
work_u6osxdbbyvcabphnodfjupybae	116	1	Prescribing	prescribing	NN
work_u6osxdbbyvcabphnodfjupybae	116	2	plan	plan	NN
work_u6osxdbbyvcabphnodfjupybae	116	3	data	datum	NNS
work_u6osxdbbyvcabphnodfjupybae	116	4	are	be	VBP
work_u6osxdbbyvcabphnodfjupybae	116	5	shown	show	VBN
work_u6osxdbbyvcabphnodfjupybae	116	6	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	116	7	each	each	DT
work_u6osxdbbyvcabphnodfjupybae	116	8	specific	specific	JJ
work_u6osxdbbyvcabphnodfjupybae	116	9	re-	re-	JJ
work_u6osxdbbyvcabphnodfjupybae	116	10	search	search	NN
work_u6osxdbbyvcabphnodfjupybae	116	11	event	event	NN
work_u6osxdbbyvcabphnodfjupybae	116	12	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	116	13	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	116	14	inflection	inflection	NN
work_u6osxdbbyvcabphnodfjupybae	116	15	point	point	NN
work_u6osxdbbyvcabphnodfjupybae	116	16	coinciding	coincide	VBG
work_u6osxdbbyvcabphnodfjupybae	116	17	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	116	18	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	116	19	Hoosier	Hoosier	NNP
work_u6osxdbbyvcabphnodfjupybae	116	20	Oncology	Oncology	NNP
work_u6osxdbbyvcabphnodfjupybae	116	21	Group	Group	NNP
work_u6osxdbbyvcabphnodfjupybae	116	22	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	116	23	HOG	HOG	NNP
work_u6osxdbbyvcabphnodfjupybae	116	24	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	116	25	data	datum	NNS
work_u6osxdbbyvcabphnodfjupybae	116	26	presentation	presentation	NN
work_u6osxdbbyvcabphnodfjupybae	116	27	at	at	IN
work_u6osxdbbyvcabphnodfjupybae	116	28	Ameri-	Ameri-	NNP
work_u6osxdbbyvcabphnodfjupybae	116	29	can	can	MD
work_u6osxdbbyvcabphnodfjupybae	116	30	Society	Society	NNP
work_u6osxdbbyvcabphnodfjupybae	116	31	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	116	32	Clinical	Clinical	NNP
work_u6osxdbbyvcabphnodfjupybae	116	33	Oncology	Oncology	NNP
work_u6osxdbbyvcabphnodfjupybae	116	34	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	116	35	ASCO	ASCO	NNP
work_u6osxdbbyvcabphnodfjupybae	116	36	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	116	37	2007	2007	CD
work_u6osxdbbyvcabphnodfjupybae	116	38	.	.	.
work_u6osxdbbyvcabphnodfjupybae	117	1	TABLE	TABLE	NNP
work_u6osxdbbyvcabphnodfjupybae	117	2	1	1	CD
work_u6osxdbbyvcabphnodfjupybae	117	3	.	.	.
work_u6osxdbbyvcabphnodfjupybae	118	1	Prescribing	Prescribing	NNP
work_u6osxdbbyvcabphnodfjupybae	118	2	Plan	Plan	NNP
work_u6osxdbbyvcabphnodfjupybae	118	3	Data	Data	NNP
work_u6osxdbbyvcabphnodfjupybae	118	4	from	from	IN
work_u6osxdbbyvcabphnodfjupybae	118	5	Research	Research	NNP
work_u6osxdbbyvcabphnodfjupybae	118	6	Events	event	NNS
work_u6osxdbbyvcabphnodfjupybae	118	7	Held	hold	VBN
work_u6osxdbbyvcabphnodfjupybae	118	8	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	118	9	February	February	NNP
work_u6osxdbbyvcabphnodfjupybae	118	10	2008	2008	CD
work_u6osxdbbyvcabphnodfjupybae	118	11	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	118	12	April	April	NNP
work_u6osxdbbyvcabphnodfjupybae	118	13	2008	2008	CD
work_u6osxdbbyvcabphnodfjupybae	118	14	Demonstrate	Demonstrate	NNP
work_u6osxdbbyvcabphnodfjupybae	118	15	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	118	16	Persisting	persisting	NN
work_u6osxdbbyvcabphnodfjupybae	118	17	Shift	shift	VB
work_u6osxdbbyvcabphnodfjupybae	118	18	Away	away	RB
work_u6osxdbbyvcabphnodfjupybae	118	19	from	from	IN
work_u6osxdbbyvcabphnodfjupybae	118	20	Use	Use	NNP
work_u6osxdbbyvcabphnodfjupybae	118	21	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	118	22	Docetaxel	Docetaxel	NNP
work_u6osxdbbyvcabphnodfjupybae	118	23	Consolidation	Consolidation	NNP
work_u6osxdbbyvcabphnodfjupybae	118	24	After	after	IN
work_u6osxdbbyvcabphnodfjupybae	118	25	ASCO	ASCO	NNP
work_u6osxdbbyvcabphnodfjupybae	118	26	2007	2007	CD
work_u6osxdbbyvcabphnodfjupybae	118	27	Regimen	Regimen	NNP
work_u6osxdbbyvcabphnodfjupybae	118	28	February	February	NNP
work_u6osxdbbyvcabphnodfjupybae	118	29	23	23	CD
work_u6osxdbbyvcabphnodfjupybae	118	30	,	,	,
work_u6osxdbbyvcabphnodfjupybae	118	31	2008	2008	CD
work_u6osxdbbyvcabphnodfjupybae	118	32	,	,	,
work_u6osxdbbyvcabphnodfjupybae	118	33	n	n	NNP
work_u6osxdbbyvcabphnodfjupybae	118	34	�	�	NNP
work_u6osxdbbyvcabphnodfjupybae	118	35	109	109	CD
work_u6osxdbbyvcabphnodfjupybae	118	36	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	118	37	%	%	NN
work_u6osxdbbyvcabphnodfjupybae	118	38	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	118	39	April	April	NNP
work_u6osxdbbyvcabphnodfjupybae	118	40	05	05	CD
work_u6osxdbbyvcabphnodfjupybae	118	41	,	,	,
work_u6osxdbbyvcabphnodfjupybae	118	42	2008	2008	CD
work_u6osxdbbyvcabphnodfjupybae	118	43	,	,	,
work_u6osxdbbyvcabphnodfjupybae	118	44	n	n	NNP
work_u6osxdbbyvcabphnodfjupybae	118	45	�	�	NNP
work_u6osxdbbyvcabphnodfjupybae	118	46	61	61	CD
work_u6osxdbbyvcabphnodfjupybae	118	47	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	118	48	%	%	NN
work_u6osxdbbyvcabphnodfjupybae	118	49	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	118	50	CT	CT	NNP
work_u6osxdbbyvcabphnodfjupybae	118	51	/	/	SYM
work_u6osxdbbyvcabphnodfjupybae	118	52	TRT	TRT	NNP
work_u6osxdbbyvcabphnodfjupybae	118	53	1	1	CD
work_u6osxdbbyvcabphnodfjupybae	118	54	5	5	CD
work_u6osxdbbyvcabphnodfjupybae	118	55	CT	CT	NNP
work_u6osxdbbyvcabphnodfjupybae	118	56	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	118	57	CT	CT	NNP
work_u6osxdbbyvcabphnodfjupybae	118	58	/	/	SYM
work_u6osxdbbyvcabphnodfjupybae	118	59	TRT	TRT	NNP
work_u6osxdbbyvcabphnodfjupybae	118	60	8	8	CD
work_u6osxdbbyvcabphnodfjupybae	118	61	10	10	CD
work_u6osxdbbyvcabphnodfjupybae	118	62	CT	CT	NNP
work_u6osxdbbyvcabphnodfjupybae	118	63	/	/	SYM
work_u6osxdbbyvcabphnodfjupybae	118	64	TRT	TRT	NNP
work_u6osxdbbyvcabphnodfjupybae	118	65	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	118	66	HOG	HOG	NNP
work_u6osxdbbyvcabphnodfjupybae	118	67	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	118	68	39	39	CD
work_u6osxdbbyvcabphnodfjupybae	118	69	44	44	CD
work_u6osxdbbyvcabphnodfjupybae	118	70	CT	CT	NNP
work_u6osxdbbyvcabphnodfjupybae	118	71	/	/	SYM
work_u6osxdbbyvcabphnodfjupybae	118	72	TRT	TRT	NNP
work_u6osxdbbyvcabphnodfjupybae	118	73	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	118	74	same	same	JJ
work_u6osxdbbyvcabphnodfjupybae	118	75	CT	CT	NNP
work_u6osxdbbyvcabphnodfjupybae	118	76	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	118	77	LAMP	LAMP	NNP
work_u6osxdbbyvcabphnodfjupybae	118	78	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	118	79	26	26	CD
work_u6osxdbbyvcabphnodfjupybae	118	80	23	23	CD
work_u6osxdbbyvcabphnodfjupybae	118	81	CT	CT	NNP
work_u6osxdbbyvcabphnodfjupybae	118	82	/	/	SYM
work_u6osxdbbyvcabphnodfjupybae	118	83	TRT	trt	NN
work_u6osxdbbyvcabphnodfjupybae	118	84	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	118	85	doc	doc	NNP
work_u6osxdbbyvcabphnodfjupybae	118	86	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	118	87	SWOG	swog	NN
work_u6osxdbbyvcabphnodfjupybae	118	88	9504	9504	CD
work_u6osxdbbyvcabphnodfjupybae	118	89	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	118	90	19	19	CD
work_u6osxdbbyvcabphnodfjupybae	118	91	18	18	CD
work_u6osxdbbyvcabphnodfjupybae	118	92	CT	CT	NNP
work_u6osxdbbyvcabphnodfjupybae	118	93	/	/	SYM
work_u6osxdbbyvcabphnodfjupybae	118	94	TRT	TRT	NNP
work_u6osxdbbyvcabphnodfjupybae	118	95	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	118	96	doc	doc	NNP
work_u6osxdbbyvcabphnodfjupybae	118	97	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	118	98	erlotinib	erlotinib	NN
work_u6osxdbbyvcabphnodfjupybae	118	99	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	118	100	0023	0023	CD
work_u6osxdbbyvcabphnodfjupybae	118	101	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	118	102	3	3	CD
work_u6osxdbbyvcabphnodfjupybae	118	103	0	0	CD
work_u6osxdbbyvcabphnodfjupybae	118	104	CT	CT	NNP
work_u6osxdbbyvcabphnodfjupybae	118	105	alone	alone	RB
work_u6osxdbbyvcabphnodfjupybae	118	106	1	1	CD
work_u6osxdbbyvcabphnodfjupybae	118	107	0	0	CD
work_u6osxdbbyvcabphnodfjupybae	118	108	Other	other	JJ
work_u6osxdbbyvcabphnodfjupybae	118	109	1	1	CD
work_u6osxdbbyvcabphnodfjupybae	118	110	0	0	CD
work_u6osxdbbyvcabphnodfjupybae	118	111	CT	CT	NNP
work_u6osxdbbyvcabphnodfjupybae	118	112	/	/	SYM
work_u6osxdbbyvcabphnodfjupybae	118	113	TRT	TRT	NNP
work_u6osxdbbyvcabphnodfjupybae	118	114	,	,	,
work_u6osxdbbyvcabphnodfjupybae	118	115	chemotherapy	chemotherapy	NNP
work_u6osxdbbyvcabphnodfjupybae	118	116	/	/	SYM
work_u6osxdbbyvcabphnodfjupybae	118	117	thoracic	thoracic	NNP
work_u6osxdbbyvcabphnodfjupybae	118	118	radiotherapy	radiotherapy	NNP
work_u6osxdbbyvcabphnodfjupybae	118	119	;	;	:
work_u6osxdbbyvcabphnodfjupybae	118	120	HOG	HOG	NNP
work_u6osxdbbyvcabphnodfjupybae	118	121	,	,	,
work_u6osxdbbyvcabphnodfjupybae	118	122	Hoosier	Hoosier	NNP
work_u6osxdbbyvcabphnodfjupybae	118	123	Oncology	Oncology	NNP
work_u6osxdbbyvcabphnodfjupybae	118	124	Group	Group	NNP
work_u6osxdbbyvcabphnodfjupybae	118	125	;	;	:
work_u6osxdbbyvcabphnodfjupybae	118	126	LAMP	LAMP	NNP
work_u6osxdbbyvcabphnodfjupybae	118	127	,	,	,
work_u6osxdbbyvcabphnodfjupybae	118	128	locally	locally	RB
work_u6osxdbbyvcabphnodfjupybae	118	129	advanced	advance	VBD
work_u6osxdbbyvcabphnodfjupybae	118	130	multi	multi	JJ
work_u6osxdbbyvcabphnodfjupybae	118	131	-	-	JJ
work_u6osxdbbyvcabphnodfjupybae	118	132	modality	modality	JJ
work_u6osxdbbyvcabphnodfjupybae	118	133	protocol	protocol	NN
work_u6osxdbbyvcabphnodfjupybae	118	134	;	;	:
work_u6osxdbbyvcabphnodfjupybae	118	135	SWOG	SWOG	NNP
work_u6osxdbbyvcabphnodfjupybae	118	136	,	,	,
work_u6osxdbbyvcabphnodfjupybae	118	137	Southwest	Southwest	NNP
work_u6osxdbbyvcabphnodfjupybae	118	138	Oncology	Oncology	NNP
work_u6osxdbbyvcabphnodfjupybae	118	139	Group	Group	NNP
work_u6osxdbbyvcabphnodfjupybae	118	140	.	.	.
work_u6osxdbbyvcabphnodfjupybae	119	1	Green	Green	NNP
work_u6osxdbbyvcabphnodfjupybae	119	2	et	et	FW
work_u6osxdbbyvcabphnodfjupybae	119	3	al	al	NNP
work_u6osxdbbyvcabphnodfjupybae	119	4	.	.	.
work_u6osxdbbyvcabphnodfjupybae	120	1	Journal	Journal	NNP
work_u6osxdbbyvcabphnodfjupybae	120	2	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	120	3	Thoracic	Thoracic	NNP
work_u6osxdbbyvcabphnodfjupybae	120	4	Oncology	Oncology	NNP
work_u6osxdbbyvcabphnodfjupybae	120	5	•	•	NNP
work_u6osxdbbyvcabphnodfjupybae	120	6	Volume	volume	NN
work_u6osxdbbyvcabphnodfjupybae	120	7	4	4	CD
work_u6osxdbbyvcabphnodfjupybae	120	8	,	,	,
work_u6osxdbbyvcabphnodfjupybae	120	9	Number	number	NN
work_u6osxdbbyvcabphnodfjupybae	120	10	8	8	CD
work_u6osxdbbyvcabphnodfjupybae	120	11	,	,	,
work_u6osxdbbyvcabphnodfjupybae	120	12	August	August	NNP
work_u6osxdbbyvcabphnodfjupybae	120	13	2009	2009	CD
work_u6osxdbbyvcabphnodfjupybae	120	14	Copyright	copyright	NN
work_u6osxdbbyvcabphnodfjupybae	120	15	©	©	NNP
work_u6osxdbbyvcabphnodfjupybae	120	16	2009	2009	CD
work_u6osxdbbyvcabphnodfjupybae	120	17	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	120	18	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	120	19	International	International	NNP
work_u6osxdbbyvcabphnodfjupybae	120	20	Association	Association	NNP
work_u6osxdbbyvcabphnodfjupybae	120	21	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	120	22	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	120	23	Study	Study	NNP
work_u6osxdbbyvcabphnodfjupybae	120	24	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	120	25	Lung	Lung	NNP
work_u6osxdbbyvcabphnodfjupybae	120	26	Cancer986	Cancer986	NNP
work_u6osxdbbyvcabphnodfjupybae	120	27	chemoradiotherapy	chemoradiotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	120	28	as	as	IN
work_u6osxdbbyvcabphnodfjupybae	120	29	used	use	VBN
work_u6osxdbbyvcabphnodfjupybae	120	30	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	120	31	SWOG	SWOG	NNP
work_u6osxdbbyvcabphnodfjupybae	120	32	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	120	33	or	or	CC
work_u6osxdbbyvcabphnodfjupybae	120	34	without	without	IN
work_u6osxdbbyvcabphnodfjupybae	120	35	do-	do-	DT
work_u6osxdbbyvcabphnodfjupybae	120	36	cetaxel	cetaxel	NN
work_u6osxdbbyvcabphnodfjupybae	120	37	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	120	38	patients	patient	NNS
work_u6osxdbbyvcabphnodfjupybae	120	39	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	120	40	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	120	41	III	III	NNP
work_u6osxdbbyvcabphnodfjupybae	120	42	NSCLC	NSCLC	NNP
work_u6osxdbbyvcabphnodfjupybae	120	43	were	be	VBD
work_u6osxdbbyvcabphnodfjupybae	120	44	presented	present	VBN
work_u6osxdbbyvcabphnodfjupybae	120	45	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	120	46	Hanna	Hanna	NNP
work_u6osxdbbyvcabphnodfjupybae	120	47	et	et	NNP
work_u6osxdbbyvcabphnodfjupybae	120	48	al.7	al.7	NNS
work_u6osxdbbyvcabphnodfjupybae	120	49	Although	although	IN
work_u6osxdbbyvcabphnodfjupybae	120	50	some	some	DT
work_u6osxdbbyvcabphnodfjupybae	120	51	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	120	52	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	120	53	patients	patient	NNS
work_u6osxdbbyvcabphnodfjupybae	120	54	included	include	VBN
work_u6osxdbbyvcabphnodfjupybae	120	55	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	120	56	this	this	DT
work_u6osxdbbyvcabphnodfjupybae	120	57	study	study	NN
work_u6osxdbbyvcabphnodfjupybae	120	58	had	have	VBD
work_u6osxdbbyvcabphnodfjupybae	120	59	baseline	baseline	JJ
work_u6osxdbbyvcabphnodfjupybae	120	60	characteristics	characteristic	NNS
work_u6osxdbbyvcabphnodfjupybae	120	61	,	,	,
work_u6osxdbbyvcabphnodfjupybae	120	62	especially	especially	RB
work_u6osxdbbyvcabphnodfjupybae	120	63	less	less	RBR
work_u6osxdbbyvcabphnodfjupybae	120	64	optimal	optimal	JJ
work_u6osxdbbyvcabphnodfjupybae	120	65	pulmonary	pulmonary	JJ
work_u6osxdbbyvcabphnodfjupybae	120	66	function	function	NN
work_u6osxdbbyvcabphnodfjupybae	120	67	,	,	,
work_u6osxdbbyvcabphnodfjupybae	120	68	that	that	WDT
work_u6osxdbbyvcabphnodfjupybae	120	69	were	be	VBD
work_u6osxdbbyvcabphnodfjupybae	120	70	different	different	JJ
work_u6osxdbbyvcabphnodfjupybae	120	71	from	from	IN
work_u6osxdbbyvcabphnodfjupybae	120	72	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	120	73	SWOG	SWOG	NNP
work_u6osxdbbyvcabphnodfjupybae	120	74	study	study	NN
work_u6osxdbbyvcabphnodfjupybae	120	75	participants	participant	NNS
work_u6osxdbbyvcabphnodfjupybae	120	76	,	,	,
work_u6osxdbbyvcabphnodfjupybae	120	77	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	120	78	core	core	JJ
work_u6osxdbbyvcabphnodfjupybae	120	79	comparison	comparison	NN
work_u6osxdbbyvcabphnodfjupybae	120	80	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	120	81	CT	CT	NNP
work_u6osxdbbyvcabphnodfjupybae	120	82	/	/	SYM
work_u6osxdbbyvcabphnodfjupybae	120	83	TRT	TRT	NNP
work_u6osxdbbyvcabphnodfjupybae	120	84	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	120	85	or	or	CC
work_u6osxdbbyvcabphnodfjupybae	120	86	without	without	IN
work_u6osxdbbyvcabphnodfjupybae	120	87	consolidation	consolidation	NN
work_u6osxdbbyvcabphnodfjupybae	120	88	addressed	address	VBD
work_u6osxdbbyvcabphnodfjupybae	120	89	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	120	90	critical	critical	JJ
work_u6osxdbbyvcabphnodfjupybae	120	91	question	question	NN
work_u6osxdbbyvcabphnodfjupybae	120	92	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	120	93	whether	whether	IN
work_u6osxdbbyvcabphnodfjupybae	120	94	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	120	95	addition	addition	NN
work_u6osxdbbyvcabphnodfjupybae	120	96	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	120	97	consolidation	consolidation	NN
work_u6osxdbbyvcabphnodfjupybae	120	98	chemotherapy	chemotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	120	99	would	would	MD
work_u6osxdbbyvcabphnodfjupybae	120	100	significantly	significantly	RB
work_u6osxdbbyvcabphnodfjupybae	120	101	improve	improve	VB
work_u6osxdbbyvcabphnodfjupybae	120	102	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	120	103	survival	survival	NN
work_u6osxdbbyvcabphnodfjupybae	120	104	outcome	outcome	NN
work_u6osxdbbyvcabphnodfjupybae	120	105	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	120	106	patients	patient	NNS
work_u6osxdbbyvcabphnodfjupybae	120	107	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	120	108	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	120	109	III	iii	CD
work_u6osxdbbyvcabphnodfjupybae	120	110	NSCLC	NSCLC	NNP
work_u6osxdbbyvcabphnodfjupybae	120	111	.	.	.
work_u6osxdbbyvcabphnodfjupybae	121	1	The	the	DT
work_u6osxdbbyvcabphnodfjupybae	121	2	data	datum	NNS
work_u6osxdbbyvcabphnodfjupybae	121	3	from	from	IN
work_u6osxdbbyvcabphnodfjupybae	121	4	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	121	5	2007	2007	CD
work_u6osxdbbyvcabphnodfjupybae	121	6	presentation	presentation	NN
work_u6osxdbbyvcabphnodfjupybae	121	7	were	be	VBD
work_u6osxdbbyvcabphnodfjupybae	121	8	clear	clear	JJ
work_u6osxdbbyvcabphnodfjupybae	121	9	.	.	.
work_u6osxdbbyvcabphnodfjupybae	122	1	In	in	IN
work_u6osxdbbyvcabphnodfjupybae	122	2	every	every	DT
work_u6osxdbbyvcabphnodfjupybae	122	3	relevant	relevant	JJ
work_u6osxdbbyvcabphnodfjupybae	122	4	treatment	treatment	NN
work_u6osxdbbyvcabphnodfjupybae	122	5	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	122	6	efficacy	efficacy	NN
work_u6osxdbbyvcabphnodfjupybae	122	7	comparison	comparison	NN
work_u6osxdbbyvcabphnodfjupybae	122	8	there	there	EX
work_u6osxdbbyvcabphnodfjupybae	122	9	was	be	VBD
work_u6osxdbbyvcabphnodfjupybae	122	10	no	no	DT
work_u6osxdbbyvcabphnodfjupybae	122	11	improvement	improvement	NN
work_u6osxdbbyvcabphnodfjupybae	122	12	,	,	,
work_u6osxdbbyvcabphnodfjupybae	122	13	let	let	VB
work_u6osxdbbyvcabphnodfjupybae	122	14	alone	alone	RB
work_u6osxdbbyvcabphnodfjupybae	122	15	no	no	DT
work_u6osxdbbyvcabphnodfjupybae	122	16	significant	significant	JJ
work_u6osxdbbyvcabphnodfjupybae	122	17	benefit	benefit	NN
work_u6osxdbbyvcabphnodfjupybae	122	18	,	,	,
work_u6osxdbbyvcabphnodfjupybae	122	19	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	122	20	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	122	21	addition	addition	NN
work_u6osxdbbyvcabphnodfjupybae	122	22	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	122	23	docetaxel	docetaxel	NNP
work_u6osxdbbyvcabphnodfjupybae	122	24	consolidation	consolidation	NN
work_u6osxdbbyvcabphnodfjupybae	122	25	.	.	.
work_u6osxdbbyvcabphnodfjupybae	123	1	At	at	IN
work_u6osxdbbyvcabphnodfjupybae	123	2	ASCO	ASCO	NNP
work_u6osxdbbyvcabphnodfjupybae	123	3	2008	2008	CD
work_u6osxdbbyvcabphnodfjupybae	123	4	,	,	,
work_u6osxdbbyvcabphnodfjupybae	123	5	further	further	JJ
work_u6osxdbbyvcabphnodfjupybae	123	6	follow	follow	NN
work_u6osxdbbyvcabphnodfjupybae	123	7	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	123	8	up	up	NN
work_u6osxdbbyvcabphnodfjupybae	123	9	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	123	10	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	123	11	HOG	HOG	NNP
work_u6osxdbbyvcabphnodfjupybae	123	12	trial	trial	NN
work_u6osxdbbyvcabphnodfjupybae	123	13	again	again	RB
work_u6osxdbbyvcabphnodfjupybae	123	14	showed	show	VBD
work_u6osxdbbyvcabphnodfjupybae	123	15	no	no	DT
work_u6osxdbbyvcabphnodfjupybae	123	16	benefit	benefit	NN
work_u6osxdbbyvcabphnodfjupybae	123	17	from	from	IN
work_u6osxdbbyvcabphnodfjupybae	123	18	docetaxel	docetaxel	NNP
work_u6osxdbbyvcabphnodfjupybae	123	19	consolidation.11	consolidation.11	NNP
work_u6osxdbbyvcabphnodfjupybae	123	20	However	however	RB
work_u6osxdbbyvcabphnodfjupybae	123	21	,	,	,
work_u6osxdbbyvcabphnodfjupybae	123	22	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	123	23	2007	2007	CD
work_u6osxdbbyvcabphnodfjupybae	123	24	presentation	presentation	NN
work_u6osxdbbyvcabphnodfjupybae	123	25	did	do	VBD
work_u6osxdbbyvcabphnodfjupybae	123	26	highlight	highlight	VB
work_u6osxdbbyvcabphnodfjupybae	123	27	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	123	28	toxicity	toxicity	NN
work_u6osxdbbyvcabphnodfjupybae	123	29	risks	risk	NNS
work_u6osxdbbyvcabphnodfjupybae	123	30	associated	associate	VBN
work_u6osxdbbyvcabphnodfjupybae	123	31	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	123	32	docetaxel	docetaxel	NNP
work_u6osxdbbyvcabphnodfjupybae	123	33	consolidation	consolidation	NN
work_u6osxdbbyvcabphnodfjupybae	123	34	.	.	.
work_u6osxdbbyvcabphnodfjupybae	124	1	These	these	DT
work_u6osxdbbyvcabphnodfjupybae	124	2	included	include	VBD
work_u6osxdbbyvcabphnodfjupybae	124	3	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	124	4	24.7	24.7	CD
work_u6osxdbbyvcabphnodfjupybae	124	5	%	%	NN
work_u6osxdbbyvcabphnodfjupybae	124	6	rate	rate	NN
work_u6osxdbbyvcabphnodfjupybae	124	7	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	124	8	grade	grade	NN
work_u6osxdbbyvcabphnodfjupybae	124	9	3	3	CD
work_u6osxdbbyvcabphnodfjupybae	124	10	or	or	CC
work_u6osxdbbyvcabphnodfjupybae	124	11	4	4	CD
work_u6osxdbbyvcabphnodfjupybae	124	12	neutropenia	neutropenia	NN
work_u6osxdbbyvcabphnodfjupybae	124	13	,	,	,
work_u6osxdbbyvcabphnodfjupybae	124	14	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	124	15	10.9	10.9	CD
work_u6osxdbbyvcabphnodfjupybae	124	16	%	%	NN
work_u6osxdbbyvcabphnodfjupybae	124	17	rate	rate	NN
work_u6osxdbbyvcabphnodfjupybae	124	18	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	124	19	febrile	febrile	NN
work_u6osxdbbyvcabphnodfjupybae	124	20	neutropenia	neutropenia	NN
work_u6osxdbbyvcabphnodfjupybae	124	21	,	,	,
work_u6osxdbbyvcabphnodfjupybae	124	22	an	an	DT
work_u6osxdbbyvcabphnodfjupybae	124	23	8.2	8.2	CD
work_u6osxdbbyvcabphnodfjupybae	124	24	%	%	NN
work_u6osxdbbyvcabphnodfjupybae	124	25	rate	rate	NN
work_u6osxdbbyvcabphnodfjupybae	124	26	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	124	27	grade	grade	NN
work_u6osxdbbyvcabphnodfjupybae	124	28	3	3	CD
work_u6osxdbbyvcabphnodfjupybae	124	29	pneumonitis	pneumonitis	NN
work_u6osxdbbyvcabphnodfjupybae	124	30	,	,	,
work_u6osxdbbyvcabphnodfjupybae	124	31	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	124	32	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	124	33	5.5	5.5	CD
work_u6osxdbbyvcabphnodfjupybae	124	34	%	%	NN
work_u6osxdbbyvcabphnodfjupybae	124	35	treatment	treatment	NN
work_u6osxdbbyvcabphnodfjupybae	124	36	related	relate	VBN
work_u6osxdbbyvcabphnodfjupybae	124	37	death	death	NN
work_u6osxdbbyvcabphnodfjupybae	124	38	rate	rate	NN
work_u6osxdbbyvcabphnodfjupybae	124	39	.	.	.
work_u6osxdbbyvcabphnodfjupybae	125	1	The	the	DT
work_u6osxdbbyvcabphnodfjupybae	125	2	findings	finding	NNS
work_u6osxdbbyvcabphnodfjupybae	125	3	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	125	4	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	125	5	HOG	HOG	NNP
work_u6osxdbbyvcabphnodfjupybae	125	6	trial	trial	NN
work_u6osxdbbyvcabphnodfjupybae	125	7	support	support	VBP
work_u6osxdbbyvcabphnodfjupybae	125	8	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	125	9	transition	transition	NN
work_u6osxdbbyvcabphnodfjupybae	125	10	away	away	RB
work_u6osxdbbyvcabphnodfjupybae	125	11	from	from	IN
work_u6osxdbbyvcabphnodfjupybae	125	12	docetaxel	docetaxel	NNP
work_u6osxdbbyvcabphnodfjupybae	125	13	consolidation,12	consolidation,12	NNP
work_u6osxdbbyvcabphnodfjupybae	125	14	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	125	15	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	125	16	trend	trend	NN
work_u6osxdbbyvcabphnodfjupybae	125	17	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	125	18	this	this	DT
work_u6osxdbbyvcabphnodfjupybae	125	19	direction	direction	NN
work_u6osxdbbyvcabphnodfjupybae	125	20	among	among	IN
work_u6osxdbbyvcabphnodfjupybae	125	21	American	american	JJ
work_u6osxdbbyvcabphnodfjupybae	125	22	medical	medical	JJ
work_u6osxdbbyvcabphnodfjupybae	125	23	oncologists	oncologist	NNS
work_u6osxdbbyvcabphnodfjupybae	125	24	is	be	VBZ
work_u6osxdbbyvcabphnodfjupybae	125	25	clear	clear	JJ
work_u6osxdbbyvcabphnodfjupybae	125	26	from	from	IN
work_u6osxdbbyvcabphnodfjupybae	125	27	our	-PRON-	PRP$
work_u6osxdbbyvcabphnodfjupybae	125	28	data	datum	NNS
work_u6osxdbbyvcabphnodfjupybae	125	29	.	.	.
work_u6osxdbbyvcabphnodfjupybae	126	1	However	however	RB
work_u6osxdbbyvcabphnodfjupybae	126	2	,	,	,
work_u6osxdbbyvcabphnodfjupybae	126	3	two	two	CD
work_u6osxdbbyvcabphnodfjupybae	126	4	surprising	surprising	JJ
work_u6osxdbbyvcabphnodfjupybae	126	5	results	result	NNS
work_u6osxdbbyvcabphnodfjupybae	126	6	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	126	7	our	-PRON-	PRP$
work_u6osxdbbyvcabphnodfjupybae	126	8	research	research	NN
work_u6osxdbbyvcabphnodfjupybae	126	9	are	be	VBP
work_u6osxdbbyvcabphnodfjupybae	126	10	evident	evident	JJ
work_u6osxdbbyvcabphnodfjupybae	126	11	.	.	.
work_u6osxdbbyvcabphnodfjupybae	127	1	First	first	RB
work_u6osxdbbyvcabphnodfjupybae	127	2	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	127	3	foremost	foremost	RB
work_u6osxdbbyvcabphnodfjupybae	127	4	,	,	,
work_u6osxdbbyvcabphnodfjupybae	127	5	nearly	nearly	RB
work_u6osxdbbyvcabphnodfjupybae	127	6	20	20	CD
work_u6osxdbbyvcabphnodfjupybae	127	7	%	%	NN
work_u6osxdbbyvcabphnodfjupybae	127	8	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	127	9	those	those	DT
work_u6osxdbbyvcabphnodfjupybae	127	10	oncologists	oncologist	NNS
work_u6osxdbbyvcabphnodfjupybae	127	11	studied	study	VBN
work_u6osxdbbyvcabphnodfjupybae	127	12	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	127	13	2008	2008	CD
work_u6osxdbbyvcabphnodfjupybae	127	14	are	be	VBP
work_u6osxdbbyvcabphnodfjupybae	127	15	still	still	RB
work_u6osxdbbyvcabphnodfjupybae	127	16	planning	plan	VBG
work_u6osxdbbyvcabphnodfjupybae	127	17	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	127	18	SWOG	swog	NN
work_u6osxdbbyvcabphnodfjupybae	127	19	9504	9504	CD
work_u6osxdbbyvcabphnodfjupybae	127	20	approach	approach	NN
work_u6osxdbbyvcabphnodfjupybae	127	21	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	127	22	docetaxel	docetaxel	NNP
work_u6osxdbbyvcabphnodfjupybae	127	23	consolidation	consolidation	NN
work_u6osxdbbyvcabphnodfjupybae	127	24	.	.	.
work_u6osxdbbyvcabphnodfjupybae	128	1	This	this	DT
work_u6osxdbbyvcabphnodfjupybae	128	2	seems	seem	VBZ
work_u6osxdbbyvcabphnodfjupybae	128	3	difficult	difficult	JJ
work_u6osxdbbyvcabphnodfjupybae	128	4	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	128	5	justify	justify	VB
work_u6osxdbbyvcabphnodfjupybae	128	6	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	128	7	light	light	NN
work_u6osxdbbyvcabphnodfjupybae	128	8	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	128	9	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	128	10	toxicity	toxicity	NN
work_u6osxdbbyvcabphnodfjupybae	128	11	produced	produce	VBN
work_u6osxdbbyvcabphnodfjupybae	128	12	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	128	13	this	this	DT
work_u6osxdbbyvcabphnodfjupybae	128	14	strategy	strategy	NN
work_u6osxdbbyvcabphnodfjupybae	128	15	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	128	16	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	128	17	failure	failure	NN
work_u6osxdbbyvcabphnodfjupybae	128	18	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	128	19	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	128	20	phase	phase	NN
work_u6osxdbbyvcabphnodfjupybae	128	21	III	iii	CD
work_u6osxdbbyvcabphnodfjupybae	128	22	comparison	comparison	NN
work_u6osxdbbyvcabphnodfjupybae	128	23	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	128	24	suggest	suggest	VB
work_u6osxdbbyvcabphnodfjupybae	128	25	any	any	DT
work_u6osxdbbyvcabphnodfjupybae	128	26	benefit	benefit	NN
work_u6osxdbbyvcabphnodfjupybae	128	27	.	.	.
work_u6osxdbbyvcabphnodfjupybae	129	1	Whether	whether	IN
work_u6osxdbbyvcabphnodfjupybae	129	2	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	129	3	SWOG	SWOG	NNP
work_u6osxdbbyvcabphnodfjupybae	129	4	Lung	Lung	NNP
work_u6osxdbbyvcabphnodfjupybae	129	5	commit-	commit-	VBD
work_u6osxdbbyvcabphnodfjupybae	129	6	tee	tee	NN
work_u6osxdbbyvcabphnodfjupybae	129	7	will	will	MD
work_u6osxdbbyvcabphnodfjupybae	129	8	decide	decide	VB
work_u6osxdbbyvcabphnodfjupybae	129	9	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	129	10	retest	retest	VB
work_u6osxdbbyvcabphnodfjupybae	129	11	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	129	12	chemoradiotherapy	chemoradiotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	129	13	followed	follow	VBN
work_u6osxdbbyvcabphnodfjupybae	129	14	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	129	15	consolidation	consolidation	NN
work_u6osxdbbyvcabphnodfjupybae	129	16	strategy	strategy	NN
work_u6osxdbbyvcabphnodfjupybae	129	17	remains	remain	VBZ
work_u6osxdbbyvcabphnodfjupybae	129	18	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	129	19	be	be	VB
work_u6osxdbbyvcabphnodfjupybae	129	20	seen	see	VBN
work_u6osxdbbyvcabphnodfjupybae	129	21	.	.	.
work_u6osxdbbyvcabphnodfjupybae	130	1	More	more	RBR
work_u6osxdbbyvcabphnodfjupybae	130	2	globally	globally	RB
work_u6osxdbbyvcabphnodfjupybae	130	3	,	,	,
work_u6osxdbbyvcabphnodfjupybae	130	4	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	130	5	majority	majority	NN
work_u6osxdbbyvcabphnodfjupybae	130	6	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	130	7	all	all	PDT
work_u6osxdbbyvcabphnodfjupybae	130	8	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	130	9	oncologists	oncologist	NNS
work_u6osxdbbyvcabphnodfjupybae	130	10	studied	study	VBD
work_u6osxdbbyvcabphnodfjupybae	130	11	after	after	IN
work_u6osxdbbyvcabphnodfjupybae	130	12	ASCO	ASCO	NNS
work_u6osxdbbyvcabphnodfjupybae	130	13	2007	2007	CD
work_u6osxdbbyvcabphnodfjupybae	130	14	continue	continue	VBP
work_u6osxdbbyvcabphnodfjupybae	130	15	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	130	16	report	report	VB
work_u6osxdbbyvcabphnodfjupybae	130	17	plans	plan	NNS
work_u6osxdbbyvcabphnodfjupybae	130	18	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	130	19	use	use	VB
work_u6osxdbbyvcabphnodfjupybae	130	20	more	more	JJR
work_u6osxdbbyvcabphnodfjupybae	130	21	than	than	IN
work_u6osxdbbyvcabphnodfjupybae	130	22	two	two	CD
work_u6osxdbbyvcabphnodfjupybae	130	23	cycles	cycle	NNS
work_u6osxdbbyvcabphnodfjupybae	130	24	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	130	25	chemotherapy	chemotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	130	26	as	as	IN
work_u6osxdbbyvcabphnodfjupybae	130	27	part	part	NN
work_u6osxdbbyvcabphnodfjupybae	130	28	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	130	29	their	-PRON-	PRP$
work_u6osxdbbyvcabphnodfjupybae	130	30	preferred	preferred	JJ
work_u6osxdbbyvcabphnodfjupybae	130	31	treatment	treatment	NN
work_u6osxdbbyvcabphnodfjupybae	130	32	recom-	recom-	NN
work_u6osxdbbyvcabphnodfjupybae	130	33	mendation	mendation	NN
work_u6osxdbbyvcabphnodfjupybae	130	34	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	130	35	fit	fit	JJ
work_u6osxdbbyvcabphnodfjupybae	130	36	patients	patient	NNS
work_u6osxdbbyvcabphnodfjupybae	130	37	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	130	38	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	130	39	III	iii	CD
work_u6osxdbbyvcabphnodfjupybae	130	40	NSCLC	NSCLC	NNP
work_u6osxdbbyvcabphnodfjupybae	130	41	.	.	.
work_u6osxdbbyvcabphnodfjupybae	131	1	For	for	IN
work_u6osxdbbyvcabphnodfjupybae	131	2	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	131	3	largest	large	JJS
work_u6osxdbbyvcabphnodfjupybae	131	4	single	single	JJ
work_u6osxdbbyvcabphnodfjupybae	131	5	subgroup	subgroup	NN
work_u6osxdbbyvcabphnodfjupybae	131	6	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	131	7	those	those	DT
work_u6osxdbbyvcabphnodfjupybae	131	8	oncologists	oncologist	NNS
work_u6osxdbbyvcabphnodfjupybae	131	9	,	,	,
work_u6osxdbbyvcabphnodfjupybae	131	10	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	131	11	preferred	preferred	JJ
work_u6osxdbbyvcabphnodfjupybae	131	12	recommendation	recommendation	NN
work_u6osxdbbyvcabphnodfjupybae	131	13	now	now	RB
work_u6osxdbbyvcabphnodfjupybae	131	14	involves	involve	VBZ
work_u6osxdbbyvcabphnodfjupybae	131	15	immediate	immediate	JJ
work_u6osxdbbyvcabphnodfjupybae	131	16	induction	induction	NNP
work_u6osxdbbyvcabphnodfjupybae	131	17	che-	che-	NNS
work_u6osxdbbyvcabphnodfjupybae	131	18	moradiotherapy	moradiotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	131	19	followed	follow	VBD
work_u6osxdbbyvcabphnodfjupybae	131	20	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	131	21	two	two	CD
work_u6osxdbbyvcabphnodfjupybae	131	22	added	add	VBN
work_u6osxdbbyvcabphnodfjupybae	131	23	cycles	cycle	NNS
work_u6osxdbbyvcabphnodfjupybae	131	24	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	131	25	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	131	26	same	same	JJ
work_u6osxdbbyvcabphnodfjupybae	131	27	chemotherapy	chemotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	131	28	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	131	29	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	131	30	consolidation	consolidation	NN
work_u6osxdbbyvcabphnodfjupybae	131	31	setting	set	VBG
work_u6osxdbbyvcabphnodfjupybae	131	32	.	.	.
work_u6osxdbbyvcabphnodfjupybae	132	1	Although	although	IN
work_u6osxdbbyvcabphnodfjupybae	132	2	this	this	DT
work_u6osxdbbyvcabphnodfjupybae	132	3	decision	decision	NN
work_u6osxdbbyvcabphnodfjupybae	132	4	is	be	VBZ
work_u6osxdbbyvcabphnodfjupybae	132	5	consistent	consistent	JJ
work_u6osxdbbyvcabphnodfjupybae	132	6	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	132	7	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	132	8	model	model	NN
work_u6osxdbbyvcabphnodfjupybae	132	9	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	132	10	adjuvant	adjuvant	JJ
work_u6osxdbbyvcabphnodfjupybae	132	11	chemo-	chemo-	NN
work_u6osxdbbyvcabphnodfjupybae	132	12	therapy	therapy	NN
work_u6osxdbbyvcabphnodfjupybae	132	13	widely	widely	RB
work_u6osxdbbyvcabphnodfjupybae	132	14	applied	apply	VBD
work_u6osxdbbyvcabphnodfjupybae	132	15	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	132	16	patients	patient	NNS
work_u6osxdbbyvcabphnodfjupybae	132	17	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	132	18	completely	completely	RB
work_u6osxdbbyvcabphnodfjupybae	132	19	re-	re-	RB
work_u6osxdbbyvcabphnodfjupybae	132	20	sected	secte	VBN
work_u6osxdbbyvcabphnodfjupybae	132	21	solid	solid	JJ
work_u6osxdbbyvcabphnodfjupybae	132	22	tumors	tumor	NNS
work_u6osxdbbyvcabphnodfjupybae	132	23	,	,	,
work_u6osxdbbyvcabphnodfjupybae	132	24	there	there	EX
work_u6osxdbbyvcabphnodfjupybae	132	25	are	be	VBP
work_u6osxdbbyvcabphnodfjupybae	132	26	no	no	DT
work_u6osxdbbyvcabphnodfjupybae	132	27	phase	phase	NN
work_u6osxdbbyvcabphnodfjupybae	132	28	III	iii	CD
work_u6osxdbbyvcabphnodfjupybae	132	29	data	datum	NNS
work_u6osxdbbyvcabphnodfjupybae	132	30	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	132	31	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	132	32	lung	lung	NN
work_u6osxdbbyvcabphnodfjupybae	132	33	cancer	cancer	NN
work_u6osxdbbyvcabphnodfjupybae	132	34	setting	set	VBG
work_u6osxdbbyvcabphnodfjupybae	132	35	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	132	36	support	support	VB
work_u6osxdbbyvcabphnodfjupybae	132	37	it	-PRON-	PRP
work_u6osxdbbyvcabphnodfjupybae	132	38	,	,	,
work_u6osxdbbyvcabphnodfjupybae	132	39	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	132	40	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	132	41	toxicity	toxicity	NN
work_u6osxdbbyvcabphnodfjupybae	132	42	risks	risk	NNS
work_u6osxdbbyvcabphnodfjupybae	132	43	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	132	44	economic	economic	JJ
work_u6osxdbbyvcabphnodfjupybae	132	45	costs	cost	NNS
work_u6osxdbbyvcabphnodfjupybae	132	46	associated	associate	VBN
work_u6osxdbbyvcabphnodfjupybae	132	47	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	132	48	it	-PRON-	PRP
work_u6osxdbbyvcabphnodfjupybae	132	49	are	be	VBP
work_u6osxdbbyvcabphnodfjupybae	132	50	formidable	formidable	JJ
work_u6osxdbbyvcabphnodfjupybae	132	51	.	.	.
work_u6osxdbbyvcabphnodfjupybae	133	1	Cur-	cur-	VB
work_u6osxdbbyvcabphnodfjupybae	133	2	rently	rently	RB
work_u6osxdbbyvcabphnodfjupybae	133	3	,	,	,
work_u6osxdbbyvcabphnodfjupybae	133	4	there	there	EX
work_u6osxdbbyvcabphnodfjupybae	133	5	are	be	VBP
work_u6osxdbbyvcabphnodfjupybae	133	6	no	no	DT
work_u6osxdbbyvcabphnodfjupybae	133	7	plans	plan	NNS
work_u6osxdbbyvcabphnodfjupybae	133	8	among	among	IN
work_u6osxdbbyvcabphnodfjupybae	133	9	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	133	10	American	American	NNP
work_u6osxdbbyvcabphnodfjupybae	133	11	National	National	NNP
work_u6osxdbbyvcabphnodfjupybae	133	12	Cancer	Cancer	NNP
work_u6osxdbbyvcabphnodfjupybae	133	13	Institute	Institute	NNP
work_u6osxdbbyvcabphnodfjupybae	133	14	sponsored	sponsor	VBD
work_u6osxdbbyvcabphnodfjupybae	133	15	cooperative	cooperative	JJ
work_u6osxdbbyvcabphnodfjupybae	133	16	groups	group	NNS
work_u6osxdbbyvcabphnodfjupybae	133	17	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	133	18	retest	retest	VB
work_u6osxdbbyvcabphnodfjupybae	133	19	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	133	20	role	role	NN
work_u6osxdbbyvcabphnodfjupybae	133	21	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	133	22	chemotherapy	chemotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	133	23	consolidation	consolidation	NN
work_u6osxdbbyvcabphnodfjupybae	133	24	,	,	,
work_u6osxdbbyvcabphnodfjupybae	133	25	e.g.	e.g.	RB
work_u6osxdbbyvcabphnodfjupybae	133	26	,	,	,
work_u6osxdbbyvcabphnodfjupybae	133	27	immediate	immediate	JJ
work_u6osxdbbyvcabphnodfjupybae	133	28	con-	con-	NN
work_u6osxdbbyvcabphnodfjupybae	133	29	current	current	JJ
work_u6osxdbbyvcabphnodfjupybae	133	30	chemoradiation	chemoradiation	NN
work_u6osxdbbyvcabphnodfjupybae	133	31	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	133	32	or	or	CC
work_u6osxdbbyvcabphnodfjupybae	133	33	without	without	IN
work_u6osxdbbyvcabphnodfjupybae	133	34	two	two	CD
work_u6osxdbbyvcabphnodfjupybae	133	35	added	add	VBN
work_u6osxdbbyvcabphnodfjupybae	133	36	cycles	cycle	NNS
work_u6osxdbbyvcabphnodfjupybae	133	37	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	133	38	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	133	39	same	same	JJ
work_u6osxdbbyvcabphnodfjupybae	133	40	chemotherapy	chemotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	133	41	as	as	IN
work_u6osxdbbyvcabphnodfjupybae	133	42	consolidation	consolidation	NN
work_u6osxdbbyvcabphnodfjupybae	133	43	.	.	.
work_u6osxdbbyvcabphnodfjupybae	134	1	Although	although	IN
work_u6osxdbbyvcabphnodfjupybae	134	2	such	such	PDT
work_u6osxdbbyvcabphnodfjupybae	134	3	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	134	4	trial	trial	NN
work_u6osxdbbyvcabphnodfjupybae	134	5	would	would	MD
work_u6osxdbbyvcabphnodfjupybae	134	6	add	add	VB
work_u6osxdbbyvcabphnodfjupybae	134	7	to	to	IN
work_u6osxdbbyvcabphnodfjupybae	134	8	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	134	9	evidence	evidence	NN
work_u6osxdbbyvcabphnodfjupybae	134	10	base	base	NN
work_u6osxdbbyvcabphnodfjupybae	134	11	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	134	12	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	134	13	III	iii	CD
work_u6osxdbbyvcabphnodfjupybae	134	14	disease	disease	NN
work_u6osxdbbyvcabphnodfjupybae	134	15	,	,	,
work_u6osxdbbyvcabphnodfjupybae	134	16	there	there	EX
work_u6osxdbbyvcabphnodfjupybae	134	17	are	be	VBP
work_u6osxdbbyvcabphnodfjupybae	134	18	scant	scant	JJ
work_u6osxdbbyvcabphnodfjupybae	134	19	to	to	IN
work_u6osxdbbyvcabphnodfjupybae	134	20	no	no	DT
work_u6osxdbbyvcabphnodfjupybae	134	21	compelling	compelling	JJ
work_u6osxdbbyvcabphnodfjupybae	134	22	phase	phase	NN
work_u6osxdbbyvcabphnodfjupybae	134	23	II	ii	CD
work_u6osxdbbyvcabphnodfjupybae	134	24	data	datum	NNS
work_u6osxdbbyvcabphnodfjupybae	134	25	that	that	WDT
work_u6osxdbbyvcabphnodfjupybae	134	26	support	support	VBP
work_u6osxdbbyvcabphnodfjupybae	134	27	such	such	PDT
work_u6osxdbbyvcabphnodfjupybae	134	28	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	134	29	resource	resource	NN
work_u6osxdbbyvcabphnodfjupybae	134	30	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	134	31	intensive	intensive	JJ
work_u6osxdbbyvcabphnodfjupybae	134	32	undertaking	undertaking	NN
work_u6osxdbbyvcabphnodfjupybae	134	33	.	.	.
work_u6osxdbbyvcabphnodfjupybae	135	1	The	the	DT
work_u6osxdbbyvcabphnodfjupybae	135	2	changing	change	VBG
work_u6osxdbbyvcabphnodfjupybae	135	3	approach	approach	NN
work_u6osxdbbyvcabphnodfjupybae	135	4	to	to	IN
work_u6osxdbbyvcabphnodfjupybae	135	5	definitive	definitive	JJ
work_u6osxdbbyvcabphnodfjupybae	135	6	nonoperative	nonoperative	JJ
work_u6osxdbbyvcabphnodfjupybae	135	7	management	management	NN
work_u6osxdbbyvcabphnodfjupybae	135	8	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	135	9	patients	patient	NNS
work_u6osxdbbyvcabphnodfjupybae	135	10	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	135	11	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	135	12	III	III	NNP
work_u6osxdbbyvcabphnodfjupybae	135	13	NSCLC	NSCLC	NNP
work_u6osxdbbyvcabphnodfjupybae	135	14	is	be	VBZ
work_u6osxdbbyvcabphnodfjupybae	135	15	clearly	clearly	RB
work_u6osxdbbyvcabphnodfjupybae	135	16	demonstrated	demonstrate	VBN
work_u6osxdbbyvcabphnodfjupybae	135	17	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	135	18	our	-PRON-	PRP$
work_u6osxdbbyvcabphnodfjupybae	135	19	research	research	NN
work_u6osxdbbyvcabphnodfjupybae	135	20	.	.	.
work_u6osxdbbyvcabphnodfjupybae	136	1	We	-PRON-	PRP
work_u6osxdbbyvcabphnodfjupybae	136	2	will	will	MD
work_u6osxdbbyvcabphnodfjupybae	136	3	continue	continue	VB
work_u6osxdbbyvcabphnodfjupybae	136	4	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	136	5	monitor	monitor	VB
work_u6osxdbbyvcabphnodfjupybae	136	6	prescribing	prescribing	NN
work_u6osxdbbyvcabphnodfjupybae	136	7	plans	plan	NNS
work_u6osxdbbyvcabphnodfjupybae	136	8	proposed	propose	VBN
work_u6osxdbbyvcabphnodfjupybae	136	9	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	136	10	American	american	JJ
work_u6osxdbbyvcabphnodfjupybae	136	11	medical	medical	JJ
work_u6osxdbbyvcabphnodfjupybae	136	12	oncolo-	oncolo-	NN
work_u6osxdbbyvcabphnodfjupybae	136	13	gists	gist	NNS
work_u6osxdbbyvcabphnodfjupybae	136	14	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	136	15	patients	patient	NNS
work_u6osxdbbyvcabphnodfjupybae	136	16	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	136	17	regionally	regionally	RB
work_u6osxdbbyvcabphnodfjupybae	136	18	advanced	advanced	JJ
work_u6osxdbbyvcabphnodfjupybae	136	19	NSCLC	NSCLC	NNP
work_u6osxdbbyvcabphnodfjupybae	136	20	.	.	.
work_u6osxdbbyvcabphnodfjupybae	137	1	It	-PRON-	PRP
work_u6osxdbbyvcabphnodfjupybae	137	2	is	be	VBZ
work_u6osxdbbyvcabphnodfjupybae	137	3	hoped	hope	VBN
work_u6osxdbbyvcabphnodfjupybae	137	4	that	that	IN
work_u6osxdbbyvcabphnodfjupybae	137	5	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	137	6	trends	trend	NNS
work_u6osxdbbyvcabphnodfjupybae	137	7	away	away	RB
work_u6osxdbbyvcabphnodfjupybae	137	8	from	from	IN
work_u6osxdbbyvcabphnodfjupybae	137	9	docetaxel	docetaxel	NNP
work_u6osxdbbyvcabphnodfjupybae	137	10	consolidation	consolidation	NN
work_u6osxdbbyvcabphnodfjupybae	137	11	will	will	MD
work_u6osxdbbyvcabphnodfjupybae	137	12	continue	continue	VB
work_u6osxdbbyvcabphnodfjupybae	137	13	.	.	.
work_u6osxdbbyvcabphnodfjupybae	138	1	This	this	DT
work_u6osxdbbyvcabphnodfjupybae	138	2	is	be	VBZ
work_u6osxdbbyvcabphnodfjupybae	138	3	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	138	4	critical	critical	JJ
work_u6osxdbbyvcabphnodfjupybae	138	5	setting	setting	NN
work_u6osxdbbyvcabphnodfjupybae	138	6	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	138	7	which	which	WDT
work_u6osxdbbyvcabphnodfjupybae	138	8	patients	patient	NNS
work_u6osxdbbyvcabphnodfjupybae	138	9	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	138	10	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	138	11	new	new	JJ
work_u6osxdbbyvcabphnodfjupybae	138	12	diagnosis	diagnosis	NN
work_u6osxdbbyvcabphnodfjupybae	138	13	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	138	14	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	138	15	III	III	NNP
work_u6osxdbbyvcabphnodfjupybae	138	16	NSCLC	NSCLC	NNP
work_u6osxdbbyvcabphnodfjupybae	138	17	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	138	18	their	-PRON-	PRP$
work_u6osxdbbyvcabphnodfjupybae	138	19	treating	treating	NN
work_u6osxdbbyvcabphnodfjupybae	138	20	oncologists	oncologist	NNS
work_u6osxdbbyvcabphnodfjupybae	138	21	should	should	MD
work_u6osxdbbyvcabphnodfjupybae	138	22	come	come	VB
work_u6osxdbbyvcabphnodfjupybae	138	23	together	together	RB
work_u6osxdbbyvcabphnodfjupybae	138	24	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	138	25	participate	participate	VB
work_u6osxdbbyvcabphnodfjupybae	138	26	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	138	27	well-	well-	NN
work_u6osxdbbyvcabphnodfjupybae	138	28	designed	design	VBN
work_u6osxdbbyvcabphnodfjupybae	138	29	clinical	clinical	JJ
work_u6osxdbbyvcabphnodfjupybae	138	30	trials	trial	NNS
work_u6osxdbbyvcabphnodfjupybae	138	31	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	138	32	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	138	33	potential	potential	NN
work_u6osxdbbyvcabphnodfjupybae	138	34	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	138	35	generate	generate	VB
work_u6osxdbbyvcabphnodfjupybae	138	36	new	new	JJ
work_u6osxdbbyvcabphnodfjupybae	138	37	leads	lead	NNS
work_u6osxdbbyvcabphnodfjupybae	138	38	or	or	CC
work_u6osxdbbyvcabphnodfjupybae	138	39	definitive	definitive	JJ
work_u6osxdbbyvcabphnodfjupybae	138	40	data	datum	NNS
work_u6osxdbbyvcabphnodfjupybae	138	41	concerning	concern	VBG
work_u6osxdbbyvcabphnodfjupybae	138	42	better	well	JJR
work_u6osxdbbyvcabphnodfjupybae	138	43	approaches	approach	NNS
work_u6osxdbbyvcabphnodfjupybae	138	44	to	to	TO
work_u6osxdbbyvcabphnodfjupybae	138	45	achieve	achieve	VB
work_u6osxdbbyvcabphnodfjupybae	138	46	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	138	47	jointly	jointly	RB
work_u6osxdbbyvcabphnodfjupybae	138	48	shared	share	VBN
work_u6osxdbbyvcabphnodfjupybae	138	49	goal	goal	NN
work_u6osxdbbyvcabphnodfjupybae	138	50	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	138	51	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	138	52	longer	long	JJR
work_u6osxdbbyvcabphnodfjupybae	138	53	duration	duration	NN
work_u6osxdbbyvcabphnodfjupybae	138	54	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	138	55	quality	quality	NN
work_u6osxdbbyvcabphnodfjupybae	138	56	life	life	NN
work_u6osxdbbyvcabphnodfjupybae	138	57	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	138	58	an	an	DT
work_u6osxdbbyvcabphnodfjupybae	138	59	enhanced	enhance	VBN
work_u6osxdbbyvcabphnodfjupybae	138	60	opportunity	opportunity	NN
work_u6osxdbbyvcabphnodfjupybae	138	61	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	138	62	long	long	JJ
work_u6osxdbbyvcabphnodfjupybae	138	63	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	138	64	term	term	NN
work_u6osxdbbyvcabphnodfjupybae	138	65	disease	disease	NN
work_u6osxdbbyvcabphnodfjupybae	138	66	control	control	NN
work_u6osxdbbyvcabphnodfjupybae	138	67	.	.	.
work_u6osxdbbyvcabphnodfjupybae	139	1	ACKNOWLEDGMENTS	acknowledgment	NNS
work_u6osxdbbyvcabphnodfjupybae	139	2	The	the	DT
work_u6osxdbbyvcabphnodfjupybae	139	3	authors	author	NNS
work_u6osxdbbyvcabphnodfjupybae	139	4	acknowledge	acknowledge	VBP
work_u6osxdbbyvcabphnodfjupybae	139	5	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	139	6	kind	kind	JJ
work_u6osxdbbyvcabphnodfjupybae	139	7	statistical	statistical	JJ
work_u6osxdbbyvcabphnodfjupybae	139	8	advice	advice	NN
work_u6osxdbbyvcabphnodfjupybae	139	9	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	139	10	Dr.	Dr.	NNP
work_u6osxdbbyvcabphnodfjupybae	139	11	Stephen	Stephen	NNP
work_u6osxdbbyvcabphnodfjupybae	139	12	George	George	NNP
work_u6osxdbbyvcabphnodfjupybae	139	13	,	,	,
work_u6osxdbbyvcabphnodfjupybae	139	14	Professor	Professor	NNP
work_u6osxdbbyvcabphnodfjupybae	139	15	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	139	16	Biostatistics	Biostatistics	NNP
work_u6osxdbbyvcabphnodfjupybae	139	17	,	,	,
work_u6osxdbbyvcabphnodfjupybae	139	18	Duke	Duke	NNP
work_u6osxdbbyvcabphnodfjupybae	139	19	University	University	NNP
work_u6osxdbbyvcabphnodfjupybae	139	20	.	.	.
work_u6osxdbbyvcabphnodfjupybae	140	1	REFERENCES	reference	NNS
work_u6osxdbbyvcabphnodfjupybae	140	2	1	1	CD
work_u6osxdbbyvcabphnodfjupybae	140	3	.	.	.
work_u6osxdbbyvcabphnodfjupybae	141	1	Jemal	Jemal	NNP
work_u6osxdbbyvcabphnodfjupybae	141	2	A	A	NNP
work_u6osxdbbyvcabphnodfjupybae	141	3	,	,	,
work_u6osxdbbyvcabphnodfjupybae	141	4	Siegel	Siegel	NNP
work_u6osxdbbyvcabphnodfjupybae	141	5	R	R	NNP
work_u6osxdbbyvcabphnodfjupybae	141	6	,	,	,
work_u6osxdbbyvcabphnodfjupybae	141	7	Ward	Ward	NNP
work_u6osxdbbyvcabphnodfjupybae	141	8	E	E	NNP
work_u6osxdbbyvcabphnodfjupybae	141	9	,	,	,
work_u6osxdbbyvcabphnodfjupybae	141	10	et	et	NNP
work_u6osxdbbyvcabphnodfjupybae	141	11	al	al	NNP
work_u6osxdbbyvcabphnodfjupybae	141	12	.	.	.
work_u6osxdbbyvcabphnodfjupybae	142	1	Cancer	cancer	NN
work_u6osxdbbyvcabphnodfjupybae	142	2	statistics	statistic	NNS
work_u6osxdbbyvcabphnodfjupybae	142	3	2008	2008	CD
work_u6osxdbbyvcabphnodfjupybae	142	4	.	.	.
work_u6osxdbbyvcabphnodfjupybae	143	1	CA	CA	NNP
work_u6osxdbbyvcabphnodfjupybae	143	2	Cancer	Cancer	NNP
work_u6osxdbbyvcabphnodfjupybae	143	3	J	J	NNP
work_u6osxdbbyvcabphnodfjupybae	143	4	Clin	Clin	NNP
work_u6osxdbbyvcabphnodfjupybae	143	5	2008;58:71–96	2008;58:71–96	CD
work_u6osxdbbyvcabphnodfjupybae	143	6	.	.	.
work_u6osxdbbyvcabphnodfjupybae	144	1	2	2	LS
work_u6osxdbbyvcabphnodfjupybae	144	2	.	.	.
work_u6osxdbbyvcabphnodfjupybae	145	1	Farray	Farray	NNP
work_u6osxdbbyvcabphnodfjupybae	145	2	D	D	NNP
work_u6osxdbbyvcabphnodfjupybae	145	3	,	,	,
work_u6osxdbbyvcabphnodfjupybae	145	4	Mirkovic	Mirkovic	NNP
work_u6osxdbbyvcabphnodfjupybae	145	5	N	N	NNP
work_u6osxdbbyvcabphnodfjupybae	145	6	,	,	,
work_u6osxdbbyvcabphnodfjupybae	145	7	Albain	Albain	NNP
work_u6osxdbbyvcabphnodfjupybae	145	8	KS	KS	NNP
work_u6osxdbbyvcabphnodfjupybae	145	9	.	.	.
work_u6osxdbbyvcabphnodfjupybae	146	1	Multimodality	multimodality	NN
work_u6osxdbbyvcabphnodfjupybae	146	2	therapy	therapy	NN
work_u6osxdbbyvcabphnodfjupybae	146	3	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	146	4	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	146	5	III	iii	CD
work_u6osxdbbyvcabphnodfjupybae	146	6	non	non	JJ
work_u6osxdbbyvcabphnodfjupybae	146	7	-	-	JJ
work_u6osxdbbyvcabphnodfjupybae	146	8	small	small	JJ
work_u6osxdbbyvcabphnodfjupybae	146	9	cell	cell	NN
work_u6osxdbbyvcabphnodfjupybae	146	10	lung	lung	NN
work_u6osxdbbyvcabphnodfjupybae	146	11	cancer	cancer	NN
work_u6osxdbbyvcabphnodfjupybae	146	12	.	.	.
work_u6osxdbbyvcabphnodfjupybae	147	1	J	J	NNP
work_u6osxdbbyvcabphnodfjupybae	147	2	Clin	Clin	NNP
work_u6osxdbbyvcabphnodfjupybae	147	3	Oncol	Oncol	NNP
work_u6osxdbbyvcabphnodfjupybae	147	4	2005;23:3257–3269	2005;23:3257–3269	CD
work_u6osxdbbyvcabphnodfjupybae	147	5	.	.	.
work_u6osxdbbyvcabphnodfjupybae	148	1	3	3	LS
work_u6osxdbbyvcabphnodfjupybae	148	2	.	.	.
work_u6osxdbbyvcabphnodfjupybae	149	1	Vokes	voke	NNS
work_u6osxdbbyvcabphnodfjupybae	149	2	EE	EE	NNP
work_u6osxdbbyvcabphnodfjupybae	149	3	,	,	,
work_u6osxdbbyvcabphnodfjupybae	149	4	Herndon	Herndon	NNP
work_u6osxdbbyvcabphnodfjupybae	149	5	JE	JE	NNP
work_u6osxdbbyvcabphnodfjupybae	149	6	II	II	NNP
work_u6osxdbbyvcabphnodfjupybae	149	7	,	,	,
work_u6osxdbbyvcabphnodfjupybae	149	8	Kelley	Kelley	NNP
work_u6osxdbbyvcabphnodfjupybae	149	9	MJ	MJ	NNP
work_u6osxdbbyvcabphnodfjupybae	149	10	,	,	,
work_u6osxdbbyvcabphnodfjupybae	149	11	et	et	NNP
work_u6osxdbbyvcabphnodfjupybae	149	12	al	al	NNP
work_u6osxdbbyvcabphnodfjupybae	149	13	.	.	.
work_u6osxdbbyvcabphnodfjupybae	150	1	;	;	:
work_u6osxdbbyvcabphnodfjupybae	150	2	Cancer	Cancer	NNP
work_u6osxdbbyvcabphnodfjupybae	150	3	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	150	4	Leukemia	Leukemia	NNP
work_u6osxdbbyvcabphnodfjupybae	150	5	Group	Group	NNP
work_u6osxdbbyvcabphnodfjupybae	150	6	B.	B.	NNP
work_u6osxdbbyvcabphnodfjupybae	151	1	Induction	induction	NN
work_u6osxdbbyvcabphnodfjupybae	151	2	chemotherapy	chemotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	151	3	followed	follow	VBN
work_u6osxdbbyvcabphnodfjupybae	151	4	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	151	5	chemoradiotherapy	chemoradiotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	151	6	com-	com-	NN
work_u6osxdbbyvcabphnodfjupybae	151	7	pared	pare	VBD
work_u6osxdbbyvcabphnodfjupybae	151	8	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	151	9	chemoradiotherapy	chemoradiotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	151	10	alone	alone	RB
work_u6osxdbbyvcabphnodfjupybae	151	11	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	151	12	regionally	regionally	RB
work_u6osxdbbyvcabphnodfjupybae	151	13	advanced	advance	VBN
work_u6osxdbbyvcabphnodfjupybae	151	14	unresect-	unresect-	JJ
work_u6osxdbbyvcabphnodfjupybae	151	15	able	able	JJ
work_u6osxdbbyvcabphnodfjupybae	151	16	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	151	17	III	iii	CD
work_u6osxdbbyvcabphnodfjupybae	151	18	non	non	JJ
work_u6osxdbbyvcabphnodfjupybae	151	19	-	-	JJ
work_u6osxdbbyvcabphnodfjupybae	151	20	small	small	JJ
work_u6osxdbbyvcabphnodfjupybae	151	21	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	151	22	cell	cell	NN
work_u6osxdbbyvcabphnodfjupybae	151	23	lung	lung	NN
work_u6osxdbbyvcabphnodfjupybae	151	24	cancer	cancer	NN
work_u6osxdbbyvcabphnodfjupybae	151	25	:	:	:
work_u6osxdbbyvcabphnodfjupybae	151	26	Cancer	Cancer	NNP
work_u6osxdbbyvcabphnodfjupybae	151	27	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	151	28	Leukemia	Leukemia	NNP
work_u6osxdbbyvcabphnodfjupybae	151	29	Group	Group	NNP
work_u6osxdbbyvcabphnodfjupybae	151	30	B.	B.	NNP
work_u6osxdbbyvcabphnodfjupybae	151	31	J	J	NNP
work_u6osxdbbyvcabphnodfjupybae	151	32	Clin	Clin	NNP
work_u6osxdbbyvcabphnodfjupybae	151	33	Oncol	Oncol	NNP
work_u6osxdbbyvcabphnodfjupybae	151	34	2007;25:1698	2007;25:1698	CD
work_u6osxdbbyvcabphnodfjupybae	151	35	–	–	:
work_u6osxdbbyvcabphnodfjupybae	151	36	1704	1704	CD
work_u6osxdbbyvcabphnodfjupybae	151	37	.	.	.
work_u6osxdbbyvcabphnodfjupybae	152	1	4	4	LS
work_u6osxdbbyvcabphnodfjupybae	152	2	.	.	.
work_u6osxdbbyvcabphnodfjupybae	153	1	Gandara	Gandara	NNP
work_u6osxdbbyvcabphnodfjupybae	153	2	DR	DR	NNP
work_u6osxdbbyvcabphnodfjupybae	153	3	,	,	,
work_u6osxdbbyvcabphnodfjupybae	153	4	Chansky	Chansky	NNP
work_u6osxdbbyvcabphnodfjupybae	153	5	K	K	NNP
work_u6osxdbbyvcabphnodfjupybae	153	6	,	,	,
work_u6osxdbbyvcabphnodfjupybae	153	7	Albain	Albain	NNP
work_u6osxdbbyvcabphnodfjupybae	153	8	KS	KS	NNP
work_u6osxdbbyvcabphnodfjupybae	153	9	,	,	,
work_u6osxdbbyvcabphnodfjupybae	153	10	et	et	NNP
work_u6osxdbbyvcabphnodfjupybae	153	11	al	al	NNP
work_u6osxdbbyvcabphnodfjupybae	153	12	.	.	.
work_u6osxdbbyvcabphnodfjupybae	154	1	Long	long	JJ
work_u6osxdbbyvcabphnodfjupybae	154	2	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	154	3	term	term	NN
work_u6osxdbbyvcabphnodfjupybae	154	4	survival	survival	NN
work_u6osxdbbyvcabphnodfjupybae	154	5	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	154	6	concurrent	concurrent	JJ
work_u6osxdbbyvcabphnodfjupybae	154	7	chemoradiation	chemoradiation	NN
work_u6osxdbbyvcabphnodfjupybae	154	8	therapy	therapy	NN
work_u6osxdbbyvcabphnodfjupybae	154	9	followed	follow	VBN
work_u6osxdbbyvcabphnodfjupybae	154	10	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	154	11	consolidation	consolidation	NN
work_u6osxdbbyvcabphnodfjupybae	154	12	docetaxel	docetaxel	NNP
work_u6osxdbbyvcabphnodfjupybae	154	13	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	154	14	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	154	15	IIIB	IIIB	NNP
work_u6osxdbbyvcabphnodfjupybae	154	16	non	non	JJ
work_u6osxdbbyvcabphnodfjupybae	154	17	-	-	JJ
work_u6osxdbbyvcabphnodfjupybae	154	18	small	small	JJ
work_u6osxdbbyvcabphnodfjupybae	154	19	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	154	20	cell	cell	NN
work_u6osxdbbyvcabphnodfjupybae	154	21	lung	lung	NN
work_u6osxdbbyvcabphnodfjupybae	154	22	cancer	cancer	NN
work_u6osxdbbyvcabphnodfjupybae	154	23	:	:	:
work_u6osxdbbyvcabphnodfjupybae	154	24	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	154	25	phase	phase	NN
work_u6osxdbbyvcabphnodfjupybae	154	26	II	II	NNP
work_u6osxdbbyvcabphnodfjupybae	154	27	Southwest	Southwest	NNP
work_u6osxdbbyvcabphnodfjupybae	154	28	Oncology	Oncology	NNP
work_u6osxdbbyvcabphnodfjupybae	154	29	Group	Group	NNP
work_u6osxdbbyvcabphnodfjupybae	154	30	Study	Study	NNP
work_u6osxdbbyvcabphnodfjupybae	154	31	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	154	32	S9504	S9504	NNP
work_u6osxdbbyvcabphnodfjupybae	154	33	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	154	34	.	.	.
work_u6osxdbbyvcabphnodfjupybae	155	1	Clin	Clin	NNP
work_u6osxdbbyvcabphnodfjupybae	155	2	Lung	Lung	NNP
work_u6osxdbbyvcabphnodfjupybae	155	3	Cancer	Cancer	NNP
work_u6osxdbbyvcabphnodfjupybae	155	4	2006;8:116	2006;8:116	CD
work_u6osxdbbyvcabphnodfjupybae	155	5	–	–	:
work_u6osxdbbyvcabphnodfjupybae	155	6	121	121	CD
work_u6osxdbbyvcabphnodfjupybae	155	7	.	.	.
work_u6osxdbbyvcabphnodfjupybae	156	1	5	5	CD
work_u6osxdbbyvcabphnodfjupybae	156	2	.	.	.
work_u6osxdbbyvcabphnodfjupybae	157	1	Belani	Belani	NNP
work_u6osxdbbyvcabphnodfjupybae	157	2	CP	CP	NNP
work_u6osxdbbyvcabphnodfjupybae	157	3	,	,	,
work_u6osxdbbyvcabphnodfjupybae	157	4	Choy	Choy	NNP
work_u6osxdbbyvcabphnodfjupybae	157	5	H	H	NNP
work_u6osxdbbyvcabphnodfjupybae	157	6	,	,	,
work_u6osxdbbyvcabphnodfjupybae	157	7	Bonomi	Bonomi	NNP
work_u6osxdbbyvcabphnodfjupybae	157	8	P	P	NNP
work_u6osxdbbyvcabphnodfjupybae	157	9	,	,	,
work_u6osxdbbyvcabphnodfjupybae	157	10	et	et	NNP
work_u6osxdbbyvcabphnodfjupybae	157	11	al	al	NNP
work_u6osxdbbyvcabphnodfjupybae	157	12	.	.	.
work_u6osxdbbyvcabphnodfjupybae	158	1	Combined	combine	VBN
work_u6osxdbbyvcabphnodfjupybae	158	2	chemoradiotherapy	chemoradiotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	158	3	regimens	regimen	NNS
work_u6osxdbbyvcabphnodfjupybae	158	4	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	158	5	paclitaxel	paclitaxel	NNP
work_u6osxdbbyvcabphnodfjupybae	158	6	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	158	7	carboplatin	carboplatin	NNP
work_u6osxdbbyvcabphnodfjupybae	158	8	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	158	9	locally	locally	RB
work_u6osxdbbyvcabphnodfjupybae	158	10	advanced	advanced	JJ
work_u6osxdbbyvcabphnodfjupybae	158	11	non	non	JJ
work_u6osxdbbyvcabphnodfjupybae	158	12	-	-	JJ
work_u6osxdbbyvcabphnodfjupybae	158	13	small-	small-	JJ
work_u6osxdbbyvcabphnodfjupybae	158	14	cell	cell	NN
work_u6osxdbbyvcabphnodfjupybae	158	15	lung	lung	NN
work_u6osxdbbyvcabphnodfjupybae	158	16	cancer	cancer	NN
work_u6osxdbbyvcabphnodfjupybae	158	17	:	:	:
work_u6osxdbbyvcabphnodfjupybae	158	18	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	158	19	randomized	randomized	JJ
work_u6osxdbbyvcabphnodfjupybae	158	20	phase	phase	NN
work_u6osxdbbyvcabphnodfjupybae	158	21	II	II	NNP
work_u6osxdbbyvcabphnodfjupybae	158	22	locally	locally	RB
work_u6osxdbbyvcabphnodfjupybae	158	23	advanced	advanced	JJ
work_u6osxdbbyvcabphnodfjupybae	158	24	multi	multi	JJ
work_u6osxdbbyvcabphnodfjupybae	158	25	-	-	JJ
work_u6osxdbbyvcabphnodfjupybae	158	26	modality	modality	JJ
work_u6osxdbbyvcabphnodfjupybae	158	27	protocol	protocol	NN
work_u6osxdbbyvcabphnodfjupybae	158	28	.	.	.
work_u6osxdbbyvcabphnodfjupybae	159	1	J	J	NNP
work_u6osxdbbyvcabphnodfjupybae	159	2	Clin	Clin	NNP
work_u6osxdbbyvcabphnodfjupybae	159	3	Oncol	Oncol	NNP
work_u6osxdbbyvcabphnodfjupybae	159	4	2005;23:5883–5891	2005;23:5883–5891	CD
work_u6osxdbbyvcabphnodfjupybae	159	5	.	.	.
work_u6osxdbbyvcabphnodfjupybae	160	1	6	6	CD
work_u6osxdbbyvcabphnodfjupybae	160	2	.	.	.
work_u6osxdbbyvcabphnodfjupybae	161	1	Green	Green	NNP
work_u6osxdbbyvcabphnodfjupybae	161	2	MR	MR	NNP
work_u6osxdbbyvcabphnodfjupybae	161	3	,	,	,
work_u6osxdbbyvcabphnodfjupybae	161	4	West	West	NNP
work_u6osxdbbyvcabphnodfjupybae	161	5	H	H	NNP
work_u6osxdbbyvcabphnodfjupybae	161	6	,	,	,
work_u6osxdbbyvcabphnodfjupybae	161	7	Socinski	Socinski	NNP
work_u6osxdbbyvcabphnodfjupybae	161	8	MA	MA	NNP
work_u6osxdbbyvcabphnodfjupybae	161	9	,	,	,
work_u6osxdbbyvcabphnodfjupybae	161	10	et	et	NNP
work_u6osxdbbyvcabphnodfjupybae	161	11	al	al	NNP
work_u6osxdbbyvcabphnodfjupybae	161	12	.	.	.
work_u6osxdbbyvcabphnodfjupybae	162	1	Management	management	NN
work_u6osxdbbyvcabphnodfjupybae	162	2	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	162	3	N3	N3	NNP
work_u6osxdbbyvcabphnodfjupybae	162	4	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	162	5	IIIB	IIIB	NNP
work_u6osxdbbyvcabphnodfjupybae	162	6	NSCLC	nsclc	NN
work_u6osxdbbyvcabphnodfjupybae	162	7	:	:	:
work_u6osxdbbyvcabphnodfjupybae	162	8	changes	change	NNS
work_u6osxdbbyvcabphnodfjupybae	162	9	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	162	10	US	US	NNP
work_u6osxdbbyvcabphnodfjupybae	162	11	medical	medical	JJ
work_u6osxdbbyvcabphnodfjupybae	162	12	oncologists	oncologist	NNS
work_u6osxdbbyvcabphnodfjupybae	162	13	prescribing	prescribe	VBG
work_u6osxdbbyvcabphnodfjupybae	162	14	plans	plan	NNS
work_u6osxdbbyvcabphnodfjupybae	162	15	following	follow	VBG
work_u6osxdbbyvcabphnodfjupybae	162	16	ASCO	ASCO	NNS
work_u6osxdbbyvcabphnodfjupybae	162	17	2007	2007	CD
work_u6osxdbbyvcabphnodfjupybae	162	18	.	.	.
work_u6osxdbbyvcabphnodfjupybae	163	1	J	J	NNP
work_u6osxdbbyvcabphnodfjupybae	163	2	Clin	Clin	NNP
work_u6osxdbbyvcabphnodfjupybae	163	3	Oncol	Oncol	NNP
work_u6osxdbbyvcabphnodfjupybae	163	4	2008;26(Suppl	2008;26(suppl	CD
work_u6osxdbbyvcabphnodfjupybae	163	5	1):7579	1):7579	CD
work_u6osxdbbyvcabphnodfjupybae	163	6	.	.	.
work_u6osxdbbyvcabphnodfjupybae	164	1	7	7	LS
work_u6osxdbbyvcabphnodfjupybae	164	2	.	.	.
work_u6osxdbbyvcabphnodfjupybae	165	1	Hanna	Hanna	NNP
work_u6osxdbbyvcabphnodfjupybae	165	2	NH	NH	NNP
work_u6osxdbbyvcabphnodfjupybae	165	3	,	,	,
work_u6osxdbbyvcabphnodfjupybae	165	4	Neubauer	Neubauer	NNP
work_u6osxdbbyvcabphnodfjupybae	165	5	M	M	NNP
work_u6osxdbbyvcabphnodfjupybae	165	6	,	,	,
work_u6osxdbbyvcabphnodfjupybae	165	7	Ansari	Ansari	NNP
work_u6osxdbbyvcabphnodfjupybae	165	8	R	R	NNP
work_u6osxdbbyvcabphnodfjupybae	165	9	,	,	,
work_u6osxdbbyvcabphnodfjupybae	165	10	et	et	NNP
work_u6osxdbbyvcabphnodfjupybae	165	11	al	al	NNP
work_u6osxdbbyvcabphnodfjupybae	165	12	.	.	.
work_u6osxdbbyvcabphnodfjupybae	166	1	Phase	phase	NN
work_u6osxdbbyvcabphnodfjupybae	166	2	III	iii	CD
work_u6osxdbbyvcabphnodfjupybae	166	3	trial	trial	NN
work_u6osxdbbyvcabphnodfjupybae	166	4	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	166	5	cisplatin	cisplatin	NN
work_u6osxdbbyvcabphnodfjupybae	166	6	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	166	7	P	p	NN
work_u6osxdbbyvcabphnodfjupybae	166	8	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	166	9	plus	plus	CC
work_u6osxdbbyvcabphnodfjupybae	166	10	etoposide	etoposide	NN
work_u6osxdbbyvcabphnodfjupybae	166	11	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	166	12	E	e	NN
work_u6osxdbbyvcabphnodfjupybae	166	13	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	166	14	plus	plus	CC
work_u6osxdbbyvcabphnodfjupybae	166	15	concurrent	concurrent	JJ
work_u6osxdbbyvcabphnodfjupybae	166	16	chest	chest	NN
work_u6osxdbbyvcabphnodfjupybae	166	17	radiation	radiation	NN
work_u6osxdbbyvcabphnodfjupybae	166	18	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	166	19	XRT	XRT	NNP
work_u6osxdbbyvcabphnodfjupybae	166	20	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	166	21	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	166	22	or	or	CC
work_u6osxdbbyvcabphnodfjupybae	166	23	without	without	IN
work_u6osxdbbyvcabphnodfjupybae	166	24	consolidation	consolidation	NN
work_u6osxdbbyvcabphnodfjupybae	166	25	docetaxel	docetaxel	NNS
work_u6osxdbbyvcabphnodfjupybae	166	26	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	166	27	D	D	NNP
work_u6osxdbbyvcabphnodfjupybae	166	28	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	166	29	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	166	30	patients	patient	NNS
work_u6osxdbbyvcabphnodfjupybae	166	31	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	166	32	pts	pts	NNP
work_u6osxdbbyvcabphnodfjupybae	166	33	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	166	34	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	166	35	inoperable	inoperable	JJ
work_u6osxdbbyvcabphnodfjupybae	166	36	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	166	37	III	iii	CD
work_u6osxdbbyvcabphnodfjupybae	166	38	non	non	JJ
work_u6osxdbbyvcabphnodfjupybae	166	39	-	-	JJ
work_u6osxdbbyvcabphnodfjupybae	166	40	small	small	JJ
work_u6osxdbbyvcabphnodfjupybae	166	41	cell	cell	NN
work_u6osxdbbyvcabphnodfjupybae	166	42	lung	lung	NN
work_u6osxdbbyvcabphnodfjupybae	166	43	cancer	cancer	NN
work_u6osxdbbyvcabphnodfjupybae	166	44	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	166	45	NSCLC	NSCLC	NNP
work_u6osxdbbyvcabphnodfjupybae	166	46	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	166	47	:	:	:
work_u6osxdbbyvcabphnodfjupybae	166	48	HOG	HOG	NNP
work_u6osxdbbyvcabphnodfjupybae	166	49	LUN	LUN	NNP
work_u6osxdbbyvcabphnodfjupybae	166	50	01	01	CD
work_u6osxdbbyvcabphnodfjupybae	166	51	-	-	SYM
work_u6osxdbbyvcabphnodfjupybae	166	52	24	24	CD
work_u6osxdbbyvcabphnodfjupybae	166	53	/	/	SYM
work_u6osxdbbyvcabphnodfjupybae	166	54	USO-023	uso-023	CD
work_u6osxdbbyvcabphnodfjupybae	166	55	.	.	.
work_u6osxdbbyvcabphnodfjupybae	167	1	J	J	NNP
work_u6osxdbbyvcabphnodfjupybae	167	2	Clin	Clin	NNP
work_u6osxdbbyvcabphnodfjupybae	167	3	Oncol	Oncol	NNP
work_u6osxdbbyvcabphnodfjupybae	167	4	2007;25(Suppl	2007;25(suppl	CD
work_u6osxdbbyvcabphnodfjupybae	167	5	18S):7512	18S):7512	NNS
work_u6osxdbbyvcabphnodfjupybae	167	6	.	.	.
work_u6osxdbbyvcabphnodfjupybae	168	1	8	8	LS
work_u6osxdbbyvcabphnodfjupybae	168	2	.	.	.
work_u6osxdbbyvcabphnodfjupybae	169	1	Pignon	Pignon	NNP
work_u6osxdbbyvcabphnodfjupybae	169	2	JP	JP	NNP
work_u6osxdbbyvcabphnodfjupybae	169	3	,	,	,
work_u6osxdbbyvcabphnodfjupybae	169	4	Tribodet	Tribodet	NNP
work_u6osxdbbyvcabphnodfjupybae	169	5	H	H	NNP
work_u6osxdbbyvcabphnodfjupybae	169	6	,	,	,
work_u6osxdbbyvcabphnodfjupybae	169	7	Scagliotti	Scagliotti	NNP
work_u6osxdbbyvcabphnodfjupybae	169	8	GV	GV	NNP
work_u6osxdbbyvcabphnodfjupybae	169	9	,	,	,
work_u6osxdbbyvcabphnodfjupybae	169	10	et	et	NNP
work_u6osxdbbyvcabphnodfjupybae	169	11	al	al	NNP
work_u6osxdbbyvcabphnodfjupybae	169	12	.	.	.
work_u6osxdbbyvcabphnodfjupybae	170	1	;	;	:
work_u6osxdbbyvcabphnodfjupybae	170	2	LACE	LACE	NNP
work_u6osxdbbyvcabphnodfjupybae	170	3	Collaborative	Collaborative	NNP
work_u6osxdbbyvcabphnodfjupybae	170	4	Group	Group	NNP
work_u6osxdbbyvcabphnodfjupybae	170	5	.	.	.
work_u6osxdbbyvcabphnodfjupybae	171	1	Lung	lung	NN
work_u6osxdbbyvcabphnodfjupybae	171	2	adjuvant	adjuvant	NN
work_u6osxdbbyvcabphnodfjupybae	171	3	cisplatin	cisplatin	NN
work_u6osxdbbyvcabphnodfjupybae	171	4	evaluation	evaluation	NN
work_u6osxdbbyvcabphnodfjupybae	171	5	:	:	:
work_u6osxdbbyvcabphnodfjupybae	171	6	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	171	7	pooled	pool	VBN
work_u6osxdbbyvcabphnodfjupybae	171	8	analysis	analysis	NN
work_u6osxdbbyvcabphnodfjupybae	171	9	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	171	10	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	171	11	LACE	LACE	NNP
work_u6osxdbbyvcabphnodfjupybae	171	12	Collaborative	Collaborative	NNP
work_u6osxdbbyvcabphnodfjupybae	171	13	Group	Group	NNP
work_u6osxdbbyvcabphnodfjupybae	171	14	.	.	.
work_u6osxdbbyvcabphnodfjupybae	172	1	J	J	NNP
work_u6osxdbbyvcabphnodfjupybae	172	2	Clin	Clin	NNP
work_u6osxdbbyvcabphnodfjupybae	172	3	Oncol	Oncol	NNP
work_u6osxdbbyvcabphnodfjupybae	172	4	2008;26:3552–3559	2008;26:3552–3559	CD
work_u6osxdbbyvcabphnodfjupybae	172	5	.	.	.
work_u6osxdbbyvcabphnodfjupybae	173	1	9	9	CD
work_u6osxdbbyvcabphnodfjupybae	173	2	.	.	.
work_u6osxdbbyvcabphnodfjupybae	174	1	Albain	Albain	NNP
work_u6osxdbbyvcabphnodfjupybae	174	2	KS	KS	NNP
work_u6osxdbbyvcabphnodfjupybae	174	3	,	,	,
work_u6osxdbbyvcabphnodfjupybae	174	4	Crowley	Crowley	NNP
work_u6osxdbbyvcabphnodfjupybae	174	5	JJ	JJ	NNP
work_u6osxdbbyvcabphnodfjupybae	174	6	,	,	,
work_u6osxdbbyvcabphnodfjupybae	174	7	Turrisi	Turrisi	NNP
work_u6osxdbbyvcabphnodfjupybae	174	8	AT	AT	NNP
work_u6osxdbbyvcabphnodfjupybae	174	9	III	III	NNP
work_u6osxdbbyvcabphnodfjupybae	174	10	,	,	,
work_u6osxdbbyvcabphnodfjupybae	174	11	et	et	NNP
work_u6osxdbbyvcabphnodfjupybae	174	12	al	al	NNP
work_u6osxdbbyvcabphnodfjupybae	174	13	.	.	.
work_u6osxdbbyvcabphnodfjupybae	175	1	Concurrent	concurrent	JJ
work_u6osxdbbyvcabphnodfjupybae	175	2	cisplatin	cisplatin	NN
work_u6osxdbbyvcabphnodfjupybae	175	3	,	,	,
work_u6osxdbbyvcabphnodfjupybae	175	4	etoposide	etoposide	NN
work_u6osxdbbyvcabphnodfjupybae	175	5	,	,	,
work_u6osxdbbyvcabphnodfjupybae	175	6	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	175	7	chest	chest	NN
work_u6osxdbbyvcabphnodfjupybae	175	8	radiotherapy	radiotherapy	NN
work_u6osxdbbyvcabphnodfjupybae	175	9	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	175	10	pathologic	pathologic	JJ
work_u6osxdbbyvcabphnodfjupybae	175	11	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	175	12	IIIB	IIIB	NNP
work_u6osxdbbyvcabphnodfjupybae	175	13	non	non	JJ
work_u6osxdbbyvcabphnodfjupybae	175	14	-	-	JJ
work_u6osxdbbyvcabphnodfjupybae	175	15	small	small	JJ
work_u6osxdbbyvcabphnodfjupybae	175	16	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	175	17	cell	cell	NN
work_u6osxdbbyvcabphnodfjupybae	175	18	lung	lung	NN
work_u6osxdbbyvcabphnodfjupybae	175	19	cancer	cancer	NN
work_u6osxdbbyvcabphnodfjupybae	175	20	:	:	:
work_u6osxdbbyvcabphnodfjupybae	175	21	a	a	DT
work_u6osxdbbyvcabphnodfjupybae	175	22	Southwest	Southwest	NNP
work_u6osxdbbyvcabphnodfjupybae	175	23	Oncology	Oncology	NNP
work_u6osxdbbyvcabphnodfjupybae	175	24	Group	Group	NNP
work_u6osxdbbyvcabphnodfjupybae	175	25	phase	phase	NN
work_u6osxdbbyvcabphnodfjupybae	175	26	II	ii	CD
work_u6osxdbbyvcabphnodfjupybae	175	27	study	study	NN
work_u6osxdbbyvcabphnodfjupybae	175	28	,	,	,
work_u6osxdbbyvcabphnodfjupybae	175	29	SWOG	SWOG	NNP
work_u6osxdbbyvcabphnodfjupybae	175	30	9019	9019	CD
work_u6osxdbbyvcabphnodfjupybae	175	31	.	.	.
work_u6osxdbbyvcabphnodfjupybae	176	1	J	J	NNP
work_u6osxdbbyvcabphnodfjupybae	176	2	Clin	Clin	NNP
work_u6osxdbbyvcabphnodfjupybae	176	3	Oncol	Oncol	NNP
work_u6osxdbbyvcabphnodfjupybae	176	4	2002;20:3454	2002;20:3454	CD
work_u6osxdbbyvcabphnodfjupybae	176	5	–	–	:
work_u6osxdbbyvcabphnodfjupybae	176	6	3460	3460	CD
work_u6osxdbbyvcabphnodfjupybae	176	7	.	.	.
work_u6osxdbbyvcabphnodfjupybae	177	1	10	10	CD
work_u6osxdbbyvcabphnodfjupybae	177	2	.	.	.
work_u6osxdbbyvcabphnodfjupybae	178	1	Kelly	Kelly	NNP
work_u6osxdbbyvcabphnodfjupybae	178	2	K	K	NNP
work_u6osxdbbyvcabphnodfjupybae	178	3	,	,	,
work_u6osxdbbyvcabphnodfjupybae	178	4	Chansky	Chansky	NNP
work_u6osxdbbyvcabphnodfjupybae	178	5	K	K	NNP
work_u6osxdbbyvcabphnodfjupybae	178	6	,	,	,
work_u6osxdbbyvcabphnodfjupybae	178	7	Gaspar	Gaspar	NNP
work_u6osxdbbyvcabphnodfjupybae	178	8	LE	LE	NNP
work_u6osxdbbyvcabphnodfjupybae	178	9	,	,	,
work_u6osxdbbyvcabphnodfjupybae	178	10	et	et	NNP
work_u6osxdbbyvcabphnodfjupybae	178	11	al	al	NNP
work_u6osxdbbyvcabphnodfjupybae	178	12	.	.	.
work_u6osxdbbyvcabphnodfjupybae	179	1	Phase	phase	NN
work_u6osxdbbyvcabphnodfjupybae	179	2	III	III	NNP
work_u6osxdbbyvcabphnodfjupybae	179	3	Trial	trial	NN
work_u6osxdbbyvcabphnodfjupybae	179	4	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	179	5	maintenance	maintenance	NN
work_u6osxdbbyvcabphnodfjupybae	179	6	gefitinib	gefitinib	JJ
work_u6osxdbbyvcabphnodfjupybae	179	7	or	or	CC
work_u6osxdbbyvcabphnodfjupybae	179	8	placebo	placebo	NN
work_u6osxdbbyvcabphnodfjupybae	179	9	after	after	IN
work_u6osxdbbyvcabphnodfjupybae	179	10	concurrent	concurrent	JJ
work_u6osxdbbyvcabphnodfjupybae	179	11	chemoradiotherapy	chemoradiotherapy	NNP
work_u6osxdbbyvcabphnodfjupybae	179	12	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	179	13	docetaxel	docetaxel	NNP
work_u6osxdbbyvcabphnodfjupybae	179	14	consolidation	consolidation	NN
work_u6osxdbbyvcabphnodfjupybae	179	15	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	179	16	inoperable	inoperable	JJ
work_u6osxdbbyvcabphnodfjupybae	179	17	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	179	18	III	iii	CD
work_u6osxdbbyvcabphnodfjupybae	179	19	non	non	JJ
work_u6osxdbbyvcabphnodfjupybae	179	20	-	-	JJ
work_u6osxdbbyvcabphnodfjupybae	179	21	small	small	JJ
work_u6osxdbbyvcabphnodfjupybae	179	22	cell	cell	NN
work_u6osxdbbyvcabphnodfjupybae	179	23	lung	lung	NN
work_u6osxdbbyvcabphnodfjupybae	179	24	cancer	cancer	NN
work_u6osxdbbyvcabphnodfjupybae	179	25	:	:	:
work_u6osxdbbyvcabphnodfjupybae	179	26	SWOG	SWOG	NNP
work_u6osxdbbyvcabphnodfjupybae	179	27	S0023	S0023	NNP
work_u6osxdbbyvcabphnodfjupybae	179	28	.	.	.
work_u6osxdbbyvcabphnodfjupybae	180	1	J	J	NNP
work_u6osxdbbyvcabphnodfjupybae	180	2	Clin	Clin	NNP
work_u6osxdbbyvcabphnodfjupybae	180	3	Oncol	Oncol	NNP
work_u6osxdbbyvcabphnodfjupybae	180	4	2008:2450	2008:2450	NNP
work_u6osxdbbyvcabphnodfjupybae	180	5	–	–	:
work_u6osxdbbyvcabphnodfjupybae	180	6	2456	2456	CD
work_u6osxdbbyvcabphnodfjupybae	180	7	.	.	.
work_u6osxdbbyvcabphnodfjupybae	181	1	11	11	CD
work_u6osxdbbyvcabphnodfjupybae	181	2	.	.	.
work_u6osxdbbyvcabphnodfjupybae	182	1	Mina	Mina	NNP
work_u6osxdbbyvcabphnodfjupybae	182	2	LA	LA	NNP
work_u6osxdbbyvcabphnodfjupybae	182	3	,	,	,
work_u6osxdbbyvcabphnodfjupybae	182	4	Neubauer	Neubauer	NNP
work_u6osxdbbyvcabphnodfjupybae	182	5	MA	MA	NNP
work_u6osxdbbyvcabphnodfjupybae	182	6	,	,	,
work_u6osxdbbyvcabphnodfjupybae	182	7	Ansari	Ansari	NNP
work_u6osxdbbyvcabphnodfjupybae	182	8	RH	RH	NNP
work_u6osxdbbyvcabphnodfjupybae	182	9	,	,	,
work_u6osxdbbyvcabphnodfjupybae	182	10	et	et	NNP
work_u6osxdbbyvcabphnodfjupybae	182	11	al	al	NNP
work_u6osxdbbyvcabphnodfjupybae	182	12	.	.	.
work_u6osxdbbyvcabphnodfjupybae	183	1	Phase	phase	NN
work_u6osxdbbyvcabphnodfjupybae	183	2	III	iii	CD
work_u6osxdbbyvcabphnodfjupybae	183	3	trial	trial	NN
work_u6osxdbbyvcabphnodfjupybae	183	4	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	183	5	cisplatin	cisplatin	NN
work_u6osxdbbyvcabphnodfjupybae	183	6	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	183	7	P	p	NN
work_u6osxdbbyvcabphnodfjupybae	183	8	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	183	9	plus	plus	CC
work_u6osxdbbyvcabphnodfjupybae	183	10	etoposide	etoposide	NN
work_u6osxdbbyvcabphnodfjupybae	183	11	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	183	12	E	e	NN
work_u6osxdbbyvcabphnodfjupybae	183	13	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	183	14	plus	plus	CC
work_u6osxdbbyvcabphnodfjupybae	183	15	concurrent	concurrent	JJ
work_u6osxdbbyvcabphnodfjupybae	183	16	chest	chest	NN
work_u6osxdbbyvcabphnodfjupybae	183	17	radiation	radiation	NN
work_u6osxdbbyvcabphnodfjupybae	183	18	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	183	19	XRT	XRT	NNP
work_u6osxdbbyvcabphnodfjupybae	183	20	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	183	21	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	183	22	or	or	CC
work_u6osxdbbyvcabphnodfjupybae	183	23	without	without	IN
work_u6osxdbbyvcabphnodfjupybae	183	24	consolidation	consolidation	NN
work_u6osxdbbyvcabphnodfjupybae	183	25	docetaxel	docetaxel	NNS
work_u6osxdbbyvcabphnodfjupybae	183	26	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	183	27	D	D	NNP
work_u6osxdbbyvcabphnodfjupybae	183	28	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	183	29	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	183	30	patients	patient	NNS
work_u6osxdbbyvcabphnodfjupybae	183	31	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	183	32	pts	pts	NNP
work_u6osxdbbyvcabphnodfjupybae	183	33	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	183	34	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	183	35	inoperable	inoperable	JJ
work_u6osxdbbyvcabphnodfjupybae	183	36	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	183	37	III	iii	CD
work_u6osxdbbyvcabphnodfjupybae	183	38	non	non	JJ
work_u6osxdbbyvcabphnodfjupybae	183	39	-	-	JJ
work_u6osxdbbyvcabphnodfjupybae	183	40	small	small	JJ
work_u6osxdbbyvcabphnodfjupybae	183	41	cell	cell	NN
work_u6osxdbbyvcabphnodfjupybae	183	42	lung	lung	NN
work_u6osxdbbyvcabphnodfjupybae	183	43	cancer	cancer	NN
work_u6osxdbbyvcabphnodfjupybae	183	44	(	(	-LRB-
work_u6osxdbbyvcabphnodfjupybae	183	45	NSCLC	NSCLC	NNP
work_u6osxdbbyvcabphnodfjupybae	183	46	)	)	-RRB-
work_u6osxdbbyvcabphnodfjupybae	183	47	:	:	:
work_u6osxdbbyvcabphnodfjupybae	183	48	HOG	HOG	NNP
work_u6osxdbbyvcabphnodfjupybae	183	49	LUN	LUN	NNP
work_u6osxdbbyvcabphnodfjupybae	183	50	01	01	CD
work_u6osxdbbyvcabphnodfjupybae	183	51	-	-	SYM
work_u6osxdbbyvcabphnodfjupybae	183	52	24	24	CD
work_u6osxdbbyvcabphnodfjupybae	183	53	/	/	SYM
work_u6osxdbbyvcabphnodfjupybae	183	54	USO-023	uso-023	CD
work_u6osxdbbyvcabphnodfjupybae	183	55	—	—	:
work_u6osxdbbyvcabphnodfjupybae	183	56	updated	update	VBN
work_u6osxdbbyvcabphnodfjupybae	183	57	results	result	NNS
work_u6osxdbbyvcabphnodfjupybae	183	58	.	.	.
work_u6osxdbbyvcabphnodfjupybae	184	1	J	J	NNP
work_u6osxdbbyvcabphnodfjupybae	184	2	Clin	Clin	NNP
work_u6osxdbbyvcabphnodfjupybae	184	3	Oncol	Oncol	NNP
work_u6osxdbbyvcabphnodfjupybae	184	4	2008;26(Suppl	2008;26(suppl	CD
work_u6osxdbbyvcabphnodfjupybae	184	5	15S):7519	15S):7519	NNS
work_u6osxdbbyvcabphnodfjupybae	184	6	.	.	.
work_u6osxdbbyvcabphnodfjupybae	185	1	12	12	CD
work_u6osxdbbyvcabphnodfjupybae	185	2	.	.	.
work_u6osxdbbyvcabphnodfjupybae	186	1	Hanna	Hanna	NNP
work_u6osxdbbyvcabphnodfjupybae	186	2	N	N	NNP
work_u6osxdbbyvcabphnodfjupybae	186	3	,	,	,
work_u6osxdbbyvcabphnodfjupybae	186	4	Neubauer	Neubauer	NNP
work_u6osxdbbyvcabphnodfjupybae	186	5	M	M	NNP
work_u6osxdbbyvcabphnodfjupybae	186	6	,	,	,
work_u6osxdbbyvcabphnodfjupybae	186	7	Yiannoutsos	Yiannoutsos	NNP
work_u6osxdbbyvcabphnodfjupybae	186	8	C	C	NNP
work_u6osxdbbyvcabphnodfjupybae	186	9	,	,	,
work_u6osxdbbyvcabphnodfjupybae	186	10	et	et	NNP
work_u6osxdbbyvcabphnodfjupybae	186	11	al	al	NNP
work_u6osxdbbyvcabphnodfjupybae	186	12	.	.	.
work_u6osxdbbyvcabphnodfjupybae	187	1	;	;	:
work_u6osxdbbyvcabphnodfjupybae	187	2	Hoosier	Hoosier	NNP
work_u6osxdbbyvcabphnodfjupybae	187	3	Oncology	Oncology	NNP
work_u6osxdbbyvcabphnodfjupybae	187	4	Group	Group	NNP
work_u6osxdbbyvcabphnodfjupybae	187	5	;	;	:
work_u6osxdbbyvcabphnodfjupybae	187	6	US	US	NNP
work_u6osxdbbyvcabphnodfjupybae	187	7	Oncology	Oncology	NNP
work_u6osxdbbyvcabphnodfjupybae	187	8	.	.	.
work_u6osxdbbyvcabphnodfjupybae	188	1	Phase	phase	NN
work_u6osxdbbyvcabphnodfjupybae	188	2	III	iii	CD
work_u6osxdbbyvcabphnodfjupybae	188	3	study	study	NN
work_u6osxdbbyvcabphnodfjupybae	188	4	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	188	5	cisplatin	cisplatin	NN
work_u6osxdbbyvcabphnodfjupybae	188	6	,	,	,
work_u6osxdbbyvcabphnodfjupybae	188	7	etoposide	etoposide	NN
work_u6osxdbbyvcabphnodfjupybae	188	8	,	,	,
work_u6osxdbbyvcabphnodfjupybae	188	9	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	188	10	concurrent	concurrent	JJ
work_u6osxdbbyvcabphnodfjupybae	188	11	chest	chest	NN
work_u6osxdbbyvcabphnodfjupybae	188	12	radiation	radiation	NN
work_u6osxdbbyvcabphnodfjupybae	188	13	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	188	14	or	or	CC
work_u6osxdbbyvcabphnodfjupybae	188	15	without	without	IN
work_u6osxdbbyvcabphnodfjupybae	188	16	consolidation	consolidation	NN
work_u6osxdbbyvcabphnodfjupybae	188	17	docetaxel	docetaxel	NNS
work_u6osxdbbyvcabphnodfjupybae	188	18	in	in	IN
work_u6osxdbbyvcabphnodfjupybae	188	19	patients	patient	NNS
work_u6osxdbbyvcabphnodfjupybae	188	20	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	188	21	inoperable	inoperable	JJ
work_u6osxdbbyvcabphnodfjupybae	188	22	stage	stage	NN
work_u6osxdbbyvcabphnodfjupybae	188	23	III	iii	CD
work_u6osxdbbyvcabphnodfjupybae	188	24	non	non	JJ
work_u6osxdbbyvcabphnodfjupybae	188	25	-	-	JJ
work_u6osxdbbyvcabphnodfjupybae	188	26	small	small	JJ
work_u6osxdbbyvcabphnodfjupybae	188	27	-	-	HYPH
work_u6osxdbbyvcabphnodfjupybae	188	28	cell	cell	NN
work_u6osxdbbyvcabphnodfjupybae	188	29	lung	lung	NN
work_u6osxdbbyvcabphnodfjupybae	188	30	cancer	cancer	NN
work_u6osxdbbyvcabphnodfjupybae	188	31	:	:	:
work_u6osxdbbyvcabphnodfjupybae	188	32	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	188	33	Hoosier	Hoosier	NNP
work_u6osxdbbyvcabphnodfjupybae	188	34	Oncology	Oncology	NNP
work_u6osxdbbyvcabphnodfjupybae	188	35	Group	Group	NNP
work_u6osxdbbyvcabphnodfjupybae	188	36	and	and	CC
work_u6osxdbbyvcabphnodfjupybae	188	37	U.S.	U.S.	NNP
work_u6osxdbbyvcabphnodfjupybae	188	38	Oncology	Oncology	NNP
work_u6osxdbbyvcabphnodfjupybae	188	39	.	.	.
work_u6osxdbbyvcabphnodfjupybae	189	1	J	J	NNP
work_u6osxdbbyvcabphnodfjupybae	189	2	Clin	Clin	NNP
work_u6osxdbbyvcabphnodfjupybae	189	3	Oncol	Oncol	NNP
work_u6osxdbbyvcabphnodfjupybae	189	4	2008;26:5755–5760	2008;26:5755–5760	CD
work_u6osxdbbyvcabphnodfjupybae	189	5	.	.	.
work_u6osxdbbyvcabphnodfjupybae	190	1	Journal	Journal	NNP
work_u6osxdbbyvcabphnodfjupybae	190	2	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	190	3	Thoracic	Thoracic	NNP
work_u6osxdbbyvcabphnodfjupybae	190	4	Oncology	Oncology	NNP
work_u6osxdbbyvcabphnodfjupybae	190	5	•	•	NNP
work_u6osxdbbyvcabphnodfjupybae	190	6	Volume	volume	NN
work_u6osxdbbyvcabphnodfjupybae	190	7	4	4	CD
work_u6osxdbbyvcabphnodfjupybae	190	8	,	,	,
work_u6osxdbbyvcabphnodfjupybae	190	9	Number	number	NN
work_u6osxdbbyvcabphnodfjupybae	190	10	8	8	CD
work_u6osxdbbyvcabphnodfjupybae	190	11	,	,	,
work_u6osxdbbyvcabphnodfjupybae	190	12	August	August	NNP
work_u6osxdbbyvcabphnodfjupybae	190	13	2009	2009	CD
work_u6osxdbbyvcabphnodfjupybae	190	14	Impact	Impact	NNP
work_u6osxdbbyvcabphnodfjupybae	190	15	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	190	16	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	190	17	ASCO	ASCO	NNP
work_u6osxdbbyvcabphnodfjupybae	190	18	2007	2007	CD
work_u6osxdbbyvcabphnodfjupybae	190	19	Presentation	Presentation	NNP
work_u6osxdbbyvcabphnodfjupybae	190	20	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	190	21	HOG	HOG	NNP
work_u6osxdbbyvcabphnodfjupybae	190	22	Lun	Lun	NNP
work_u6osxdbbyvcabphnodfjupybae	190	23	01	01	CD
work_u6osxdbbyvcabphnodfjupybae	190	24	-	-	SYM
work_u6osxdbbyvcabphnodfjupybae	190	25	24	24	CD
work_u6osxdbbyvcabphnodfjupybae	190	26	/	/	SYM
work_u6osxdbbyvcabphnodfjupybae	190	27	USO-023	uso-023	CD
work_u6osxdbbyvcabphnodfjupybae	190	28	Copyright	copyright	NN
work_u6osxdbbyvcabphnodfjupybae	190	29	©	©	NN
work_u6osxdbbyvcabphnodfjupybae	190	30	2009	2009	CD
work_u6osxdbbyvcabphnodfjupybae	190	31	by	by	IN
work_u6osxdbbyvcabphnodfjupybae	190	32	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	190	33	International	International	NNP
work_u6osxdbbyvcabphnodfjupybae	190	34	Association	Association	NNP
work_u6osxdbbyvcabphnodfjupybae	190	35	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	190	36	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	190	37	Study	Study	NNP
work_u6osxdbbyvcabphnodfjupybae	190	38	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	190	39	Lung	Lung	NNP
work_u6osxdbbyvcabphnodfjupybae	190	40	Cancer	Cancer	NNP
work_u6osxdbbyvcabphnodfjupybae	190	41	987	987	CD
work_u6osxdbbyvcabphnodfjupybae	190	42	Impact	impact	NN
work_u6osxdbbyvcabphnodfjupybae	190	43	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	190	44	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	190	45	ASCO	ASCO	NNP
work_u6osxdbbyvcabphnodfjupybae	190	46	2007	2007	CD
work_u6osxdbbyvcabphnodfjupybae	190	47	Presentation	Presentation	NNP
work_u6osxdbbyvcabphnodfjupybae	190	48	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	190	49	HOG	HOG	NNP
work_u6osxdbbyvcabphnodfjupybae	190	50	Lun	Lun	NNP
work_u6osxdbbyvcabphnodfjupybae	190	51	01	01	CD
work_u6osxdbbyvcabphnodfjupybae	190	52	-	-	SYM
work_u6osxdbbyvcabphnodfjupybae	190	53	24	24	CD
work_u6osxdbbyvcabphnodfjupybae	190	54	/	/	SYM
work_u6osxdbbyvcabphnodfjupybae	190	55	USO-023	uso-023	CD
work_u6osxdbbyvcabphnodfjupybae	190	56	on	on	IN
work_u6osxdbbyvcabphnodfjupybae	190	57	the	the	DT
work_u6osxdbbyvcabphnodfjupybae	190	58	Prescribing	Prescribing	NNP
work_u6osxdbbyvcabphnodfjupybae	190	59	Plans	Plans	NNPS
work_u6osxdbbyvcabphnodfjupybae	190	60	of	of	IN
work_u6osxdbbyvcabphnodfjupybae	190	61	American	American	NNP
work_u6osxdbbyvcabphnodfjupybae	190	62	Medical	Medical	NNP
work_u6osxdbbyvcabphnodfjupybae	190	63	Oncologists	Oncologists	NNPS
work_u6osxdbbyvcabphnodfjupybae	190	64	for	for	IN
work_u6osxdbbyvcabphnodfjupybae	190	65	Patients	Patients	NNPS
work_u6osxdbbyvcabphnodfjupybae	190	66	with	with	IN
work_u6osxdbbyvcabphnodfjupybae	190	67	Stage	Stage	NNP
work_u6osxdbbyvcabphnodfjupybae	190	68	IIIB	IIIB	NNP
work_u6osxdbbyvcabphnodfjupybae	190	69	Non	non	JJ
work_u6osxdbbyvcabphnodfjupybae	190	70	-	-	JJ
work_u6osxdbbyvcabphnodfjupybae	190	71	small	small	JJ
work_u6osxdbbyvcabphnodfjupybae	190	72	Cell	Cell	NNP
work_u6osxdbbyvcabphnodfjupybae	190	73	Lung	Lung	NNP
work_u6osxdbbyvcabphnodfjupybae	190	74	Cancer	Cancer	NNP
work_u6osxdbbyvcabphnodfjupybae	190	75	METHODS	METHODS	NNP
work_u6osxdbbyvcabphnodfjupybae	190	76	RESULTS	results	NN
work_u6osxdbbyvcabphnodfjupybae	190	77	DISCUSSION	discussion	NN
work_u6osxdbbyvcabphnodfjupybae	190	78	ACKNOWLEDGMENTS	acknowledgment	NNS
work_u6osxdbbyvcabphnodfjupybae	190	79	REFERENCES	reference	NNS